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Abstract
T helper 17 (Th17) and Foxp3+ T regulatory (Treg) cells are antagonistic in their development, function,
and abundance. Th17 cells protect against mucosal surface colonization by pathogenic organisms but
are important drivers of autoimmune disease, while Treg cells play key anti-inflammatory roles in
suppressing immune cell activation. Surprisingly, when mouse CD4 T cells lack Ndfip1, a co-activator of
Nedd4-family E3 ubiquitin ligases, an increase in both Th17 and Treg cells is observed. This work
investigates how Ndfip1 regulates these two cell types in order to promote immune homeostasis. We find
that Ndfip1 opposes Th17 cell identity while enforcing Treg lineage stability in order to prevent
spontaneous inflammatory disease. Ndfip1 drives the degradation of RORγT, which is essential for Th17
identity and cytokine production. Therefore, in Th17 cells, the absence of Ndfip1 results in reduced
degradation and accumulation of RORγT. Upon in vivo transfer, Ndfip1-deficient Th17 cells are more
powerful inducers of colitis through increased cytokine production and recruitment of inflammatory
neutrophils, indicating that Ndfip1 dampens Th17 cell function to limit pathogenicity. In contrast, Ndfip1
promotes Treg cell function by enforcing lineage stability and preventing the expansion of IL-4-producing
Treg cells. Thus the deletion of Ndfip1 in Treg cells leads to inflammation in the skin, lungs, and spleen
driven by activated Treg cells that are highly proliferative, IL-4 producers. These Treg cells more likely to
lose Foxp3 and become IL-4-producing TH2 cells. Proteomic and seahorse metabolic profiling indicated
that these cells have altered metabolism marked by elevated glycolysis and mTORC1 signaling pathways.
Therefore, Treg cells require Ndfip1 to suppress mTORC1 activity, limit glycolytic metabolism, and prevent
IL-4 production to preserve lineage stability. Our data indicates that Ndfip1 similarly limits the expansion
and proliferation of both Th17 and Treg cells but antagonizes the identity and function of proinflammatory
Th17 cells while promoting Treg cell stability and function, with the overarching aim of preventing
spontaneous inflammatory disease.
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ABSTRACT
NDFIP1 REGULATES THE IDENTITY AND PATHOGENICITY OF TH17 AND TREG
CELLS TO PROMOTE NORMAL IMMUNE HOMEOSTASIS
Awo Akosua Kesewa Layman
Paula M. Oliver
T helper 17 (Th17) and Foxp3+ T regulatory (Treg) cells are antagonistic in their
development, function, and abundance. Th17 cells protect against mucosal surface
colonization by pathogenic organisms but are important drivers of autoimmune
disease, while Treg cells play key anti-inflammatory roles in suppressing immune
cell activation. Surprisingly, when mouse CD4 T cells lack Ndfip1, a co-activator of
Nedd4-family E3 ubiquitin ligases, an increase in both Th17 and Treg cells is
observed. This work investigates how Ndfip1 regulates these two cell types in order
to promote immune homeostasis. We find that Ndfip1 opposes Th17 cell identity
while enforcing Treg lineage stability in order to prevent spontaneous inflammatory
disease. Ndfip1 drives the degradation of RORγT, which is essential for Th17
identity and cytokine production. Therefore, in Th17 cells, the absence of Ndfip1
results in reduced degradation and accumulation of RORγT. Upon in vivo transfer,
Ndfip1-deficient Th17 cells are more powerful inducers of colitis through increased
cytokine production and recruitment of inflammatory neutrophils, indicating that
Ndfip1 dampens Th17 cell function to limit pathogenicity. In contrast, Ndfip1
promotes Treg cell function by enforcing lineage stability and preventing the
vii

expansion of IL-4-producing Treg cells. Thus the deletion of Ndfip1 in Treg cells
leads to inflammation in the skin, lungs, and spleen driven by activated Treg cells
that are highly proliferative, IL-4 producers. These Treg cells more likely to lose
Foxp3 and become IL-4-producing TH2 cells. Proteomic and seahorse metabolic
profiling indicated that these cells have altered metabolism marked by elevated
glycolysis and mTORC1 signaling pathways. Therefore, Treg cells require Ndfip1 to
suppress mTORC1 activity, limit glycolytic metabolism, and prevent IL-4 production
to preserve lineage stability. Our data indicates that Ndfip1 similarly limits the
expansion and proliferation of both Th17 and Treg cells but antagonizes the identity
and function of proinflammatory Th17 cells while promoting Treg cell stability and
function, with the overarching aim of preventing spontaneous inflammatory disease.
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PREFACE
In the field of immunology, the golden standard for determining whether a protein
is important for the normal functioning of the human body often involves knocking
out that protein of interest in an animal model, and investigating whether there is
evidence of dysfunction of one or several organ systems in the absence of that
protein. This then lays the foundation for further investigation into cell types that
express the protein, timing of its expression, and pathways through which it exerts
its functions. Thus, the discovery that mice which lack a protein called Ndfip1
(Nedd4-family

interacting

protein1)

develop

a

severe,

spontaneous,

autoinflammatory disease resulting in morbidity and eventual mortality after 12-16
weeks was the initial evidence that Ndfip1 is important in enforcing immune
homeostasis. This discovery was followed by the development of mice that lack
Ndfip1 only in CD4 and CD8 T cells, and the recognition that these mice develop
disease which is very similar to the global Ndfip1 knockout animals. This led to the
realization that Ndfip1 may function in a regulatory capacity in one or several T cell
subsets to limit immune cell-mediated inflammation. In my thesis work, I
investigate a role for Ndfip1 in two subsets of CD4 T cells: Th17 cells and Regulatory
T (Treg) cells. This work identifies for the first time that Ndfip1 represses Th17
identity while promoting Treg identity in order to prevent pathogenic function of
these cells.
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CHAPTER 1: Introduction1
The human body is exposed to potentially pathogenic microorganisms at
barrier sites such as the skin, lungs, and GI tract. To mount an effective response
against these pathogens, the immune system must recruit cells with effector
responses that are appropriate for the task at hand. Several types of CD4+ T cells
can be recruited, including T helper cells known as Th1, Th2, and Th17, T follicular
helper (Tfh) cells, and regulatory T cells (Tregs) (Fig. 1a). These cells help to
maintain normal immune homeostasis in the face of constantly changing microbes
in the environment. As these cells differentiate from a common progenitor, the
composition of their intracellular milieu of proteins changes to appropriately guide
their effector function. One underappreciated process that impacts both levels and
functions of effector fate-determining factors is ubiquitylation.
Ubiquitylation and deubiquitylation
Ubiquitylation is the post-translational addition of ubiquitin to a substrate
protein. Ubiquitylation of a substrate requires the sequential action of three classes
of enzymes: the E1 or ubiquitin activating enzyme, the E2 or ubiquitin conjugating
enzyme, and the E3 ubiquitin ligase. E1s activate ubiquitin by the formation of a
thiol ester with the carboxyl group of glycine 76 on ubiquitin1. The ubiquitin is then
transferred to a catalytic cysteine on an E22, which then associates with an E3
ubiquitin ligase that is in a complex with a substrate. The E3 may serve as a scaffold
This chapter has previously been published as: Layman, A. A. K. & Oliver, P. M.
Ubiquitin Ligases and Deubiquitinating Enzymes in CD4+ T Cell Effector Fate Choice and
Function. J. Immunol. 196, 3975–3982 (2016).

1

1

to facilitate the transfer of ubiquitin from the E2 to the substrate, as is the case for
RING (Really Interesting New Gene) type E3s3,4. Alternatively, HECT (Homologous to
E6AP C-Terminus)5 and the RBR (RING-between-RING) type E3s6,7 first receive the
ubiquitin onto a catalytic cysteine residue before transferring it to a lysine on the
substrate. E3 ligases can thus identify the substrate and also dictate the formation of
ubiquitin linkages, driving the mono-, multi-mono-, or polyubiquitylation of the
substrate.
Ubiquitin has seven accessible lysines on its surface, K6, K11, K27, K29, K33,
K48 or K63, each of which can be a point of attachment for ubiquitin chains8–11.
Furthermore, the amino terminal methionine of ubiquitin (M1) can also serve as a
point of attachment for linear chains in a reaction catalyzed by an E3 ubiquitin
ligase complex called the linear ubiquitylation assembly complex (LUBAC)12.
Ubiquitin chains can alter the fate of a substrate by changing its cellular location,
promoting its interactions with other proteins, or driving degradation.
Ubiquitylation of protein substrates may be modified or reversed by enzymes called
deubiquitinating enzymes (DUBs). The ~100 DUBs encoded by the human genome
are split into five main families based on their structural domains. These five
families are the ubiquitin-specific proteases (USPs); the ubiquitin carboxy-terminal
hydrolases (UCHs); the ovarian tumor-related proteases (OTUs); the MachadoJoseph

disease

domain

proteases

(MJDs)

Metalloproteases (JAMMs)13.

2

and

the

JAB1/MPN/Mov34

Ubiquitylation affects CD4+ T cell fate, identity, and function.
When a naïve T cell encounters an antigen presenting cell (APC) expressing a
peptide antigen displayed on its MHC (pMHC), the naïve T cell can get primed to
become an effector T cell14,15. The sequence of events that leads to the formation of
an effector requires that the T cell receive three signals: pMHC, costimulation, and
cytokine16,17. Ubiquitylation can influence each of these signals within a T cell by
altering the levels and functions of signaling intermediates or by influencing
transcription factors that drive CD4+ T cell identity and function. Many E3 ligases
have known roles in regulating T cell activation and co-stimulation. These include
the RING E3 ligases: Cbl-b18–22, TRAC-123, Peli124 and the HECT E3 ligases: Itch and
Nedd425–29, as reviewed30–33.
The role of Ubiquitylation in the generation of Th1 cells
Th1 cells are important for the clearance of intracellular pathogens. They
differentiate from naïve CD4+ T cells in response to pMHC and costimulation in a
cytokine milieu containing IL-12 and IFNγ. IL-12 signaling induces the
phosphorylation of Jak2 and Tyk2, leading to STAT4 activation which in turn drives
IFNγ production34. IFNγ receptor signaling through STAT1 induces expression of the
transcription factor T-Box Expressed In T Cells (T-bet)35. T-bet, transactivates the
IFNγ gene to drive further IFNγ cytokine production35 and increases expression of
the IL-12Rβ2 to promotes more IL-12 responsiveness36. Thus, STAT1, STAT4 and Tbet help to promote Th1 cell identity.
STAT1, STAT4, and T-bet are degraded via ubiquitin-mediated networks. An
3

E3 ligase enzyme called STAT-interacting LIM (SLIM) protein (also known as
PDLIM2 or mystique) drives rapid nuclear degradation of STAT1 and STAT4 in
response to IFNα or IL-12 signaling37. SLIM has been shown to aid in
polyubiquitylation of STAT4 in vivo and in vitro37, and STAT1 in vitro38. The CD4+ T
cells in SLIM-/- mice make increased IFNγ upon in vivo challenge with heat-killed
Listeria monocytogenes37. It is however unclear whether the increased IFNγ
production by these cells leads to enhanced resistance to pathogen or rather,
enhanced immunopathology. Another E3 ligase, Smad ubiquitylation regulating
factor 1 (Smurf1), mediates K48 polyubiquitylation and degradation of STAT1 in
transformed cell lines but it remains to be shown whether this happens in T cells as
well39. STAT1 ubiquitylation is reversed by the DUB, USP1340. Furthermore, T-bet
can undergo ubiquitin-mediated degradation by a yet-unknown E3 ligase41.
However, a DUB, USP10, reverses this ubiquitylation and stabilizes T-bet42. These
findings raise the question of how else ubiquitylation influences both epigenetic
modifications and the stability of proteins that result in the decision of a naïve CD4
T cell to differentiate into a Th1 cell.
The role of Ubiquitylation in the generation of Th2 cells
Th2 cells mediate immunity against extracellular microbes, such as worms,
and facilitate clearance of allergens and toxins. Th2 cells differentiate from naïve
CD4+ T cells in response to pMHC and costimulation in the presence of the cytokine
IL-4. Th2 cells may secrete a variety of cytokines including IL-4, IL-5 and IL-13. IL-4
drives Th2 cell generation in a positive feed-forward loop43. IL-4 binds to its
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receptor, resulting in the phosphorylation and activation of STAT6, which
translocates to the nucleus and drives transcription of GATA3. GATA3 drives Th2
cell identity via both Notch-dependent and Notch-independent mechanisms44–47.
While IL-4 and STAT6 may be dispensable for in vivo generation of Th2 cells46–48,
GATA3 is required for the generation of Th2 cells44.
IL-4, GATA3, and STAT6 are regulated by ubiquitylation, either directly or
indirectly. The catalytic ubiquitin ligase, Itch, regulates Th2 cell differentiation and
identity by regulating IL-4 production. As with most catalytic E3 ligases, Itch
enzymatic activity is restrained by a closed conformational state known as
autoinhibition49. Upon T cell activation, a small membrane-bound adaptor known as
Nedd4-family interacting protein 1 (Ndfip1) is expressed which activates Itch,
allowing it to polyubiquitylate targets including JunB25,50. This results in JunB
degradation and prevents its localization to the nucleus where it would otherwise
pair with c-Maf to drive IL-4 transcription26,51,52. In mice lacking Ndfip1 or Itch,
CD4+ T cells accumulate high levels of JunB and produce excessive quantities of IL-4
resulting in a preponderance of Th2 cells25,26. Supporting this model, transgenic
mice which overexpress JunB to levels found in Th2 cells, show a specific increase in
Th2 cytokines such as IL-4 and IL-551. STAT 6 levels are regulated by two different
E3 ligases: gene related to anergy in lymphocytes (GRAIL) and Casitas B-lineage
lymphoma b (Cbl-b). GRAIL drives polyubiquitylation and degradation of STAT6,
and therefore limits the generation of Th2 cells. GRAIL is highly expressed in Th2
cells and its knockdown results in an increase in IL-4, IL-5 and IL-13 from T cells.
GRAIL knockout animals are highly susceptible to allergic inflammation and their
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naïve CD4+ T cells fail to appropriately degrade STAT6 after in vitro TCR
stimulation53. Cbl-b also drives STAT6 polyubiquitylation and degradation54. Similar
to Grail-/- animals, Cbl-b-/- animals are highly susceptible to induced allergic
inflammation due to a Th2 and Th9 bias in their T cells. The

E3

ligase,

murine

double minute 2 (Mdm2), drives GATA3 polyubiquitylation. Mdm2 is well known for
its role in ubiquitin-driven degradation of the tumor suppressor p5355,56, but Mdm2
has several other substrates including NFAT2c57,58 and GATA359. Upon TCR
stimulation, activation of the ERK-MAPK pathway leads to the association of Mdm2
with GATA3, and consequent polyubiquitylation and proteasomal degradation of
GATA359. A DUB named USP15 deubiquitinates Mdm2 and prevents its proteasomal
degradation57. Therefore ubiquitylation of GATA3 and STAT6, as well as of factors
that regulate IL-4 production, influence the generation of a Th2 cell from a naïve
CD4 T cell.
The role of Ubiquitylation in the generation of Th17 cells
Th17 cells are important for the clearance of extracellular pathogens such as
fungi. Th17 cells differentiate in the presence of a cytokine milieu containing
transforming growth factor β (TGF-β) and IL-660–62. Other cytokines such as IL-1β
and IL-23 drive differentiation and maintenance of Th17 cells and may even drive
Th17s in the absence of TGF-β63. STAT3 is induced downstream of IL-6, IL-21 and
IL-23, and cooperates with IRF4 (induced downstream of IL-1β) to elevate RORγT
levels64,65. RAR-related orphan receptor gamma T (RORγT) and alpha (RORα) are
sufficient to drive Th17 differentiation66,67.
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Several enzymes in the ubiquitin conjugation pathway can influence the
differentiation or maintenance of Th17 cells. For example, mice lacking Ndfip1 and
Itch that, as discussed in the prior section, have increased frequencies of Th2 cells,
also have increased frequencies of Th17 cells. While this may be partly due to cellextrinsic effects of IL-4 mediated inflammation driving increased pro-inflammatory
cytokines and tissue damage68, there are also more direct roles for other factors in
Th17 generation or function as will be discussed in this thesis. Similarly, mice
lacking a RING E3 ligase, Ro52/TRIM21, show increased production of
inflammatory cytokines such as IL-23, IL-6, and IL-21, and these mice have
increased frequencies of Th17 cells69. Crossing the Ro52-/- mice to IL-23p19-/- mice
abrogates tissue damage, excessive cytokine production and lowers the frequencies
of the Th17 cells, indicating that the increase in Th17 cells is indeed driven by the
dysregulated IL-23/IL-17 axis. Ro52 acts downstream of IFN (predominantly Type
II) signaling to polyubiquitylate IRF3, IRF5 and IRF8 and to target them for
degradation. This limits the production of cytokines including IL-6 and IL-23 that
would otherwise drive Th17 generation. A third example of an E3 ubiquitin ligase
that influences the Th17 cell fate choice is SLIM. As described above, SLIM can drive
degradation of STAT4 in Th1 cells, but can also limit Th17 differentiation by
promoting the proteasomal degradation of STAT370,71. Supporting this, SLIMdeficient animals show increased frequencies of Th17 and Th1 cells and are very
susceptible to Experimental Autoimmune Encephalitis (EAE), a mouse model of
multiple sclerosis71.
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Several DUBs are important for Th17 differentiation. USP4 regulates Th17s
in two ways. First, USP4 deubiquitylates Ro52 in transformed cell lines72 and thus
limits the expression of cytokines needed for Th17 generation69. Second, it directly
interacts with RORγT in primary human Th17 cells and deubiquitylates RORγT in
transformed cell lines73, which would promote Th17 cells generation. Further work
is needed to understand whether these two functions are performed by USP4 in
primary T cells and if these opposing actions serve to regulate Th17 cell abundance
in vivo. USP17 (also known as DUB-3) is a second DUB that maintains RORγT
stability74. Knockdown of USP17 in primary Th17 cells results in a decrease of
endogenous RORγT levels74. Since IL-4 and IL-6 signaling can induce USP1775, it
appears that in response to IL-6 signaling, two responses occur: first, RORγT levels
are increased downstream of STAT3 and second, RORγT protein is stabilized
downstream of USP17. How USP17 integrates these two events downstream of IL-6
signaling needs further evaluation in primary CD4+ T cells.
A third DUB involved in Th17 differentiation is DUBA (also known as
OTUD5), an OTU family DUB. DUBA facilitates the degradation of RORγT by
stabilizing a positive regulator of RORγT degradation known as UBR576. UBR5
polyubiquitylates and targets RORγT for proteasomal degradation. UBR5 itself is
regulated via polyubiquitylation. When DUBA deubiquitylates UBR5 and rescues it
from degradation, UBR5 is free to polyubiquitylate RORγT, driving its degradation
and consequently limiting Th17 differentiation. T-cell specific loss of DUBA
therefore results in reduced levels of UBR5, stabilization of RORγT, and increased IL8

17A production in response to TCR stimulation76.
Th17 cells are heterogeneous; some are more pathogenic than others63,77,78,
depending on how the Th17 cells were generated and upon their gene expression
profile. GM-CSF secretion, for example, which occurs downstream of IL-23 signaling,
marks pathogenic Th17s which cause EAE79–82. IFNγ+ Th17 cells are also thought to
be more pathogenic than IL-17A single producers. Further work needs to be done to
clarify the role of ubiquitylation in determining the pathogenic potential and
function of a Th17 cell both during and after differentiation, and how this influences
the observed heterogeneity in Th17 cells.
The role of Ubiquitylation in the generation of T follicular helper cells
Tfh (T follicular helper) cells are CD4+ T cells that provide costimulatory help to B
cells in germinal centers to enable B cell functions83–85. Tfh cells exist in an
interdependent relationship with B cells, wherein B cells are required for
appropriate Tfh differentiation and function, and, reciprocally, Tfh cells promote the
generation of high affinity antibody producing B cells. Tfh cells differentiate from
naïve precursors in response to pMHC interactions and under the influence of
cytokines such as IL-6 and IL-21, and ICOS signaling86–90. Tfh cells can secrete
cytokines such as IL-4, and IL-21 as well as chemokines such as CXCL13, as
reviewed91. The differentiation of a naïve CD4+ T cell into a Tfh cell occurs in a stepwise fashion and requires the transcription factor, achaete-scute homologue 2
(Ascl2), to generate a Bcl6lo CXCR5+ Tfh-intermediate cell. This intermediate
undergoes maturation and complete differentiation in the presence of Bcl6 to
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generate a Bcl6hi CXCR5hi Tfh cell92. Bcl6 is thus essential for Tfh identity93–95.
Several E3 ligases affect Tfh differentiation and function by regulating Bcl6
directly or indirectly. Four of these are RING type E3 ubiquitin ligases. First, Bcl6
may be repressed by interaction with Cul3 E3 ligase, a ligase known, among other
things, to ubiquitylate histone proteins. In thymocytes, complexes of Cul3 and Bcl6
directly bind and lay down repressive epigenetic marks on two genes important for
Tfh identity, namely Batf and Bcl696. Intriguingly, this repression is epigenetically
carried over into the periphery when the T cells encounter antigen. Therefore, in
mice which lack Cul3 in T cells, Tfh cells are increased in secondary lymphoid
tissues and these cells drive germinal center B cell expansion97. Exactly how the
Cul3 Ring Ligase complex represses Bcl6 expression remains unresolved. Does the
complex directly ubiquitylate Bcl6 leading to its degradation? Or does the complex
regulate Bcl6 indirectly by ubiquitylation other proteins such as histone modifiers
that are associated with Bcl6? Second, the E3 ligase Roquin reduces expression of
ICOS, upstream of Bcl6, to limit Tfh differentiation. Roquin is a RING E3 ligase with
an RNA-binding domain that binds and silences target genes, including ICOS mRNA.
Supporting this model, mice that bear a mutation in the gene encoding Roquin, (also
called sanroque mice), have increased ICOS levels in both naïve and activated T
cells. This leads to a T-cell-intrinsic increase in Tfh differentiation, large numbers of
germinal centers, and increased serum antibodies of various IgG isotypes, among
other defects98. Bcl6 is regulated by two other E3 ligases in diffuse large B cell
lymphomas (DLBCLs)99,100. Pellino1 E3 ligase (PELI1) directs K63 (non-degradative)
chains on Bcl6 leading to Bcl6 stabilization in transgenic mice overexpressing
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human PELI199. Furthermore, in these lymphoma cell lines, another E3 ligase,
FBXO11, that normally marks Bcl6 for degradation, is found to undergo loss of
function mutations100. Follow up of these observations in primary T cells will be
crucial in determining whether PELI1 and FBXO11 have roles in regulating Bcl6 and
consequently in Tfh differentiation in vivo.
The HECT-type E3 ligase Itch also regulates the differentiation of Tfh cells.
Mice lacking Itch globally or only in their T cells are unable to generate Tfh cells
following infection with vaccinia virus101. In Itch-deficient T cells, Foxo1 is not
appropriately degraded and Tfh development can be rescued by knockdown of
Foxo1 or by forced expression of Bcl6, suggesting that the defect is upstream of
Bcl6101. ICOS signaling converges on this pathway by transiently inactivating Foxo1
in order to relieve Foxo1 repression of Bcl6 and to allow Tfh differentiation
downstream of short-term ICOS signals102. Surprisingly, knockout of Foxo1 in T cells
does not lead to aberrantly increased Tfh differentiation but, instead, to a lack of
formation of germinal centers or Tfh cells102. This suggests that the expression of
proteins such as Foxo1 is precisely modulated to allow the development of Tfh cells
and the formation of germinal centers. Foxo1 is important for regulatory T cell
generation and function103 and Itch-deficient T cells have decreased Tfh cells, and
defective Treg numbers and function101,104, therefore it will be important to
determine whether Foxo1 levels are changed in Itch-/- Treg cells and how defects in
Itch-deficient Treg cells influence observed defects in Itch-deficient Tfh cells.
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Further work is needed to explore the role of other ubiquitin-mediated pathways in
Tfh identity.
The role of Ubiquitylation in the generation of Regulatory T cells
Tregs are a subset of CD4+ T cells that are capable of suppressing the actions
and functions of other immune cell type types105,106. Several distinct subsets of Tregs
have been described including the Foxp3- Tr1 cells (Type 1 regulatory T cells),
Foxp3+ Th3 cells, and the Foxp3+ thymic-derived Tregs. Foxp3+ regulatory T cells
develop in the thymus, when TCR/CD28 and IL-2 signaling drives expression of the
transcription factor Foxp3107. Foxp3 is central to the function of this major subset of
Tregs and mutations in Foxp3 in both mice and men leads to non-functional Tregs
and autoimmunity108. Foxp3+ Tregs may also be induced in the periphery through
the action of TGF-β and IL-2. TGF-β signals through the complementary proteins,
Smad2 and Smad3, to drive Foxp3 transcription109. IL-2 binding to the IL-2R
complex leads to JAK1 and JAK 3 recruitment and eventual recruitment and
activation of STAT5 which in turn drives expression of Foxp3110,111.
Two E3 ligases can regulate Foxp3 stability: Stub1 and Cbl-b. Stub1 (also
known as CHIP or carboxyl terminus of Hsc70-interacting protein), interacts with
both Hsp70 and Foxp3 to drive K48-linked polyubiquitylation of Foxp3112. Exposure
of the Jurkat T cell line to inflammatory cues such as LPS and IL-1β drives the
translocation of Stub1 into the nucleus, where it interacts with Hsp70, and drives
the ubiquitin-mediated proteasomal degradation of Foxp3. Overexpression of Stub1
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in Tregs and subsequent cotransfer of these cells together with naïve T cells into a
lymphoreplete host resulted in loss of Foxp3 in the Tregs and subsequent
conversion of these cells into IFNγ+ Th-1 like effector cells112. Cbl-b, has been shown
to ubiquitylate Foxp3 by working together with Stub1. Specifically, Cbl-b binds
ubiquitylated Foxp3 downstream of TCR/CD28 signaling, and recruits it to Stub1,
allowing

additional

ubiquitylation

of

Foxp3

and

increased

proteasomal

degradation113.
E3 ligases may also influence Tregs by affecting their function. One such
example is the regulation of Treg function by the E3 ligase von Hippel-Lindau,
VHL114. Under normal oxygen levels (normoxia), an oxygen sensor named Hypoxiainducible

Factor

alpha

(HIF1α)

is

hydroxylated,

recognized

and

then

polyubiquitylated by VHL. This results in proteasomal degradation of HIF1α. Under
conditions of low oxygen stress (hypoxia), HIF1α is not degraded by VHL, and is free
to drive the transcription of genes necessary for surviving hypoxia. HIF1α also
serves as a switch between Th17 and Treg fates115,116. HIF1α can directly bind
RORγT and p300 to drive transcription of IL-17A and promote Th17 identity while
simultaneously binding and targeting Foxp3 for degradation to repress Treg
differentiation115. Interestingly, mice lacking VHL only in their Tregs develop a
disease characterized by large numbers of IFNγ+ Tregs which infiltrate tissue and
fail to suppress conventional T cells or prevent colitis114. In VHL-deficient Tregs,
stabilized HIF1α drives the IFNγ promoter resulting in large amounts of secreted
IFNγ and poor function of these Tregs114. Why HIF1α specifically drives IFNγ
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production is not understood. It would be interesting to explore the chromatin
landscape to understand whether the IFNγ promoter is accessible while promoters
for other cytokines are not.
The HECT-type E3 ubiquitin ligase Itch also regulates Treg differentiation
and function. Mice encoding a Treg-specific deletion of the E3 ligase Itch develop a
Th2-mediated disease characterized by infiltration of activated T cells into mucosal
sites and show particularly severe inflammation in the airways104. The inability of
Itch-deficient Tregs to suppress Th2-mediated inflammation supports other
published studies showing that mice that lack Ndfip1 express an inactive form of
Itch that fails to degrade JunB and limit IL-4 production25. Thus T cells from mice
that lack Ndfip1 are defective in induced Treg (iTreg) generation due to high IL-4
production117. Two E3 ligases, Smurf2118 and β-TrCP (FBXW1)119, ubiquitylate and
degrade a protein called EZH2 in neurons and transformed cells respectively.
Importantly, EZH2-deficient Foxp3+ Tregs are unable to suppress inflammation in
vivo and show an increased loss of Foxp3120. EZH2 forms part of the polycomb
repressive complex 2 (PRC2) that trimethylates histone H3 in order to repress gene
transcription. Whether these E3 ligases function to stabilize EZH2 and reinforce
Treg identity in primary T cells will be interesting to explore in future studies.
Relatively little is known about the role of DUBs in Treg differentiation. The
USP family member CYLD (cylindromatosis) plays a role in the generation of Tregs.
In response to TGF-β signaling, K63-linked polyubiquitylation of Smad7 results in
stabilized Smad7 which activates TAK1, increases binding of AP-1 to the Foxp3
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promoter, and increases Foxp3 transcription121. CYLD opposes this process by
removing K63 chains on Smad7. In CYLD-/- T cells, unopposed K63 ubiquitylation
upon TGF-β signaling stabilizes Smad7 and drives increased differentiation of
Tregs121. These examples show that in addition to regulating Treg abundance
ubiquitin enzymes can regulate Treg differentiation and function.
Enforcing T effector and Treg cell identity is crucial for normal immune
homeostasis.
Maintaining CD4+ T helper cell identity is important for proper immune
function. On one hand, the flexibility to transition from an initial CD4+ T effector cell
into a more relevant effector cell may be important for quickly tailoring the immune
response as infection progresses. However, recent work suggests that CD4 effector
cells have the potential to lose stability and express transcription factors and
cytokines that are typically ascribed to other lineages. While it remains possible that
this helps to promote pathogen clearance, in many instances this is associated with
an ineffective immune response or correlates with inappropriate immune responses
that are seen in autoimmune diseases.
Data from patients with Crohn’s disease suggests that dual Th1/Th17 cells
may play a pathogenic role in disease122. These cells appear to retain aspects of both
Th1 and Th17 identity, expressing T-bet and RORγT and secreting both IFNγ and IL17A123,124. This co-expression of T-bet and RORγT is intriguing since T-bet is thought
to repress Th17 identity by binding Runx1, to prevent Runx1 from transactivating
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Rorc125–127. Runx1 also represses the Th2 fate by binding directly to GATA3128.
Runx1 is ubiquitylated and degraded by the E3 ligase Stub1129, placing
ubiquitylation of Runx1 squarely at the center of decisions of CD4 effector fate.
Furthermore, in vitro -derived Th1 cells bear activating H3K4me3 marks at the gene
loci for IFNγ and T-bet, as expected, but also unexpectedly at the locus for GATA3130,
suggesting that Th1 cells may be poised to take on other T helper identities. This
corroborates data by other groups showing that Th1 cells may convert to IL-4
producing cells in response to infection with Nippostrongylus brasiliensis131.
Conversely, in the absence of GATA3, CD4+ T cells enter into the Th1 rather than
Th2 cell lineage47,132. Continued research is needed to further elucidate the role of
ubiquitylation in these Th1/Th2 cell fate decisions.
Th17 cells can exhibit plasticity in vivo. In a NOD/SCID autoimmune model of
diabetes, transfer of Th17s cells leads to acquisition of T-bet and IFNγ secretion by
these cells in vivo133. Furthermore, Th17 cells can transdifferentiate into Tr1 cells
via a TGF-β/Smad3 pathway, both at steady state and during immune responses to
worms or bacterial infections134. Since Smad3 degradation in transformed cell lines
is mediated by the RING E3 ligase, ROC1135 and may be reversed by the DUB,
OTUB1136, ubiquitylation may be involved in the transdifferentiation of Th17 cells.
Bcl6 is crucial in driving Tfh lineage identity. Bcl6 levels may also be
increased

downstream

of

STAT1,

STAT3

and

STAT4137,138.

During

Th1

differentiation, there is a Tfh-like transition stage during which both Bcl6 and T-bet
are expressed. However as T-bet expression increases, Bcl6 levels decrease,
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resulting in a bias towards Th1 cell identity137,138. Interestingly, although the E3
ligase, SLIM, degrades STAT1 and STAT4 in Th1 cells37 and STAT3 in Th17 cells71, a
role for SLIM E3 ligase in regulating Tfh differentiation has not yet been reported. It
is possible that by degrading STAT1, STAT3 and STAT4, SLIM E3 ligase may keep
levels of Bcl6 low and negatively regulate Tfh differentiation at the expense of the
increased Th1 differentiation. Therefore SLIM-/- mice could show aberrantly high
Tfh differentiation. This connection remains to be explored.
Stability of Tregs continues to be a controversial topic. Some studies have
shown remarkable stability of these cells in both lymphoreplete and lymphopenic
hosts139,140. Other studies have shown that Tregs can lose Foxp3 upon transfer into
lymphopenic hosts and gain the capacity to express effector cytokines such as IL-2,
IL-17A or IL-4, IFNγ and TNFα141,142. It is not clear what determines the kind of
effector cytokines secreted by a Treg cell after it loses Foxp3. However, concerning
stability, a consensus may be that while most thymic-derived Tregs may be stable
and committed to the Treg lineage, inflammatory conditions exist that can drive
some loss of Foxp3 protein and thus Treg instability. Alternatively, there may be
conditions in which a small subset of Tregs that are not fully committed to the Treg
fate, may lose their Foxp3 expression143,144. In autoimmune arthritis, for example,
“exTregs” which acquire the capacity to secrete IL-17A can play a pathogenic role in
the disease145. Bcl6-/- Tregs are also more likely to lose Foxp3 and to express GATA3,
and to secrete Th2 cytokines and IL-17A146. Since Bcl6 may be degraded by
ubiquitylation, as discussed in the Tfh section, it will be beneficial in future studies
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to determine how ubiquitylation and degradation of Bcl6 regulates Treg stability
under steady state and under inflammatory conditions.
With over 600 E3 ligase enzymes encoded in the human genome, our
knowledge of the substrates and functions of all of these enzymes is in its infancy.
To date, relatively little is known about the contribution of these ligases to CD4
effector fate and function (Fig. 1). As gene targeting becomes more efficient, such as
with the advances of CRISPR technology, our understanding of how these ligases
function in vivo will be more fully explored. Additionally, as whole exome
sequencing becomes more commonplace, mutations in E3 ligases are likely to be
found to associate with immune-mediated disease, thus providing a more complete
understanding of how these ligases regulate immune function. Also, the continued
use of modern genetic technology such as reporter mice for many of the known
lineage-defining transcription factors and their key cytokines, future work may
continue to reveal conditions under which different T cell subsets may be unstable
and how this is regulated by ubiquitylation. Further work focusing on
understanding how ubiquitylation regulates the human proteome, should also help
shed more light on the role of ubiquitylation in regulating CD4+ T cell identity,
function and stability.
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FIGURE 1 E3 ubiquitin ligases and deubiquitinating enzymes regulate the proteins that shape
CD4+ T cell identity and function.
T helper cells differentiate from naïve CD4 T cells after T cell activation by an antigen-presenting cell
(APC), such as a dendritic cell. The effector cell fates have various roles in defense against non-self.
All of the key transcriptional factors that drive effector fates can be regulated via ubiquitylation
(mediated by the indicated E3 ubiquitin ligases) or by deubiquitinating enzymes (DUBS).
Modified from Layman, A. A. K. & Oliver, P. M. Ubiquitin Ligases and Deubiquitinating Enzymes in
CD4+ T Cell Effector Fate Choice and Function. J. Immunol. 196, 3975–3982 (2016). Copyright
2016. The American Association of Immunologists, Inc
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Ndfip1 is an adaptor in the protein ubiquitylation cascade
Ndfip1 (originally named N4WBP5) was identified from a far-western screen
as an embryonic protein that could bind to the E3 ligase called Nedd4 (Neural
precursor cell expressed developmentally down-regulated 4) protein147. Nedd4 was
known to belong a family of E3 ligases that had a conserved modular structure and
were able to bind to other proteins via their WW motifs. It was shown that the WW
motifs on Nedd4 were essential for binding to proline-rich PY motifs on Ndfip1147.
Further discoveries since then have revealed that Ndfiip1 has a transmembrane
domain, can be golgi-associated148, and has a very homologous family member
named Ndfip2 (originally, N4WBP5A)149. Excitingly, it has now been shown that
Ndfip1 is capable of binding in vitro to not just Nedd4 but all of the nine HECT E3
ligases that comprise the Nedd4 family49. These are: Nedd4, Nedd4-2, Itch, WWP1,
WWP2, Smurf1, Smurf2, NedL1 and NedL2. This has spurred many investigations
into determining which E3 ubiquitin ligases work with Ndfip1 in different cell types
as well as the functional outcomes of substrate ubiquitylation.
Ndfip1 has roles outside of T cells.
In vivo studies of Ndfip1-deficient animals indicate that Ndfip1 is capable of
working with several HECT E3 ligases and of mediating pleiotropic functions in nonT cells. Ndfip1 activates Nedd4-2 to degrade DMT1 (Divalent Metal Transporter 1)
and decrease iron storage150 in neurons. However, to carry out this same function in
hepatocytes, Ndfip1 activates a different Nedd4 E3 ligase, namely, WWP2151. In
neurons, Ndfip1 also activates an unknown E3 ligase to maintain Phosphatase and
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Tensin homolog (PTEN) nuclear localization and to suppress proliferation152. In
macrophages, Ndfip1 works with Smurf1 to target MAVS (mitochondrial antiviral
signaling protein) for degradation as a mechanism to dampen Interferon β
production39. Many of these studies of were done using in vitro over-expression or
siRNA knockdown of Ndfip1 in cell lines.
Ndfip1 is important in T cells
Most of the work done in T cells, however, has been done in vivo due to the
generation of two early mouse models of Ndfip1-deficiency. The first is the deletion
of Ndfip1 in mice using a homozygous gene trap insertion that disrupts the Ndfip1
gene25, and the second is the generation of mice bearing a truncating splice site
mutation in the Ndfip1 gene153. These two mice models have made major
contributions to our understanding of Ndfip1 in vivo biology and paved the way for
even more targeted mouse models of Ndfip1 deficiency. Mice that lack Ndfip1 in all
cells due to the homozygous gene trap insertion were the first to be generated25.
These mice showed that the loss of Ndfip1 globally led to spontaneous inflammation
in several sites including ears, liver, and spleen; and death of most mice by 14
weeks. The inflammation was driven by an increase in activated CD4, CD8 and B
cells found at the affected sites. The activated CD4 T cells in these animals made
copious amounts of IL-4 and had markedly increased proliferation. Biochemical
work established that this dysregulation was in part due to a loss of the interaction
between Ndfip1 and Itch, which is important for the ubiquitylation, and degradation
of the transcription factor, JunB, in T cells to prevent IL-4 transcription and
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production. Ndfip1-/- Rag

-/-

double knockout mice which lack Ndfip1 as well as

CD4+ and CD8+ T cells, and B cells, were generated and showed no sign of disease at
any stage in their life154. This indicated that Ndfip1 was playing an important
regulatory role in the adaptive immune system to suppress inflammatory disease.
Consequently, mice were generated that lack Ndfip1 in all CD4 and CD8 T cells
(Ndfip1fl/fl CD4 Cre animals, Ndfip1 cKO)155. The histological and cellular pathology
in these animals is strikingly similar to Ndfip1 global knockout animals, suggesting
that much of the pathology in Ndfip1-deficient animals is driven by T cells155.
To examine a role for Ndfip1 in the regulatory arm of CD4 T cell subsets, one
study looked at Treg cells generated in Ndfip1 global knockout animals117. As early
as 4 weeks of age, thymic Treg cells were increased. However, at the small bowel, a
site of induced Treg (iTreg) generation, there was a decrease in total Treg cells,
driven by a decrease in these Foxp3+ helioslo iTreg cells. Further work showed that
IL-4 produced by CD4 T cells was responsible for aborting iTreg differentiation. This
work established that an extrinsic effect of the high IL-4 in Ndfip1-/- animals is to
prevent iTreg generation and uncovered a role for Ndfip1 in promoting iTreg
differentiation in order to maintain immune homeostasis in the small bowel.
However, this work did not address whether there are changes to total Treg
numbers at other tissue sites such as the lungs or spleen, and whether Ndfip1 is
important for the function and/or maintenance of Treg cells that have already
differentiated into Foxp3+ Treg cells.
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Another study used the mice bearing the truncating splice site mutation of
the Ndfip1 gene to study the role of Ndfip1 in T cell activation153. The study revealed
that the T cell defects in Ndfip1-deficient mice was not rescued by the presence of
normal, functional Treg cells in mixed chimera models. This suggested that even if
there were defects in Treg cells, there were additional cell-autonomous defects in
the CD4 T cell effector populations. The study reiterated that Ndfip1-deficient Th2
cells have an intrinsic defect in limiting IL-4 production due to failure to degrade
JunB. Interestingly, the study was also the first to publish a cell-intrinsic increase in
IFNγ+ cells due to a loss of Ndfip1 and yet whether this finding had implications for
the role of Ndfip1 in Th1 cells was not addressed or explored. The study further
demonstrated that CD4 T cells lacking Ndfip1 continue to stay in the cell cycle and
proliferate in response to the same amount of antigen seen by a WT CD4 T cell. This
finding complemented another study which showed that activation of Ndfip1deficient CD4 T cells and their increased proliferation was in part due to a failure to
turn down IL-2 signaling even when CD28 co-stimulation had not occurred155.
Together, all of these previous studies established that Ndfip1 functions in CD4 T
cells to limit T cell activation and proliferation. However, with the exception of Th2
cells and iTreg cells, it was not understood whether or how Ndfip1 was regulating
other subtypes of CD4 T cells.
To understand Ndfip1’s role in other CD4 subtypes, one study examined
Th17 cells found in Ndfip1-deficient animals68. They found that the frequencies and
numbers of Th17 cells are increased in mice that lack Ndfip1 globally. Further
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investigation revealed that the abundance of Th17 cells could be dramatically
reduced by treating with blocking antibodies against IL-6 or by knocking out the IL4 gene. They discovered that the high IL-4 production by T cells in Ndfip1-deficient
animals leads to increased IL-5-secreting Th2 cells. The high IL-5 led to increased
recruitment of eosinophils154, which are known to both directly modulate GI
pathology and also release IL-6 that can drive increased in situ differentiation of
Th17 cells68. Thus, mice deficient in both Ndfip1 and IL-4 would be expected to
show decreases in Th17 generation due to a loss of the upstream IL-4-dependent
processes. Correspondingly, the study showed that Ndfip1 IL-4 DKO animals have
decreased lung eosinophil recruitment, decreased serum IL-6 and some reduction in
the frequency of Th17 cells. However the study failed to address whether the slight
apparent reduction in Th17 cells in the DKO animals was different from the levels
observed in an Ndfip1-deficient animal if quantified for several animals, or whether
CD4 T cells that have already differentiated in to Th17 cells require Ndfip1 for their
function.
Lastly, one study examined CD8 T cell identity and function in mice which
lack Ndfip1 globally or in the T cell compartment (Ndfip1 cKO mice) and determined
that CD8 T cells in these mice have an activation and virtual memory phenotype that
is a completely CD8-extrinsic and results from the IL-4 rich environment in which
these CD8 T cells develop156. The phenotype was reversed in Ndfip1 IL-4 DKO
animals, showing that it was IL-4 dependent.
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These previous studies make it evident that Ndfip1 is important in CD4 T
cells for dampening activation in two ways. One, Ndfip1 regulates the timed and
orderly cell exit from the cell cycle, and two, enforces dependency on CD28 in order
to prevent autocrine IL-2 production that would bypass or decrease the need for
CD28 in T cell activation. Furthermore, Ndfip1 represses T cell proliferation in order
to limit the numbers of different T cell populations.
Investigating a cell-autonomous role for Ndfip1 in Th17 and Treg cells
requires new mouse models
However, despite all that is known about Ndfip1’s action in T cells, it is
unclear whether Ndfip1 has roles in other CD4 T cell subsets independent of its
influence on Th2 cells, and importantly, whether Ndfip1 is important in CD4 T cell
subsets beyond the differentiation step. Ndfip1’s role in limiting IL-4 production
from Th2 cells demonstrably affects multiple other immune cell types and has
hampered the ability to investigate a Th2-independent role for Ndfip1 in other CD4
T cell subsets. Therefore, for my thesis work, I wanted to determine if there was a
role for Ndfip1 in the function of Th17 and Treg cells. I needed two models that
would permit the study of Th17 and Treg cells in the absence of excessive Th2 cells.
For Th17 cells, I used mice that lack both the Ndfip1 gene and the IL-4 gene (Ndfip1
IL-4 DKO) since IL-4KO animals have very little to no Th2 cells68,157,158. To study
Treg cells, we used mice that are sufficient for Ndfip1 in all cells in the body
(including Th2 cells) but lack Ndfip1 in Foxp3+ Treg cells. With these tools in hand,
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I began investigating whether Ndfip1 plays a cell-autonomous role in regulating the
numbers and function of Th17 and Treg cells.
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CHAPTER 2: Ndfip1 drives RORγT degradation to limit Th17 cell
pathogenicity and prevent spontaneous inflammatory disease2

Introduction
Since their discovery over a decade ago, Th17 cells, or CD4+ T cells producing
the signature cytokine IL-17A, have been determined to play an important role in
defense against fungal and extracellular pathogens60–62. Th17 cells express the
transcription factors RORγT66, RORα67 and STAT3159,160 and can secrete several
additional cytokines including IL-17F, IL-22, IFNγ and TNFα. Humans bearing
mutations that prevent Th17 cell differentiation or IL-17 receptor signaling, are
susceptible to fatal candidiasis65,161–163 indicating the importance of Th17 cells in
anti-fungal immunity. On the other hand, increased numbers of Th17 cells in certain
inflammatory disorders have been correlated with disease severity. This includes
conditions such as Crohn’s disease, multiple sclerosis, rheumatoid arthritis,
psoriasis and psoriatic arthritis. Blocking antibodies that target IL-17A or IL-23, a
cytokine that increases Th17 cell numbers, have been used in clinical trials for these
diseases, with mixed results164,165. In some cases, treatment has led to increased
susceptibility to infection166–168. Thus, identifying ways to adjust the potency of
Th17 cell pathogenicity may be of therapeutic benefit.
In most cases, it is not known how the Th17 cells that drive
autoinflammatory diseases develop; whether they develop from previously
2This

chapter has previously been published as: Layman, A. A. K., Sprout, S. L., Phillips, D. &
Oliver, P. M. Ndfip1 restricts Th17 cell potency by limiting lineage stability and
proinflammatory cytokine production. Sci. Rep. 7, 39649 (2017)
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functional Th17 cells that become dysregulated or whether they can be identified ab
initio based on unique characteristics. In support of the hypothesis that pathogenic
Th17 cells may be programmed to be pathogenic at their induction, it is thought that
the inflammatory conditions under which a Th17 cells is generated may affect its
pathogenicity. Related to this, some factors that are reported to influence the
pathogenic potency of Th17 cells include their exposure to IL-23 during
differentiation. Such exposure results in the formation of a complex that contains
the transcription factors Blimp1, RORγT, STAT3, p300, HIF1α, BATF and IRF4.
Together, these factors cooperate to drive the expression of genes such as Il17a,
Il23r and Csf265,169. Furthermore, pathogenic Th17s have been reported to show a
gene profile that includes Tbx21, Csf2 and Ccl5 (Rantes), among others77. Csf2-driven
GM-CSF production in particular is thought to be important for the pathogenicity of
Th17 cells, especially in disease models such as Experimental Autoimmune
Encephalomyelitis (EAE)79,80. IFNγ expression by Th17 cells, which can be induced
by IL-23 signaling and/or high levels of Tbx21, is also associated with worse EAE
and colitis, in models of multiple sclerosis and Inflammatory Bowel Disease
(IBD)170,171. Defining mechanisms that restrict these factors and thus limit Th17 cell
pathogenicity could aid the development of therapeutics that could reduce the
pathogenic potency of Th17 cells.
Ubiquitylation of transcription factors and lineage-defining proteins is one
under-appreciated means of regulating the differentiation and function of T helper
subsets, including Th17 cells.172. Surprisingly little is known about how
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ubiquitylation of proteins affects the generation of pathogenic versus nonpathogenic Th17 cells. Ndfip1 has been indirectly implicated in the regulation of
Th17 cells. It has been shown that excessive IL-4 production from Ndfip1-deficient
Th2 cells drives tissue damage and eosinophilia, which in turn leads to an increase
in secreted factors such as IL-6, and favors in vivo Th17 generation68. However, it is
unknown whether Ndfip1 has direct roles within Th17s. Very recently, the catalytic
E3 ligase, Itch, was shown to ubiquitylate RORγT, driving its degradation and
helping to limit the generation of Th17 cells in the colon173. However, it remains
unclear how the increased levels of RORγT that occur in the absence of Itch impact
Th17 cell function.
In this study, we show that Ndfip1 or Itch E3 ligase deficiency drives an
increase in Th17 cell numbers at barrier surfaces. Increased Th17 cell abundance in
Itch- or Ndfip1-deficient animals does not depend on the well-characterized roles
for these two proteins in T cell activation or in IL-4-mediated inflammation. Ndfip1
and Itch do not control the numbers of cells differentiating into Th17 cells in vitro.
Rather, they limit the production of cytokines by the cells following differentiation.
As with their Itch-deficient counterparts, Ndfip1-deficient Th17 cells are unable to
degrade RORγT upon T cell stimulation, and increased RORγT correlated with an
elevated production of the proinflammatory cytokines IL-17A, IFNγ or GM-CSF in
vivo, Th17 cells lacking Ndfip1 were more likely than their WT counterparts to
maintain lineage commitment, based on production of IL-17A, were much more
likely to co-produce other pathogenic cytokines, and caused more severe colitis.
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Thus, Th17 cells require Ndfip1 and Itch to limit RORγT levels and prevent Th17
cells from causing severe tissue inflammation and inflammatory bowel disease.
Results
Loss of Ndfip1 results in a T cell-intrinsic increase in Th17 cell numbers
Naïve CD4 T cells differentiate into Th17 cells at mucosal surfaces such as the
lung and colon in response to TCR stimulation, co-stimulation, and the availability of
lineage-instructing cytokines including TGFβ, IL-6, IL-1β and IL-23174–176.
Downstream of these signals, proteins such as RORγT, BATF and STAT3 are
produced to drive the transcription and translation of proteins that are needed for
establishing and maintaining Th17 identity65.
In Ndfip1-deficient animals, tissue destruction mediated by potent IL-4
producing Th2 cells has been shown to cause increased IL-6 at tissue sites, and this
is thought to drive an increase in mucosal Th17 generation in vivo 154. However, it is
also possible that this increase in Th17 cells may be due to a loss of Ndfip1 within
the T cell lineage. To investigate how Ndfip1 functions within CD4 T cells to limit the
abundance of Th17 cells, we first compared the Th17 cell (CD4+ IL-17A+) frequency
and number in mice which constitutively lack Ndfip1 to those that lack Ndfip1 only
in T cells (Ndfip1fl/fl CD4-Cre, referred to as cKO mice). Consistent with previously
published data, we found an increase in the frequency of Th17 cells in the lungs
(Fig. 2.1, a, b) of mice constitutively lacking Ndfip1 over WT controls. Importantly,
with T cell-specific deletion of Ndfip1, we found similarly increased numbers of
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Th17 cells. An increase in IFNγ+ CD4 T cells in the lungs has also been described153,
supporting the possibility that Ndfip1 regulates IFNγ+ and IL-17A+ cells via a
similar mechanism. Consistent with this, both Ndfip1-deficient animals, and mice
with the T cell-specific deletion in Ndfip1, also showed an increase in IFNγ+ CD4 T
cells in the lungs compared to the WT controls (Fig. 2.1c). These data reveal that a
loss of Ndfip1 in T cells can lead to an increase in numbers of both Th17 and Th1
cells.
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FIGURE 2.1 Ndfip1 limits the abundance of Th17 cells.
Flow cytometric analysis of CD3+ CD4+ T cells among cells isolated from lungs of wild type (WT),
Ndfip1 knockout (KO), or Ndfip1fl/fl CD4-Cre (cKO) animals. Percentages of lung CD4+ T cells that
are IL-17A+ (a,b) or IFNγ+ (a, c). n=8-11 animals per genotype, analyzed at 7-9 weeks of age in 7
independent experiments using one-way ANOVA and Holm-Sidak's multiple comparisons test.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All error bars represent mean ± SEM

Mice that lack Ndfip1 constitutively, or in the T cell compartment, contain high
numbers of CD44+ CD4+T cells25,153,155. In order to become a Th17 cell, a naïve CD4
T cell must first become an activated, CD44+ cell. Thus, we next tested whether the
increase in Th17 cells was due to increased T cell activation. We gated exclusively
on CD44+ CD4 T cells (Fig. 2.2a) and then determined frequency of IL-17A+ or of
IFNγ+ cells. For Th17 cells, even after limiting our analysis to CD44+ cells, Ndfip1deficient T cells were significantly more likely to produce IL-17A (Fig. 2.2b). In
contrast, when we gated in this manner, WT and Ndfip1-deficient T cells were less
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likely to be IFNγ+ Th1 cells, but this difference was not significant (Fig. 2.2c). Taken
together these data support that Ndfip1 regulates both Th1 and Th17 cell numbers
via limiting T cell activation. However, these data also support that Ndfip1 imposes
additional restrictions that selectively limit Th17 cell abundance.
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FIGURE 2.2 Ndfip1 limits the abundance of activated Th17 cells.
(a) Flow cytometric analysis of CD3+ CD4+ T cells among cells isolated from lungs of wild type (WT),
Ndfip1 knockout (KO), or Ndfip1fl/fl CD4-Cre (cKO) animals. Percentages of CD44+ CD4+ cells that
are IL-17A+ (b) or IFNγ+ (c) in a pooled cohort. n=8-11 animals per genotype, analyzed at 7-9 weeks
of age in 7 independent experiments using one-way ANOVA and Holm-Sidak's multiple comparisons
test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. All error bars represent mean ± SEM.

Ndfip1-deficient CD4+ T cells secrete excess IL-425,117,177 and this can impact
the differentiation of alternate cell fates or affect the activation state of T cells. For
Th17

cells,

IL-4

has

been

shown

to

both

promote

or

inhibit

their

differentiation68,174,176,178. To determine whether IL-4 was responsible for the
increased Th17 cell frequencies in Ndfip1-deficient animals, we analyzed Th17 cells
in mice that lack both IL-4 and Ndfip1 (Ndfip1 IL-4 DKO animals). In the IL-4KO
controls, as in WT animals, there were very few (<1%) Th17 cells in the lungs at
steady state. However, in Ndfip1 IL-4 DKO animals, we observed increased
frequencies of Th17 cells (Fig. 2.3a,b) as well as IFNγ+ CD4 cells (Fig. 2.3c).
Consistent with our prior findings, when only CD44+ CD4+ T cells were considered,
DKO T cells were more likely to produce IL-17A (Fig. 2.3d), but there was no
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difference in the percentage of cells that made IFNγ+ (Fig. 2.3e). This indicated that
Ndfip1 limits Th17 cell numbers via an IL-4 independent mechanism.
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FIGURE 2.3 Ndfip1 limits the abundance of Th17 cells, independent of IL-4.
Flow cytometric analysis of CD3+ CD4+ T cells from lungs of Ndfip1-/- IL-4-/- (DKO) mice or IL-4-/(IL-4KO) controls, showing representative (a) or combined (b-e) data from multiple experiments.
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Ndfip1 restriction of Th17 cell numbers could be intrinsic, due to the loss of Ndfip1
within Th17 cells, or extrinsic, due to factors produced by Ndfip1-deficient T cells
that drive in vivo Th17 generation. To distinguish between these two possibilities,
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likely to be IL-17A+ (Fig. 2.4a) and IFNγ+ (Fig. 2.4b), and while activation could not
account for the increased Th17 cells (Fig. 2.4c), it explained the increased IFNγ+
cells (Fig. 2.4d). Taken together, these data support that Ndfip1 limits the numbers
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of Th17 cells in a T cell intrinsic manner via a mechanism that is not shared between
Th1 and Th17 cells, and is independent of IL-4 mediated inflammation.
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FIGURE 2.4 Ndfip1 regulates Th17 cell abundance via a cell-intrinsic mechanism.
Flow cytometric analysis of CD3+ CD4+ T cells from lungs of CD45.1 IL-4-/- (IL-4KO) and CD45.2
Ndfip1-/- IL-4-/- (DKO) mixed chimeras. (a-d) Percentages of lung IL-17A+ (a) or IFNγ+ (b) producing
cells of CD45.2 DKO or CD45.1 IL-4KO origin. (c-d) Percentages of IL-17A+ (c) or IFNγ+ (d) cells
among CD44+ T cells of CD45.2 DKO or CD45.1 IL-4KO origin. n=13 mixed chimera animals at 7-8
weeks old in 2 independent experiments using a paired t test.*p<0.05, **p<0.01, ***p<0.001,
****p<0.0001. All error bars represent mean ± SEM.

Ndfip1 does not limit the differentiation of Th17 cells in vitro
The increased numbers of Th17 cells in Ndfip1-deficient animals could
reflect an increase in the ability of naïve CD4 T cells to differentiate into Th17 cells
or an expansion of existing Th17 cells, or both. Thus, we examined Th17
differentiation in vitro. Again, to eliminate the confounding presence of IL-4, we
used Ndfip1 IL-4 DKO or IL-4KO CD4+ T cells. When we differentiated Th17 cells
using TGF-β, IL-6, IL-1β and IL-23, Ndfip1 IL-4 DKO cells were just as likely as
controls cells to become IL17A+ cells (Fig. 2.5a). We then tested different mixtures
of cytokines and found the same result (Fig. 2.5b). Next, to determine whether
Ndfip1-deficient CD4 T cells were more likely than controls to become IL-17A+ cells
when stimulated with a particular strength of TCR signal, we tested altered peptide
ligands with B3K TCR transgenic (B3K-Tg+) T cells179. In this model, B3K-Tg+
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animals contain CD4 T cells with a fixed T cell receptor that recognizes the foreign
peptide, 3K, in the context of I-Ab (MHC II). By creating amino acid substitutions of
the 3K peptide, altered peptides have been generated which have low, medium or
high T cell activation potency180. We generated Ndfip1+/+ (WT) or Ndfip1-/- B3K-Tg+
animals on a RAG1-/- background, and used a low potency (p-1K), medium potency
(p-1A) or high potency (p3K) peptides to stimulate the cells. We found that
increasing peptide potency drove higher in vitro Th17 generation (Fig. 2.6a,b).
However, Ndfip1-/- and WT CD4 T cells were equally likely to become Th17s.
Therefore Ndfip1 does not restrict in vitro Th17 differentiation.

b

Ndfip1 IL-4 DKO

<1

<1

<1

33.6

35.6

40

%CD4+ T cells

IL-4 KO
<1

IFNγ

a

20
10

0
TGFβ
IL-6
IL-1β
IL-23

IL-17A

IL-4KO
DKO

30

―

+

+

+

+

―
―
―

+
―
―

+
+
―

+
―
+

+
+
+

FIGURE 2.5 Ndfip1 does not limit the differentiation of Th17 cells in vitro.

Naïve sorted CD4+ T cells from IL-4 KO or Ndfip1 IL-4 DKO animals were cultured under
various Th17-polarizing conditions for 5 days as noted. (a) Representative Th17
differentiation using IL-1β, IL-23, TGFβ, and IL-6. (b) Average percentages of Th17 cells
generated with different combinations of TGFβ, IL-6, IL-1β and IL-23. n=5 animals per
group in at least three independent experiments, and statistical significance was tested
using a using 2-way ANOVA. All error bars represent mean ± SEM.
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Ndfip1-deficient Th17 cells are more proliferative and accumulate in vivo
To understand why Ndfip1–deficient Th17 cells numbers were elevated in
vivo, we returned to the mixed bone marrow chimera model to test Ndfip1sufficient (CD45.1+) and -deficient (CD45.2+) Th17 cells that develop in the same
cytokine environment. After reconstitution, we treated mice with 5-bromo-2'deoxyuridine (BrdU) to assess cell cycle. Following treatment, cells were isolated
from the lungs of mice and analyzed by flow cytometry. Consistent with published
data153, we found that CD4 T cells that lack Ndfip1 were more likely than control
cells to undergo proliferation in vivo (Fig. 2.7a,c). BrdU+ Ndfip1-sufficient cells in
the lung were not more likely to be Th17 cells (Fig. 2.7a-b), but BrdU+ Ndfip136

deficient cells were more likely to be Th17 cells (Fig. 2.7c-d). These data support
that cells lacking Ndfip1 are highly proliferative and that Ndfip1-deficient cells are
more likely to produce IL-17A compared to Ndfip1-sufficient cells. Furthermore,
Ndfip1-deficient T cells are more likely to make IL-17A than IFNγ.
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FIGURE 2.7 Ndfip1-deficient Th17 cells have intrinsic in vivo fitness.
CD45.2 Ndfip1 IL-4 DKO and CD45.1 IL-4KO bone marrow was injected into RAG1-/- animals and
BrdU was administered 3 days prior to harvest. BrdU+ CD4+ cells in the lungs were examined by flow
cytometry. (a) A representative plot showing the percentages of CD45.1 IL-4KO BrdU+ T cells in the
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cells from multiple mice. (c-d) Same as in a and b but showing percentages for CD45.2 DKO BrdU+
cells in the lung. n=12 mixed chimera animals in 2 independent experiments. Statistical significance
was calculated by paired two-tailed T tests. *p<0.05, **p<0.01,****p<0.0001. Error bars represent
mean ± SEM. Note: data in Fig. 2.7b does not reach significance. I mistakenly placed an error bar
in the printed journal article version of this data!

We next used a mixed T cell-transfer model to test the capacity of Ndfip1-sufficient
and -deficient Th17 cells to accumulate in a setting in which T cells of both
genotypes were similarly activated. To assess this, congenically marked CD45.1
Ndfip1-sufficient and CD45.2 Ndfip1-deficient T cells (both sets of cells also lack IL4 to eliminate any confounding effects of IL-4-driven inflammation) were
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transferred into RAG1-/- recipient mice. Since IL-17A and IFNγ are the predominant
cytokines expressed by T cells in this system, we could examine how the loss of
Ndfip1 impacts the numbers of CD4 T cells that express these cytokines.
Importantly, this was a system in which even control cells would generate a
measurable population of Th17 cells so that we could better compare Ndfip1sufficient and Ndfip1-deficient Th17s in the same environment. Naïve sorted
Ndfip1-sufficient (CD45.1) and -deficient (CD45.2) CD4+ cells were mixed at a 1:1
ratio and injected into RAG1-/- animals and 7 weeks after transfer, animals were
analyzed. Ndfip1-deficient T cells (CD45.2+) outcompeted their Ndfip1-sufficient
counterparts (CD45.1+) in the lungs (Fig. 2.8a,b). Furthermore, if we gated
specifically on Th17 cells, we found they were much more likely to be Ndfip1deficient (Fig. 2.8c,d) and this was true even after normalization for the differences
in CD4 cell frequency (Fig. 2.8e). IFNγ+ cells were less likely to be Ndfip1-deficient if
frequencies were normalized in this manner (Fig. 2.8f). Thus, Ndfip1-deficient Th17
cells are able to outnumber control cells when generated in the same setting in vivo.
We also performed similar transfers but instead placed Ndfip1-deficient and control
T cells (both were IL-4-deficient to eliminate any effect of IL-4-mediated
inflammation on Th17 cell generation in vivo) into separate RAG1-/- recipients.
Animals that received Ndfip1-deficient cells lost much more of their initial body
weight than those that received control cells (Fig. 2.9a). Furthermore, recipient
animals that received T cells lacking Ndfip1 showed a higher spleen weight to body
weight ratio, (Fig. 2.9b), increased lung cellularity, and had significantly higher
percentages and numbers of Th17 cells in their lungs (Fig. 2.9c). These data are
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consistent with the hypothesis that Ndfip1 deficient Th17 cells accumulate and
drive more pathology in vivo.
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Ndfip1 limits secretion of IL-17A upon restimulation of Th17 cells
Given that Th17 cells lacking Ndfip1 were able to accumulate in vivo, and
their heightened frequency correlated with increased pathology, we hypothesized
that Ndfip1-deficient Th17 cells could be potent producers of proinflammatory
cytokines. Limiting cytokine secretion from effector Th17 cells and controlling the
formation of memory Th17 cells helps to ensure long-term defense against
extracellular pathogens181,182. To begin to determine whether Ndifp1 regulates
proinflammatory cytokine production in Th17 cells, we first tested when Ndfip1
was expressed in Th17 cells after TCR stimulation. We generated Th17 cells in vitro,
expanded them in IL-2, and then restimulated them on plate-bound anti-CD3 and
anti-CD28 for various time points, and analyzed Ndfip1 expression by qPCR. Cells
lacking IL-4 were used since Ndfip1-deficient T cells secrete high levels of IL-4
which inhibit in vitro Th17 differentiation68. We found that Ndfip1 levels increased
over the first 6 hours, and then returned close to base line levels by 24 hours (Fig.
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2.10a). These data suggested that Ndfip1 might be particularly functional between 4
and 24 hours after restimulation. To prepare for testing Th17 producing cytokines,
we first wanted to ensure that Ndfip1-deficient and control cells had similar
numbers of Th17 cells following IL-2 expansion. Thus, we tested the cells directly
following differentiation and after expansion for percentages of cells expressing IL17A and IFNγ. We found, as in prior experiments, that cells lacking Ndfip1 and
control CD4 T cells were equally likely to differentiate into Th17 cells that expressed
IL-17A but not IFNγ (Fig. 2.10b-c). As has been reported183, we noticed a slight
decrease in the percentage of IL-17A+ cells in culture after three days of IL-2
expansion (Fig. 2.10d-e). Nevertheless, the decrease in frequency of IL-17A+ cells
was quite similar in both Ndfip1-deficient and Ndfip1-sufficient IL-4 KO cells T cells
and thus an equal number of these cells were placed on an anti-CD3 and anti-CD28 coated plate for restimulation. We then examined the secretion of IL-17A and other
proinflammatory cytokines that can be made by Th17 cells. By 6hrs post
stimulation, Th17-polarized cells lacking Ndfip1 had already begun to secrete more
IL-17A into culture, compared to their Ndfip1-sufficient counterparts (Fig. 2.10f)
and by 24 hours the IL-17A in the Ndfip1-deficient Th17 culture supernatant was
significantly higher than in cultures of control cells. Importantly, this time point
correlated with the peak of Ndfip1 expression in control cells. Furthermore, when
the supernatant was assayed to detect other Th17-related cytokines, we found that
the Ndfip1 IL-4 DKO Th17s secreted more IFNγ (Fig. 2.10g) and GM-CSF (Fig.
2.10h) than their Ndfip1-expressing control counterpart cells. These data indicate
that

Ndfip1-deficient

Th17

cells

are
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polyfunctional

and

secrete

more

proinflammatory cytokines. Another interpretation of the data, could be that there
were more IFNγ+ Th1 cells in the Ndfip1-deficient cultures prior to stimulation,
however the plots in Fig. 2.5a do not support this conclusion and when the same
experiment was performed using Th1 polarizing conditions, we found that Ndfip1deficient Th1 cells secrete less IFNγ than controls upon restimulation (Fig. 2.10i-j).
Thus, we conclude that Ndfip1 limits the secretion of proinflammatory cytokines
from Th17 cells upon re-encounter with TCR stimulus.
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FIGURE 2.10 Ndfip1 limits proinflammatory cytokine production from Th17 cells upon
restimulation.
(a) Ndfip1 mRNA expression, relative to beta actin, in restimulated Th17 cells over multiple time
points indicated. (b) Representative plot showing IL-17A+ and IFNγ+ cells after the initial 5 days of
Th17 polarization. (c) Summary data for (b) over multiple experiments. (d) Representative plot
showing IL-17A+ or IFNγ+ Th17 cells after IL-2 expansion of cells haven in panels b and c. (e)
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Summary of data over multiple experiments. Cytokines were analyzed by ELISA, following
restimulation of the Th17 cells (f-h) or of Th1 cells (i-j). (f) IL-17A (g) IFNγ and (h) GM-CSF. (i)
Representative plot showing Tbet+ IFNγ+ Th1 cells after Th1 polarization and subsequent IL-2
expansion of IL-4-/- or Ndfip1 IL-4 DKO CD4+ T cells. (j) Summary of IFNγ ELISAs from plated Th1
cells. In a-h, n=8 per genotype analyzed in 4 independent experiments. In i-j, data is pooled for n=2
Ndfip1 IL-4 DKO and n=3 IL-4-/- animals. Significance was calculated by unpaired T tests for panels c
and e and by 2-way ANOVA for panels f-j. *p<0.05 ,***p<0.001. All error bars represent mean ± SEM.

Ndfip1 mediates ubiquitylation and degradation of RORγT
RORγT is the lineage-defining transcription factor for Th17 cells66 and has
been shown to drive the production of cytokines such as IL-17A66 and GM-CSF79,80.
Since Ndfip1-deficient Th17 cells produce higher amounts of IL-17A and GM-CSF
upon restimulation, we hypothesized that Ndfip1-deficient cells might fail to
degrade RORγT. Supporting this, it was recently shown that Itch ubiquitylates and
degrades RORγT173. Given that Ndfip1 can help to activate Itch in T cells25, we tested
whether in the absence of Ndfip1, RORγT fails to be degraded. We generated Th17
cells from Ndfip1 IL-4 DKO, and IL-4 KO control cells. We then restimulated these
cells for 0.5 hours or 4 hours (Fig. 2.11a) and analyzed lysates for levels of RORγT.
We found that Ndfip1-sufficient Th17 cells decreased their levels of RORγT between
0.5 hours and 4 hours. In contrast, Th17 cells lacking Ndfip1 maintained RORγT
protein levels after stimulation. To investigate whether the decrease seen in Ndfip1sufficient Th17 cells was due to RORγT protein degradation, we stimulated the Th17
cells in the presence of cycloheximide (Fig. 2.11b). Indeed, IL-4KO Th17 cells had a
significant loss of RORγT protein levels after 4 hours of stimulation in the presence
of cycloheximide, in contrast, Ndfip1 IL-4 DKO Th17 cells maintained their RORγT
levels (Fig. 2.11c). Taken together, these data support that Ndfip1 is important for
normal RORγT protein degradation after TCR stimulation.
43

a

IL-4KO
0.5hr
4hr

Ndfip1 DKO
0.5hr
4hr

36kDa

αCD3/αCD28 (TCR) + CHX
IL-4KO
0.5hr
4hr

RORγT

68kDa

Ndfip1 DKO
0.5hr
4hr
RORγT

GAPDH

GAPDH

RORγT protein
Protein at 4hrs
relatvive to 0.5hrs

c

b

αCD3/αCD28 (TCR)

2.0
1.5
1.0
0.5
0.0

IL-4KO DKO IL-4KO DKO
TCR
TCR + CHX

FIGURE 2.11 Ndfip1 promotes RORγT degradation.
Naïve CD4+ T cells were differentiated into Th17 cells and then restimulated with αCD3/CD28 (TCR)
for 0.5hrs or for 4hrs in the absence (a) or presence (b) of cycloheximide (CHX). Lysates were
analyzed for RORγT and GAPDH levels using western blot. (c) Quantification over multiple
experiments of RORγT levels relative to GAPDH loading control. n=4 per genotype in 3 independent
experiments. All error bars represent mean ± SEM.

Itch E3 ligase is required for restricting Th17 cell abundance in vivo
Ndfip1 is a well-known activator of the E3 ligase, Itch, and related Nedd-4
family E3 ubiquitin ligases. Loss of Itch results in a spontaneous, auto-inflammatory,
Th2-predominant disease, similar to that seen in Ndfip1-deficient animals26, albeit
with a delayed onset. Recently it was shown that mice lacking Itch have colitogenic
Th17 cells which secrete can accelerate the development of colon cancer173. To
investigate whether Itch, like Ndfip1, is required for the regulation of Th17 cell
numbers and cytokine production, we generated Itch IL-4 DKO animals and
examined Th17 cells in their lungs. We found that, similar to mice lacking both
Ndfip1 and IL-4, the absence of Itch and IL-4 led to an increase in Th17 cells and
IFNγ+ cells (Fig. 2.12a-c). Furthermore, Itch IL-4 DKO CD4+T cells were more likely
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to be activated (Fig. 2.12d) and while this increase in activated cells could explain
the increase in IFNγ+ CD4+ T cells (Fig. 2.12f), it failed to explain the increase in
Th17 cells in these animals (Fig. 2.12e). Additionally, as was seen with the CD4+ T
cells lacking Ndfip1, there was no increased propensity towards in vitro Th17
differentiation in Itch-deficient CD4 T cells (Fig. 2.13a,b). However upon restimulation, Itch-deficient Th17 cells were more likely to secrete significantly higher
amounts of IL-17A, IFNγ, and GM-CSF (Fig. 2.13c-e). These data support that Ndfip1
and Itch limit Th17 cell numbers and proinflammatory cytokine secretion and this is
independent of the established roles for Ndfip1 and Itch in limiting IL-4 production
from T cells and in limiting T cell activation.
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FIGURE 2.13 Itch E3 ligase restricts proinflammatory cytokine production from Th17 cells.
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Ndfip1-deficient Th17 cells recruit more neutrophils and drive severe
mucosal barrier destruction
Secretion of proinflammatory cytokines from Th17 cells is one way Th17
cells exert pathogenic functions in vivo. These cytokines act on non-hematopoietic
cells such as stromal cells, leading to their secretion of proteins, including
chemokines, which recruit other immune cells to sites of inflammation. Additionally,
Th17 cell cytokines can directly recruit neutrophils. Uncontrolled recruitment of
immune cells to the site of inflammation increases the likelihood of
immunopathology. Mice that constitutively lack Ndfip1 develop inflammation in the
small bowel and colon by 6 weeks of age, characterized by increased frequencies of
eosinophils, likely as a consequence of Th2-inflammation154, and neutrophils. This
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inflammation was not seen when these mice are bred onto a RAG-/- background and
therefore lack B and T cells154. We examined the colons in unmanipulated mice
lacking Ndfip1 only in their T cells (cKO) or control animals at 10 weeks of age. We
observed spontaneous disruption of the mucosal layer of the colon epithelium in the
cKO animals (Fig. 2.14a). Furthermore, colons from cKO mice showed a trend
towards, but no significant, decrease in colon length (Fig. 2.14b) but higher
frequencies of neutrophils (Fig. 2.14c). However, since the cKO mice are potent IL-4
producers, and IL-4 mediated inflammation can also lead to colon inflammation, it
was not clear whether the increased neutrophils in the colons of these
unmanipulated mice was driven by an increase in Th17 cells in these mice.
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FIGURE 2.14 Loss of Ndfip1 in T cells drives a spontaneous colitis in mice.
(a) Colon histology of ten week old Ndfip1 fl/fl CD4 Cre+ (cKO) or WT (Ndfip1 fl/fl Cre- or Ndfip1
fl/+ Cre-) animals showing evidence of spontaneous colon inflammation in cKO animals. Bars
represent 100um and inset shows enlarged version of the boxed section of the image. (b) Ndfip1 fl/fl
CD4 Cre+ (cKO) and WT animals do not show differences in colon length. (c) Flow cytometry data
indicating a trend towards increased CD11b+ CD11c- Ly6G+ neutrophils in the colons of Ndfip1 fl/fl
CD4 Cre+ (cKO) versus WT animals. Data is shown for an n= 3 Ndfip1 fl/fl CD4 Cre + and n=3 WT
(Ndfip1 fl/fl Cre- or Ndfip1 fl/+ Cre-) animals at ten weeks old. All error bars represent mean ± SEM.
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Thus,

we

sought

to

test

whether

the

increased

production

of

proinflammatory cytokines by Th17 cells lacking Ndfip1 would drive increased
pathology in an environment free of IL-4, in order to focus only on the role of Ndfip1
in Th17 cells and to exclude IL-4-mediated effects. To do this, we generated Ndfip1-/IL-4-/- IL-17A-GFP mice, and IL-4-/- IL-17A-GFP controls, which lack both Ndfip1 and
IL-4 and harbor a fluorescent GFP-reporter that identifies, and thus allows
purification of, Th17 cells. We then differentiated CD4+ T cells under Th17
polarizing conditions, as detailed above, sorted IL-17A-GFP+ (Th17) cells, and
injected them into RAG1-/- recipients or analyzed them by qPCR for mRNA
expression. We found that Ndfip1-deficient Th17 cells have higher expression of
ccl5 and csf2 (which encodes GM-CSF) (Fig. 2.15a, left and middle panels), factors
associated with Th17 cell pathogenicity77. We also analyzed rorc (which encodes
RORγT), which was not different between Ndfip1-sufficient and –deficient Th17
cells (Fig. 2.15a, right panel), supporting that increased RORγT in Ndfip1-deficient
cells is not due to increased transcription. Since previous data, indicating that
Ndfip1-deficient Th17 cells produce more IL-17A, GM-CSF and IFNγ upon
restimulation was generated using Th17 cells that had been expanded in IL-2 for 3
days, we wanted to verify that expansion in IL-2 does not significantly alter the
characteristics of the Ndfip1-deficient Th17 cells. Therefore we obtained additional
mRNA expression data from Th17 cells generated as before but additionally
expanded in IL-2 for 3 days. After IL-2 expansion, Ndfip1-deficient Th17 cells
similarly showed higher expression of Csf2 and Ccl5 (Fig. 2.15b) and furthermore,
showed higher expression of the Th17-related cytokines Ifng and Tnfa but not Il21
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(Fig. 2.15c) compared to Ndfip1-sufficient Th17 cells. The gene expression levels
for transcription factors such as Rorc, Tbx21 (which encodes T-bet) and Blimp1,
which have all been associated with Th17 cell pathogenicity, were not different
between Ndfip1-sufficient and –deficient Th17 cells (Fig. 2.15d). Therefore Ndfip1deficient Th17 cells have a gene expression profile associated with pathogenicity
and this is not altered by exposure to IL-2.
We then assessed the function of these cells in vivo. By approximately 6
weeks after transfer of purified Th17 cells, mice that received Ndfip1-deficient Th17
cells had lost significantly more body weight than their Ndfip1-sufficient controls
(Fig. 2.16a). Additionally, colon histology revealed that recipients of Ndfip1deficient Th17 cells had higher incidence of transmural inflammation and erosion of
normal mucosal structure (Fig. 2.16b). Strikingly, in all recipient mice, less than
20% of all CD4 T cells recovered from the colons, whether expressing or lacking
Ndfip1, were still IL-17A+, indicating the remarkable instability of the Th17 cells in
this model (Fig. 2.16, c and d). However, mice which received Ndfip1-deficient
Th17 cells had a higher frequency of IL-17A+ cells in the colon, suggesting that
Ndfip1 limits Th17 stability (Fig. 2.16c-d). Considering our prior results, we also
tested other cytokines produced by Th17 cells including: TNFα, IFNγ, GM-CSF and
IL-10. We found that Ndfip1-deficient CD4 cells in the colon were not only more
likely to be making exclusively IL-17A, but we also found more Ndfip1-deficient IL17A+ cells that were simultaneously making TNFα, TNFα with IFNγ, or GM-CSF with
IFNγ (Fig. 2.16e). Given the well-described role of TNFα and IL-17A in driving
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neutrophil recruitment to sites of inflammation184–189, we examined the numbers of
neutrophils in the colons of the mice that received Ndfip1-deficient or –sufficient
Th17 cells. We found that recipients of Ndfip1-deficient Th17 cells had significantly
higher numbers of neutrophils (Fig. 2.16f). This was not true for other innate cells
examined such as eosinophils, dendritic cells, or monocytes (Fig. 2.16f). Thus,
Ndfip1 limits production of proinflammatory cytokines such as IL-17A, IFNγ, and
TNFα; Th17 stability; and Th17-mediated pathology.
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FIGURE 2.15 Th17 cells lacking Ndfip1 have a gene expression profile associated with
pathogenicity.
CD4+ naïve cells from IL-4 KO or DKO T cells from IL-17A GFP reporter mice were differentiated into
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subjected to qPCR analysis. n=4 mice per genotype in 2 independent differentiation experiments. All
error bars represent mean ± SEM.
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Discussion
Ndfip1 and Itch are known to limit the activation of T cells, as well as to
control the differentiation of specific lineages of T cells, namely Th2 cells and
peripherally-generated Foxp3+ regulatory T cells (iTreg cells)25,26,117. Less is known
about whether and how these proteins impact the fate or function of T cells that
have already committed to a cytokine-producing effector cell lineage. Here, we show
that Ndfip1 and Itch play an important role in Th17 cells after differentiation.
Specifically, our data reveal a new role for these proteins in limiting the abundance
and pathogenicity of Th17 cells and show that Ndfip1 and Itch regulate the effector
responses of Th17 cells following lineage specification.
This study focused predominantly on Ndfip1, an activator of Itch catalytic
activity25,50,177,190. The loss of Ndfip1 globally, or following conditional deletion in T
cells, causes spontaneous autoinflammatory disease that is associated with high
numbers of activated CD4 T cells, increased numbers of Th1, Th2, and Th17 cells,
and premature death25,68,117,153. Prior studies have detailed how Ndfip1 limits Th2
cell numbers and how the production of IL-4 can drive much of the pathological
sequela68,117. In this study, we made use of Ndfip1 IL-4 DKO animals to show that
while IL-4 over-production by Ndfip1-deficient T cells may influence the generation
of Th17 cells in vivo according to previous reports68, Ndfip1 has a previously
unrecognized cell-intrinsic role in the regulation of already-differentiated Th17
cells. Furthermore, this study also reveals, for the first time, that Ndfip1 limits the
numbers of Th1 and Th17 cells by two distinct mechanisms. We show that Ndfip1
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restricts T cell activation to limit the numbers of Th1 cells. In contrast, Ndfip1 limits
Th17 cell abundance by limiting T cell activation as well as by dampening Th17 cell
proliferation and working together with Itch to degrade RORγT.
ROR family members include RORα, RORβ and RORγ. RORγT (Retinoic Acid
Receptor Related Orphan Receptor gamma T isoform) is an isoform of RORγ that
was initially found to be expressed in the thymus191 but has now been shown to be
expressed in mature αβT cells, γδT cells as well as CD4- lamina propria cells66. Both
RORα and RORγT are important for Th17 development; mice that lack both of these
factors are entirely devoid of Th17 cells67. As a nuclear receptor, RORγT has five
important regions: a variable A-B domain or N-terminal regulatory domain; a very
conserved C domain or DNA-binding domain; a D domain or hinge region, an E
domain or Ligand-binding domain; and an F domain or C-terminal domain192. Both
RORα and RORγT respond to endogenous ligands such as cholesterols and
oxysterols, which bind to the E or ligand-binding domain and affect the
transcriptional activities of these nuclear receptors.
In Th17 cells lacking Ndfip1, RORγT levels accumulate and the Th17 cells
become polyfunctional, producing several proinflammatory cytokines and
chemokines simultaneously. Some of these factors are known to be transcriptional
targets of RORγT, namely GM-CSF, CCL5 (a.k.a. RANTES) and IL-17A, while others,
IFNγ and TNFα, are not66,79,193. Thus, it remains unclear whether the increase in
RORγT is sufficient to explain the full pathogenic potential of Th17 cells that lack
Ndfip1, or whether there remain other substrates of Ndfip1/Itch yet to be identified.
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We propose that Ndfip1 helps to degrade RORγT and thus limits the production of
CCL5, GM-CSF and IL-17A by Th17 cells.
IFNγ production by Th17 cells is mechanistically distinct from its production
by Th1 cells. In Th17 cells, IFNγ synthesis does not depend on Tbet, STAT1 or
STAT4194, and instead is linked to IL-23R signaling and the transcription factor
Blimp1194. Ndfip1-deficient Th17 cells do not show increased levels of IL-23R mRNA
compared to WT cells, however we have not explored IL23R protein levels or
protein levels of Blimp1. Blimp1 can also increase the production of IFNγ, GM-CSF,
and IL-17A from Th17 cells65,169. Interestingly, Blimp1, like RORγT, contains an L-PX-Y motif that would allow binding to the WW domains on Itch. Thus, future studies
should determine whether, like RORγT, Blimp1 is a substrate of Itch/Ndfip1.
Ndfip1-deficient Th17 cells concurrently produce TNFα, IFNγ, and IL-17A in
vivo. TNFα, also called cachexin, is an important mediator of systemic inflammation.
Mechanistically, TNFα may suppress appetite, or may act synergistically with IFNγ
to target the degradation of myosin heavy chains leading to muscle wasting195. Thus
concurrent production of TNFα and IFNγ by Ndfip1-deficient Th17 cells, coupled
with the observed destruction of the colon mucosa, may explain the severe weight
loss seen in the colitis model. Like IFNγ, TNFα production is unlikely to be driven by
RORγT since TNFα expression in Th17 cells increases upon loss of RORγT193. How
Ndfip1 regulates TNFα production is unknown and remains to be explored.
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Recently published work found that Itch ubiquitylates RORγT, targeting it for
degradation and helping to limit the abundance of Th17 cells in the colon173. We
found that Ndfip1 also controls RORγT levels. Furthermore, our data revealed that
Ndfip1 and Itch do not merely limit Th17 abundance at mucosal sites, but also limit
the pathogenic potential of these cells by restricting the amount of RORγT and,
consequently, the production of proinflammatory cytokines that Th17 cells secrete.
We find that in the absence of Ndfip1 or Itch, Th17 cells are polyfunctional and
secrete increased amounts of IL-17A, IFNγ, GM-CSF and TNFα. Of these cytokines,
increased amounts of IL-17A and TNFα are known to promote colorectal cancer
while the role of GM-CSF in colorectal cancer remains unclear196,197. Our data
suggests that the observed remarkable susceptibility of Itch-deficient mice to colitis
and colorectal cancer173 is not only because of the quantity of Th17 cells found in
the colon, but also because of the pathogenic polyfunctional quality of these Th17
cells.
We found that the loss of Ndfip1 or Itch does not lead to increased
differentiation of Th17 cells. Thus, Ndfip1 and Itch are primarily regulating RORγT
levels after the cells have increased RORγT and committed to the Th17 lineage.
Interestingly, while both Ndfip1 and Itch promote RORγT degradation, Th17 cells
lacking Itch produce higher levels of IL-17A, IFNγ and GM-CSF than Ndfip1-deficient
cells. This suggests that while Itch may require Ndfip1 for its activation in Th17
cells, it may also rely on other mechanisms of activation. We recently found that
Ndfip2 has similar functions to Ndfip1 and can also activate Itch and related E3
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ubiquitin ligases in CD4 T cells177. It remains to be seen whether Ndfip2 may also
work with Itch to limit Th17 cell proinflammatory cytokine production.
This work may have relevance in the development or treatment of diseases
such as asthma. A sub-set of patients with asthma do not respond to steroids or
other standard treatments and these patients are much more likely to have
neutrophilic accumulation in the airways198,199. Emerging data suggests that
neutralization of either Th2 cytokines alone or of Th17 cytokines alone in asthma
may worsen disease, resulting in increased inflammation in the airways200.
However, neutralization of both Th2 and Th17 cytokines ameliorate neutrophilia,
eosinophilia, and overall airway inflammation200. Our data reveals Ndfip1 as a key
regulator of both Th2- and Th17-cell functions, albeit via separate mechanisms.
Therapeutics designed to mimic Ndfip1, and activate Itch, would be predicted to
have high efficacy in treating asthma while having a minimal effect on anti-viral
immune responses, for example. Such therapies will be the focus of future studies.
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Chapter 3: Ndfip1 restricts mTORC1 signalling and glycolysis in
regulatory T cells to prevent autoinflammatory disease.3
Abstract
Foxp3+ T regulatory (Treg) cells suppress immune cell activation and
establish normal immune homeostasis. How Treg cells maintain their identity is not
completely understood. Here we show that Ndfip1, a co-activator of Nedd4-family
E3 ubiquitin ligases, is required for Treg cell stability and function. Ndfip1 deletion
in Treg cells results in autoinflammatory disease. Ndfip1-deficient Treg cells are
highly proliferative and are more likely to lose Foxp3 expression to become IL-4producing Th2 effector cells. Proteomic analyses indicate altered metabolic
signature of Ndfip1-deficient Treg cells and metabolic profiling reveals elevated
glycolysis and increased mTORC1 signalling. Ndfip1 restricts Treg cell metabolism
and IL-4 production via distinct mechanisms, as IL-4 deficiency does not prevent
hyper-proliferation or elevated mTORC1 signalling in Ndfip1-deficient Treg cells.
Thus, Ndfip1 preserves Treg lineage stability and immune homeostasis by
preventing the expansion of highly proliferative and metabolically active Treg cells,
and by preventing pathologic secretion of IL-4 from Treg cells.

3 This work is currently accepted and in press at Nature Communications with the following authors

and title: Layman, Awo Akosua Kesewa; Deng, Guoping; O’Leary, Claire E.; Tadros, Samuel; Thomas
Rajan; Dybas, Joe; Moser, Emily; Wells, Andrew; Doliba, Nicolai and Oliver, PM. Ndfip1 restricts
mTORC1 signalling and glycolysis in regulatory T cells to prevent autoinflammatory disease.

57

Introduction
Foxp3+ Regulatory T (Treg) cells are required to prevent spontaneous
immune cell activation and limit effector cell function, thereby preventing
autoimmune and inflammatory disorders105,201. While generally stable, Treg lineage
cells can show a high degree of instability in inflammatory settings. Treg cell
instability is characterized by one or more key features: loss of suppressive function,
loss of Foxp3 protein, or gain of pro-inflammatory cytokine production202.
Identifying pathways that promote Treg cell suppressive function, prevent Treg cell
production of pro-inflammatory cytokine, and/or maintain Treg cell numbers will
aid in the development of new Treg cell-based therapeutic applications.
Cellular energetics and metabolic regulation play a central role in Treg cell
function and lineage stability203. Unlike effector T cells, which rely heavily on
glycolysis, Treg cells rely on fatty acid oxidation for their energy needs204. mTOR
(mechanistic target of rapamycin) is a serine-threonine kinase, which forms part of
the mTORC1 and mTORC2 protein complexes, and is a critical regulator of cellular
metabolic processes. Both complexes have the potential to limit glycolysis in Treg
cells and thus help to maintain lineage stability and suppressive functions205,206.
While metabolic state is clearly important for Treg maintenance and function, many
factors that impact Treg cell metabolism remain unknown.
Ubiquitylation is a fundamental post-translational modification affecting
many aspects of T cell differentiation and function33,172. Nedd4 family interacting
protein 1 (Ndfip1) is a trans-membrane protein, which binds and activates Nedd4
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family E3 ubiquitin ligases148. These highly conserved catalytic E3 ligases perform
two functions in protein ubiquitylation: binding to the specific ubiquitylation target
and catalyzing the final transfer of ubiquitin. Ndfip1 activation of the Nedd4 E3
ligase Itch results in ubiquitylation and degradation of the transcription factor JunB,
thereby limiting IL-4 cytokine production from T helper type 2 (Th2) cells and Th2mediated inflammatory disease25,26.
Ndfip1-deficient mice have decreased Treg cell numbers in the small bowel, a
site of peripheral Treg generation, likely due to increased IL-4 signaling which is
inhibitory to Treg differentiation117. In the thymus, however, there is an increase in
Ndfip1-deficient Treg cells117. Whether Ndfip1 also modulates Treg function after
cells have committed to the Treg cell lineage, has not been explored. Given that Treg
specific deletion of Itch results in a Th2-biased autoinflammatory disease104, it
seems plausible that Ndfip1 might be required to support Itch function in Treg cells.
Here we show that Ndfip1 expression in Treg cells prevents spontaneous
inflammation at several sites such as lungs and skin. Ndfip1 limits both the
accumulation and proliferation of CD44+ effector Treg cells, and prevents Treg cell
production of IL-4. Consistent with increased proliferation and exposure to IL-4,
Treg cells lacking Ndfip1 show increased CNS2 methylation and are prone to lose
Foxp3 in vivo. Increased proliferation is associated with increased mTORC1
signaling and high glycolytic activity, programs that can fuel effector function in
Treg cells and contribute to lineage instability. Thus, Ndfip1 maintains lineage
identity in Treg cells and prevents these cells from aberrant acquisition of effector T
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cell programs. Ndfip1 is therefore a critical molecular sentinel that prevents
autoinflammatory disease.
Results
Treg-specific loss of Ndfip1 results in inflammation
Mice that constitutively lack Ndfip1 in all cells develop a severe
autoinflammatory disease by 6 weeks for age, resulting eventually in death25,154.
While thymic Treg frequencies in Ndfip1-deficient mice is not altered directly by the
loss of Ndfip1, but is increased due to inflammation117, Treg cell numbers are
reduced at sites of peripheral Treg induction117. Therefore to test the role of Ndfip1
within committed Treg cells, we generated mice in which Ndfip1 is conditionally
deleted in Treg cells using the Foxp3-Cre-YFP reporter mice207. We observed that
Ndfip1 mRNA is induced upon stimulation of control Ndfip1+/+Foxp3-Cre sorted
YFP+ Treg cells, and that Ndfip1 message is effectively ablated in Treg cells from
Ndfip1fl/fl Foxp3-Cre male mice, which lack Ndfip1 in all Treg cells (Fig. 3.1a).
By 9-16 weeks of age, Ndfip1fl/fl Foxp3-Cre male mice developed pronounced
splenomegaly, lymphadenopathy, and progressive dermatitis. Histologically, the
skin, esophagus, and lung showed marked immune infiltration inflammation (Fig
3.1b). Analysis of spleen weight to body weight ratios revealed that male Ndfip1fl/fl
Foxp3-Cre mice showed evidence of lymphoid expansion (Fig. 3.1c). To determine
which immune responses were contributing to the observed inflammation, we
examined serum immunoglobulin (Ig) levels. We found elevated levels of IgE and
IgG1, indicative of type-two inflammation, as well as elevated IgM (Fig. 3.1d). To
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determine the contribution of CD4 T cells to this pathology, we examined spleen and
lung of the mice and found increased activated phenotype (CD44+) CD4 T cells (Fig.
3.1e). CD4 T cells present in the lung of male Ndfip1fl/fl Foxp3-Cre animals were
more likely to express the effector cytokines IFNγ, IL-4 and IL-17A upon ex vivo
stimulation (Fig. 3.1f). These data suggested that Ndfip1 expression in Treg cells is
required for suppression of tissue inflammation and pathology.
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FIGURE 3.1 Mice lacking Ndfip1 in their Treg cells develop inflammatory disease.
(a) Ndfip1 expression assessed by qPCR before (-) or after (+) αCD3/CD28 stimulation of sorted
YFP+ Treg cells from WT and Ndfip1fl/fl Foxp3-Cre mice. A representative example of Ndfip1
expression relative to Actb after αCD3/CD28 stimulation is shown. (b) Representative H&E stained
histological sections of skin, esophagus and lung from genotypes as indicated are shown. Scale bars
represent 100uM. Far right image in panel is a representative image of spleen and lymph nodes to
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illustrate size. (c) Inflammation index, calculated as a spleen weight/body weight for male Ndfip1+/+
Foxp3-Cre (WT) and Ndfip1fl/fl Foxp3-Cre (cKO) mice at 9-16 weeks of age. (d) Levels of serum
antibody isotypes as quantified by ELISA. (e,f) T cells from lung homogenates were analyzed by flow
cytometry for (e) the percentages of CD44+ cells among CD4+ cells, and (f) percentages of CD4+ cells
making the indicated cytokines after ex vivo (P/I) stimulation. P values determined by student’s T
test, with correction for unequal variances as appropriate. *p<0.05 ** p<0.01 *** p<0.001
****p<0.0001. For panels (a) and (c-f), bars indicate mean ± SEM. Data in panel (a) is representative
of 4 male animals of each genotype, 9-16 weeks old, and for panels (c-f) each dot represents an
individual male mouse between 9-16 weeks old. All experiments were performed on at least two
independent occasions.

Ndfip1fl/fl Foxp3-Cre mice have more CD44+ eTreg cells
The observed pathology could result from a loss Treg cell numbers (as occurs with
mice lacking Foxp3208) or Treg cell function (as is seen in Treg-specific CTLA4
deficiency209). We therefore examined Treg percentages and numbers in the spleens
and lung of Ndfip1fl/flFoxp3-Cre and controls. Surprisingly, Treg cell numbers were
increased in Ndfip1fl/flFoxp3-Cre animals (Fig. 3.2a-c). Further, analysis of the Treg
cell effector proteins: Inducible T-Cell Co-Stimulator (ICOS), Programmed cell
Death-1 (PD-1), and Glucocorticoid-Induced TNFR-Related protein (GITR), revealed
increased expression on Treg cells from Ndfip1fl/flFoxp3-Cre male mice compared to
Cre+ controls (Fig. 3.2d). We did not see consistent changes in CD25 levels. Taken
together, these data suggest that the immunopathology observed in Ndfip1fl/flFoxp3Cre male mice is not due to decreased Treg numbers or loss of effector proteins
known to support Treg function.
Treg cells can be quiescent or activated; these two subsets can be
distinguished by expression of CD44 and CD62L210. Analysis of the lung of male
Ndfip1fl/fl Foxp3-Cre mice revealed an increase in frequency (Fig. 3.2e,f) and
numbers (Fig. 3.2g) of Foxp3+ cells with an activated or “effector” (eTreg)
phenotype (CD62LloCD44+). In contrast, Ndfip1fl/fl Foxp3-Cre and control mice
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contained equivalent numbers of cells with a quiescent or “central” (cTreg)
phenotype (CD62LhiCD44-) (Fig. 3.2g). WT eTreg cells show high expression of
ICOS, PD-1, and GITR while CD25 is higher on WT cTreg cells210. Therefore, the
observed increase in surface expression of ICOS, PD-1 and GITR observed on total
Treg cells from Ndfip1fl/flFoxp3-Cre animals could be due to an increased proportion
of eTreg cells. To assess this, we examined the surface expression of ICOS, GITR,
CD25 and PD-1 on the eTreg and cTreg populations. cTreg cells, as previously
described, had low levels of ICOS, GITR, and PD-1, and loss of Ndfip1 did not alter
this (Fig. 3.2h). However, cTreg cells from Ndfip1fl/flFoxp3-Cre mice had decreased
levels of CD25. Strikingly, in addition to their increased frequency, eTreg cells from
Ndfip1fl/flFoxp3-Cre mice showed higher levels of ICOS, GITR, CD25 and PD-1
compared to WT counterparts (Fig. 3.2h).
cTreg cells are thymically derived and undergo peripheral conversion to
eTreg cells under the instruction of TCR stimulation and ICOS stimulation210.
Therefore, observing increased frequency and number of eTreg cells could indicate
either increased conversion of cTreg cells or expansion of eTreg cells. An increased
cTreg conversion rate would be expected to decrease the numbers of cTreg cells,
unless compensated for by thymic output. As there was no decrease in the
peripheral numbers of cTreg cells in Ndfip1fl/fl Foxp3-Cre+ male mice, we next
examined thymic output utilizing mixed bone marrow chimera animals in which WT
(Ndfip1+/+ Foxp3-Cre+) and Ndfip1fl/fl Foxp3-Cre+ Treg cells develop in the same
environment to control for effects of inflammation. In control and mixed chimeras,
total Treg thymic output was unchanged (Fig. 3.3a). Furthermore, within the mixed
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chimeras there was no significant difference in the percent of thymic Treg cells
derived from Ndfip1 sufficient or deficient cells relative to the observed
reconstitution ratio of all thymic CD4+ T cells (Fig. 3.3b). Therefore the increase in
eTreg but not cTreg, cell number in the periphery is not driven by an increased rate
of cTreg conversion to eTreg cells.
Decreased suppressive function of Treg cells is known to lead to
inflammation. Therefore, we examined Treg cell function. In vitro, Ndfip1-deficient
and WT Treg cells suppressed proliferation of WT Tconv cells to the same degree
(Fig. 3.3c,d). We then examined Treg cell function in vivo using a model of T cell
transfer induced colitis. Similar to our results from the in vitro assays, Ndfip1deficient and WT Treg cells were equally able to prevent weight loss due to
inflammation caused by co-transferred Tconv cells (Fig. 3.3e). These data support
that the pathology observed in Ndfip1fl/flFoxp3-Cre mice is not due to a loss of Treg
number or an overall loss of Treg cell suppressive function.
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FIGURE 3.2 Regulatory T cells lacking Ndfip1 are more likely to be CD44+ and express other
markers of activated Treg cells.
Regulatory T cells from spleens and lung (a-c) or lung (d-h) of 9-16 week old male WT and Ndfip1fl/fl
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dot indicates data acquired from a single male mouse. Graphs with compiled data show mean ± SEM.
All experiments were performed on at least two independent occasions.
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congenic WT Treg cells or Ndfip1fl/fl Foxp3-Cre Treg cells (c) CFSE dilution of Tconv cells after 4 days
in culture (d) Quantification of the percentage of Tconv cells that diluted CFSE in culture (e) Weight
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changes during an in vivo suppression assay using CD45.1 CD4+ Tconv cells and CD45.2 WT or
Ndfip1fl/fl Foxp3-Cre Treg cells. Error bars indicate mean ± SEM. Each dot represents an individual
mouse. Male donors were used for mixed bone marrow chimeras (a-b). (c-e) represents data from at
least 3 male animals of each genotype. (e) represents one experiment. P values were determined by a
paired T test (a-b) and student’s T test (c-e) * p<0.05 ** p<0.01, ns= not significant.

Ndfip1 limits eTreg proliferation and levels of ICOS and GITR
The expansion of CD44+ eTreg cells in male Ndfip1fl/flFoxp3-Cre animals, in
the absence of robust changes in cTreg cells, suggested that Ndfip1 restricts eTreg
cell numbers. Additionally, our data supported that Ndfip1 limits expression of ICOS,
GITR, CD25 and PD-1 on eTreg cells. However, both expansion and phenotype of
eTreg cells could be altered in inflammatory environments, independent of an
intrinsic role for Ndfip1. To distinguish between these possibilities, we examined
Ndfip1fl/flFoxp3-Cre+/- female animals. These mice have mixtures of WT (YFP-Cre-)
and Ndfip1-deficient (YFP-Cre+) Foxp3+ Treg cells, due to X chromosome
inactivation, that can be distinguished by expression of YFP.
Surprisingly, despite the presence of WT Treg cells, female Ndfip1fl/fl Foxp3Cre+/- mice had similar inflammatory burden, as defined by ratio of spleen weight
to body weight (Fig. 3.4a) and contained equally high percentages of IFNγ, IL-4 and
IL-17A- expressing CD4 T cells, as the males (Fig. 3.4b). Compared to male animals,
which are uniformly sick beyond 16 weeks of age, female animals had lower
incidence of skin dermatitis. Ndfip1fl/flFoxp3-Cre+/- mice contained increased
numbers of total lung Treg cells (Cre+ plus Cre-), compared to Ndfip1+/+Foxp3Cre+/- counterparts (Fig. 3.5a,b). Similar to their male counterparts, female animals
had total lung Treg cells that were skewed towards the eTreg phenotype (Fig.
3.5c,d). In Ndfip1+/+ Foxp3-Cre+/- female mice, Foxp3-Cre+ (YFP+) cells were
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outnumbered by Foxp3-Cre- (YFP-) cells almost 1:3 (Fig. 3.5e). Surprisingly, in
Ndfip1fl/flFoxp3-Cre+/- females, this ratio was skewed towards YFP+ cells,
supporting an in vivo competitive advantage of Ndfip1-deficient Treg cells (Fig.
3.5f).
To identify intrinsic effects of Ndfip1 deficiency on Treg cells, in each female
animal, for each parameter examined, we first determined the ratio of the value for
YFP+ to YFP- Treg cells. The aim of this analysis strategy was to first identify
whether the presence of Cre had an effect on the ratio of YFP+ to YFP- cells in a WT
(Ndfip1+/+) animal. This ratio in a WT animal would serve as the baseline to use to
compare to Ndfip1fl/flFoxp3-Cre+/- females to see whether the loss of Ndfip1 had an
additional effect. If the expression of Cre had no effect on the parameter examined,
the ratio of YFP+ to YFP- cells would be equal to 1 in a WT animal. If Ndfip1 did not
affect the expression of the parameter examined, the YFP+:YFP- ratio in the WT and
in the Ndfip1fl/flFoxp3-Cre+/- animals would be identical. Analysis of our data
revealed that the expression of Cre decreased levels of CD44, Ki67, GITR, and PD-1
in a WT animal (i.e. YFP+:YFP- ratios were all less than 1 in WT animals).
Furthermore, Ndfip1-deficient Treg cells were significantly more likely to display an
eTreg phenotype (CD44+CD62Llo) due to the loss of Ndfip1 (Fig. 3.5g) as indicated
by the increased ratio in the Ndfip1fl/flFoxp3-Cre+/- female animal. Similarly, the
expression of the proliferative marker, Ki67 (Fig. 3.5h) was increased in Ndfip1deficient eTreg cells and eTreg cells lacking Ndfip1 also had significantly higher
levels of ICOS (Fig. 3.5i) and GITR (Fig. 3.5j). Thus, Ndfip1 restricts eTreg numbers
by limiting their proliferation and their expression of ICOS and GITR. However, the
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ratios representing levels of CD25 and PD-1 were similar between Ndfip1fl/flFoxp3Cre+/- animals and controls (Fig. 3.5k,l), suggesting that these markers were not
directly affected by the loss of Ndfip1 in Treg cells.
The expression of activation markers on Treg cells is known to increase
under inflammatory settings210. To determine how inflammatory conditions could
influence control Treg cells, we looked at the expression of surface markers by
CD44+ YFP- Treg cells from the Ndfip1+/+Foxp3-Cre+/- females or from the inflamed
environment in Ndfip1fl/flFoxp3-Cre+/- female mice. CD44+ YFP- Foxp3+ cells from
Ndfip1fl/flFoxp3-Cre+/- mice showed increased expression of ICOS, GITR, CD25 and
PD-1 (Fig. 3.6a-d). Taken together with the data in Figures 3.2, 3.4 and 3.5, this
supports that the changes in CD25 and PD-1 expression in male Ndfip1fl/flFoxp3-Cre
mice are secondary to inflammation but Ndfip1 is a regulator of ICOS and GITR on
Treg cells (Fig. 3.6e).
To further address whether the changes observed in the Ndfip1-deficient
Treg cells were driven by inflammation, we looked in young mice before the onset
on overt inflammation. We analyzed lung cells from 13-day-old female neonates.
There were no differences between the Ndfip1fl/flFoxp3-Cre+/- and Ndfip1+/+
Foxp3-Cre+/- animals in spleen weight (Fig. 3.7a), inflammation index (Fig. 3.7b),
total Foxp3+ Treg cell number or total cytokine-producing CD4 T cells (Fig. 3.7c-d).
However, lungs from Ndfip1fl/flFoxp3-Cre+/- female mice contained greater
frequencies of YFP+ Treg cells (Fig. 3.7e-f) and greater frequencies of eTreg cells
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(Fig. 3.7g). Further, these eTreg cells had higher expression of ICOS and GITR (Fig.
3.7h,i).
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FIGURE 3.4 Ndfip1fl/fl Foxp3-Cre +/- female animals develop disease.
(a) Inflammation index calculated by spleen weight/body weight for male Ndfip1fl/flFoxp3-Cre+
animals, female Ndfip1fl/fl Foxp3-Cre +/- animals, compared to male Ndfip1+/+ Foxp3-Cre + WT
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Figure 1 is added here for comparison. (b) Lung homogenates as analyzed by flow cytometry for
IFNγ, IL-4 and IL-17A cytokine production from WT Ndfip1+/+ Foxp3-Cre + male, Ndfip1fl/fl Foxp3-Cre
male, and Ndfip1fl/fl Foxp3-Cre +/- female animals. Error bars indicate mean ± SEM. P value
calculated by one way ANOVA. * p<0.05 ** p<0.01 *** p<0.001 ****p<0.0001, ns = not significant.
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FIGURE 3.5 Loss of Ndfip1 leads to an increase in eTreg cell frequency and elevated
expression of some of the markers that distinguish these cells.
(a-l) Lung homogenates, from 8-16 week old hemizygous female Ndfip1fl/fl Foxp3-Cre +/- mice and
Ndfip1+/+ Foxp3-Cre +/- controls, were analyzed ex vivo by flow cytometry. (a) Representative flow
plots showing the gating of Treg cells (previously gated as live CD3+CD4+ cells). This gating was used
to determine the overall frequencies of Treg cells (b) in mice from the indicated genotypes. (c)
Representative flow plots showing the gating of Treg cells from panel (a) that are eTreg or cTreg
cells. This gating was used to determine the (d) frequencies of eTreg cells. (e) Representative flow
plot of Treg cells as gated in panel (a) and analyzed for frequencies of YFP+ and YFP- cells. (f) Ratio of
YFP+ to YFP- Treg cells. (g-h) Percentages of (g) eTreg cells or (h) Ki-67+ eTreg cells, shown as a
ratio of YFP+:YFP- cells within each mouse to normalize for a Cre effect. (i-l) MFI of (i) ICOS, (j) GITR,
(k) CD25, and (l) PD-1 expression on eTreg cells, again shown as a ratio of YFP+:YFP-. P values
determined by student’s T test, with correction for unequal variances as appropriate. * p<0.05 **
p<0.01 *** p<0.001 ****p<0.0001, ns= not significant. Each dot shows data acquired from a single
female mouse. Graphs show mean ± SEM. All experiments were performed on at least two
independent occasions.
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Ndfip1 limits IL-4 production by regulatory T cells
Our data indicate that Ndfip1 limits eTreg cell expression of ICOS and GITR
and restricts eTreg cell proliferation. However, it remained unclear why
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Ndfip1fl/flFoxp3-Cre+/- females developed inflammation, when approximately half
of the Treg cells in these mice are Ndfip1-sufficient. This suggested a pathologic gain
of function in Ndfip1-deficient Treg cells. We thus investigated whether Ndfip1deficient Treg cells could contribute to the pool of cytokine-producing cells in the
lung of Ndfip1fl/flFoxp3-Cre male mice shown in Fig. 3.1. Effector cytokine
production by WT Treg cells is relatively rare but has been described under
inflammatory211 or lymphopenic settings142,212. Strikingly, while WT Treg cells did
not produce any IL-4 upon ex vivo stimulation, Ndfip1-deficient Treg cells could
produce IL-4, and this was detectable at both the protein (Fig. 3.8a,b) and mRNA
level (Fig. 3.8c). Ndfip1-deficient Treg cells were also more likely to produce IL-10,
IFNγ and IL-17A relative to WT controls. To determine whether this cytokine
production was due to the loss of Ndfip1, or was a result of the inflammatory
environment, we generated YFP-Cre+ mixed bone marrow chimeras. Consistent
with our data from the female mice, these mixed chimeras developed dermatitis 8
weeks after reconstitution. On analysis, CD45.1+ WT Foxp3+ cells did not produce
any IL-4 while CD45.2+ Ndfip1-deficient Foxp3+ cells in the same host expressed
significant amounts of IL-4 (Fig. 3.8d,e), supporting an intrinsic role for Ndfip1 in
limiting IL-4 production from Treg cells. Surprisingly, when we analyzed the Foxp3Tconv cells, we found a significant population of CD45.2+ cells that also expressed
IL-4 (Fig. 3.8f,g), raising the possibility that the IL-4-producing population
originated from Ndfip1fl/fl Foxp3-Cre Treg cells that had lost Foxp3.
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FIGURE 3.8 Ndfip1 prevents Treg cells from making IL-4.
(a-b) Lung homogenates from WT and Ndfip1fl/fl Foxp3-Cre male mice, 9-16 weeks old, were
stimulated ex vivo with P/I and analyzed for IL-4 production by flow cytometry. (a) Representative
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Ndfip1-deficient Treg cells lose Foxp3 expression
Given the IL-4 production by Ndfip1-deficient Treg cells, and their increased
proliferative capacity, we posited that these cells would be likely to become
methylated at their Foxp3 locus and become unstable. IL-4 receptor signaling in
Treg cells, via STAT6, results in the methylation of the Conserved Non-coding DNA
Sequence 2 (CNS2) region of the Foxp3 locus and repression of foxp3 gene
expression213. Therefore, we compared the levels of methylation at 12 CpG islands
in the Foxp3 CNS2 region in Ndfip1-sufficient and Ndfip1-deficient Treg cells, as
well as WT Tconv cells. As expected, the CNS2 CpG motifs were predominantly
methylated in Tconv cells (Fig. 3.9a)213. Both WT and Ndfip1-deficient Treg cells
had unmethylated CpG motifs in their Foxp3 promoter regions (Fig. 3.9b),
consistent with their ability to normally transcribe Foxp3 mRNA (Fig. 3.9c).
However, in Ndfip1fl/flFoxp3-Cre Treg cells, there was an increase in methylation at
the 12 examined CNS2 CpG sites, compared to WT Treg cells, which remained
unmethylated at these sites (Fig. 3.9d,e).
These data suggested that Ndfip1 deficiency, via concomitant expression of
IL-4, negatively impacts lineage stability of Treg cells. To test whether Ndfip1
sufficient and deficient Treg cells have differential responses to destabilizing
cytokines, we cultured Ndfip1-sufficient and -deficient Foxp3+ cells in stabilizing
(IL-2) or destabilizing (IL-4 plus anti-IL-2) conditions, and analyzed Foxp3
expression as a surrogate for lineage stability. We found that Ndfip1-deficient Treg
cells were equally stabilized by IL-2 and destabilized by IL-4 compared to their
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Ndfip1-sufficient counterparts (Figure 3.10a-c). Thus, Ndfip1-deficient Treg cells
are not uniquely sensitive to the destabilizing effects of IL-4; Ndfip1-deficient IL-4
producing Treg cells may just be more likely to encounter destabilizing cytokine
milieus in vivo.
To test Treg lineage stability in vivo, we sorted WT or Ndfip1-deficient
CD45.2+ YFP+ Treg cells and co-transferred them with sorted naïve CD45.1+ WT
Tconv cells into RAG1-/- hosts (Fig 3.11a). As previously observed, mice receiving
either Ndfip1-deficient or sufficient Treg cells did not develop colitis (Fig. 3.11b). At
harvest, we determined the frequencies of CD45.2+ cells that were still Foxp3+
(current Treg cells) or that had lost Foxp3 (former Treg cells). In mice that received
WT Treg cells, on average, 30% had lost Foxp3, similar to previous reports by other
groups142,206. Strikingly, in mice that had received Ndfip1-deficient Treg cells, 60%
on average had lost expression of Foxp3 (Fig. 3.11c,d). These Foxp3- CD45.2+ cells
could represent Ndfip1-deficient Treg cells that had lost Foxp3 expression in vivo, or
a very proliferative Tconv cell contamination from cell sorting. If the Foxp3- cells
represented former Treg cells, they would lack Ndfip1, due to excision following
expression of Foxp3-Cre. Contaminating Tconv cells, on the other hand, would
continue to express Ndfip1. We sorted current Treg cells, former Treg cells, and
Tconv cells and stimulated to induce Ndfip1 mRNA expression. We found that the
WT Tconv cells expressed Ndfip1 mRNA, while neither the Ndfip1fl/flFoxp3-Cre+
current Treg cells nor former Treg cells expressed detectable levels of Ndfip1 mRNA
(Fig. 3.11e). Thus, Treg cells lacking Ndfip1 were more likely to lose Foxp3
expression than their WT counterparts.
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Current (Fig. 3.11f) and former (Fig. 3.11g) Treg cells lacking Ndfip1
produced IL-4, while current and former WT Treg cells did not. Importantly, none of
the WT Tconv cells produced very much IL-4 (Fig. 3.11h). This was not true for all
cytokines since WT and Ndfip1-deficient cells were equally likely to make IFNγ
regardless of whether they were Treg cells (Fig. 3.12a,b) or co-transferred Tconv
cells (Fig. 3.12c). Additionally, compared to WT Treg cells, Ndfip1-deficient Treg
cells expanded to greater numbers in vivo (Fig. 3.12d,e) suggesting an advantage in
proliferation and/or survival of both current and former Ndfip1-deficient Treg cells.
In summary, in a setting where Treg cells are pushed to undergo
lymphopenia-induced proliferation, Ndfip1-deficient Treg cells have an advantage in
growth and expansion, which leads to a large increase total numbers of Ndfip1deficient current and and former Treg cells. Since the majority of Ndfip1-deficient
former Treg cells (~50%) make IL-4, this may explain the dramatic loss of Foxp3
observed in vivo.
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were calculated by one-way ANOVA. * p<0.05 ** p<0.01 *** p<0.001 ****p<0.0001. Graphs
show mean ± SEM.
79

a

b
100
80

40

% Foxp3+

60

***

*

95

TCR+ IL-2
% of Max

% of Max

80

*

100

TCR+ IL-4
+ ANTI-IL-2

Ndfip1fl/fl Foxp3-Cre
%Foxp3

Ndfip1fl/fl Foxp3-Cre

WT
100

WT

60

40

90
85
80

20

20

0

0

0

102

103

104

105

75

0

10

2

10

3

10

4

10

Foxp3 MFI

TCR
+IL-2

TCR
+IL-4
+ ANTI-IL-2

WT
Ndfip1fl/fl Foxp3-Cre

25000

*

20000

Foxp3 MFI

70

TCR

Foxp3

c

5

15000
10000
5000
0

TCR

TCR
+IL-2

TCR
+IL-4
+ ANTI-IL-2

FIGURE 3.10 Ndfip1-deficient Treg cells are not more likely to be destabilized by IL-4.
Representative plots (a) showing that the in vitro percentages (b) and MFI (c) of sorted YFP+ Foxp3
cells are increased in response to IL-2 and decreased in response to IL-4 and anti-IL-2. P values
calculated by one way ANOVA * p<0.05 ** p<0.01 *** p<0.001 ****p<0.0001.

80

a

CD45.2 YFP+ Treg
+
CD45.1 naive Tconv

b

c

Ndfip1fl/fl Foxp3-Cre

WT

140

5
10

130

0

1

2

3

4

5

6

7

8

61.2

36.2

0
2
0 10

9 10 11 12 13

Foxp3

Time post transfer of cells (weeks)

% of total CD45.2
CD4+ T cells

e

**

100

**

80
60
40
20

+
CD45.2+
WT

-

+
CD45.2+
Ndfip1fl/fl Foxp3-Cre

Ndfip1fl/fl Foxp3-Cre

WT

IL-4+ Current Treg
10

g

12
9
6
3

ND

%CD45.2+ IL-4+
Foxp3- CD4+

8
6
4
2

+/+

fl/fl

fl/fl

Foxp3:

-

+

-

IL-4+ Former Treg

****

80

**

h

+

+

40
20

CD45.2

Foxp3:

IL-4+ CD45.1 Tconv cell
8
6

60

4
2
0

0

0

ND

Ndfip1:

Ndfip1fl/fl Foxp3-Cre

WT

5
10

15

%CD45.1+ IL-4+
Foxp3-

Foxp3:

4
10

Ndfip1 mRNA

0

0

Foxp3:

3
10

18

Relative mRNA
(x10-4)

d

% CD45.2+ IL-4+
Foxp3+ CD4+

61.3

2
10

100

f

CD45.2 Ndfip1fl/fl
Foxp3-Cre Treg

3
10

110

90

35.9

4
10

120

analyze

CD45.2 WT
Treg

CD4

%of starting body weight

150

13 weeks

-

-

with:

CD45.2

WT Treg

Ndfip1fl/fl
Foxp3-Cre Treg

FIGURE 3.11 Ndfip1-deficient Treg cells are more likely than controls to lose Foxp3 in vivo.
(a) YFP+ Treg cells from CD45.2+ WT or Ndfip1fl/fl Foxp3-Cre mice were mixed 1:5 with CD45.1+ WT
naïve Tconv cells and transferred to RAG1-/- recipients. Cells from lung homogenates were analyzed for
Foxp3 and IL-4 expression using flow cytometry 13 weeks after transfer. (b) Graph shows
percentage change in weight over the course of the experiment. (c) A representative flow plot
showing CD45.2+ WT and Ndfip1fl/fl Foxp3-Cre cells that were analyzed for expression of Foxp3. (d)
Compiled data from multiple mice analyzed as in panel (c). (e) Lung homogenates were sorted for
Treg cells that remained Foxp3+ (current Treg cells), those that had become Foxp3- following
transfer (former Treg cells), and for CD45.1 Tconv cells, restimulated, and analyzed for Ndfip1 mRNA
by qPCR. (f) Percentages of IL-4 producing cells that remained Foxp3+ (current Treg cells) and (g)
that had become Foxp3- following transfer (former Treg cells). (h) Percentages of IL-4 producing
CD45.1 Tconv cells. All experiments were performed on at least two separate occasions. P value was
calculated by one-way ANOVA (a,d) or by unpaired T tests (f-h). *p<0.05 **p<0.01 ***p<0.001
****p<0.0001

81

a

b
%CD45.2+ I IFNγ+
Foxp3- CD4+

%CD45.2+ IFNγ+
Foxp3+ CD4+

IFNγ+ Current Treg
8
6
4
2
0

Foxp3:

*

60
40
20

Foxp3:

e

ns

40
20
0

2 105
1 105

WT Treg Ndfip1fl/fl
Foxp3-Cre Treg

Total CD45.2+ cells

# CD45.2+ CD4+ T cells

**
Cell number

IFNγ+ CD45.1 T conv cell
60

6 105

3 105

*

4 105

2 105

0

0

Foxp3:

with:

CD45.2

Total cell number
4 105

c

IFNγ+ Former Treg
80

0

+
+
CD45.2

d

Ndfip1fl/fl Foxp3-Cre

WT

% CD45.1+ IFNγ+
Foxp3- CD4+

Ndfip1fl/fl Foxp3-Cre

WT

CD45.2+
WT

+

-

+

CD45.2+
Ndfip1fl/fl Foxp3-Cre

CD45.2+
WT

CD45.2+
Ndfip1fl/fl Foxp3-Cre

FIGURE 3.12 Current and former Ndfip1-deficient Tregs are not more likely to express IFNγ
but are more likely to expand in vivo.
(a-e) I CD45.1 CD4+ Tconv cells and CD45.2 WT or Ndfip1fl/fl Foxp3-Cre YFP+ Treg cells cells were coinjected via IP at a 5 Tconv: 1 Treg ratio into RAG1-/- animals, as described in Figure 3.11. IFNγ
production by current (a) and former (b) Treg cells and from the co-transferred Tconv cells (c). (d-e)
Absolute numbers of CD45.2+ current and former Treg cells (d) or of total CD45.2+ cells (e) in
recipients of WT or Ndfip1fl/fl Foxp3-Cre Treg cells. All mice were analyzed 13 weeks after the cotransfer. Error bars indicate mean ± SEM. Each dot represents an individual recipient mouse. All
experiments were performed on at least two independent occasions using at least 2 animals of each
genotype. P value was calculated by unpaired T tests (a-c, and e) or by one-way ANOVA (d). *p<0.05
**p<0.01 ***p<0.001 ****p<0.0001 , Ns= not significant

IL-4 is dispensable for Ndfip1-deficient eTreg activation, expansion and
surface marker expression
To assess whether IL-4 is required for the phenotypic changes in Treg cells
lacking Ndfip1, we examined Treg cells in mice that lack both Ndfip1 and IL-4
(Ndfip1 IL-4 DKO mice)68. These animals lack overt signs of inflammation such as
dermatitis68,214 compared to age-matched Ndfip1fl/flFoxp3-Cre animals. However,
they do have aberrant Th17 differentiation and increased activated CD4 T cells as
previously discussed in Chapter 2. We observed increased frequencies of Treg cells
(Fig. 3.13a,b) compared to IL-4 deficient controls. The Ndfip1-deficient Treg cells
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that lacked IL-4 were more proliferative than controls, as determined by Ki67 (Fig.
3.13c). Similar to the Ndfip1fl/flFoxp3-Cre mice, Treg cells in the Ndfip1 IL-4 DKO
mice were predominantly eTreg cells (Fig. 3.13d,e). Additionally, the Ndfip1- IL-4deficient eTreg cells expressed higher levels of Ki67 (Fig. 3.13f) and ICOS (Fig.
3.13g). Thus, while IL-4 from current and former Treg cells likely contributes to the
inflammation observed in Ndfip1fl/flFoxp3-Cre mice, increased Treg cell activation,
proliferation, and ICOS expression are not due to IL-4 signaling. Thus, IL-4 is
insufficient to explain the increased fitness of Ndfip1-deficient Treg cells.
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Ndfip1-deficient eTreg cells have altered metabolic activity
To identify molecular pathways underlying the increased proliferation and
altered eTreg cell phenotype of Ndfip1 deficient Treg cells, we used label-free
quantitative proteomics to compare WT and Ndfip1-deficient cTreg and eTreg cells.
We sorted YFP+ eTreg and cTreg cells from young WT or Ndfip1fl/flFoxp3-Cre male
mice, subjected these cells to LC MS/MS analysis, and quantified proteins using
intensity based absolute quantification (iBAQ)215–217 (Fig. 3.14a). We achieved good
reproducibility of identified proteins across three experiments, pooling two to three
mice of each genotype per experiment (Fig. 3.14b). Comparing proteins identified
in control eTreg and cTreg proteomes, our data fit well with what has been
published previously on proteins unique to each sub-type. Namely, among proteins
that were significantly more abundant in cTreg than eTreg proteomes or that were
found exclusively in cTreg proteomes, defined here as having a cTreg “bias”, we
identified CD62L and Bcl2210 (Fig. 3.14c). Proteins that were increased in, or biased
toward, the eTreg proteome, included CD44 and several proteins associated with
eTreg cells such as Integrin alpha E/itgae (CD103)218 (Fig. 3.14c).
To characterize differential protein expression in Ndfip1 sufficient and
deficient Treg cells, we compared the ratio of protein abundance in eTreg:cTreg for
each of the three experiments. This revealed widespread changes in the proteomes
of Ndfip1-deficient Treg cells. Given that Ndfip1 deficiency drove changes
predominantly in eTreg cells, we focused our comparisons on the levels of proteins
identified in WT and Ndfip1-deficient eTreg cells (Fig. 3.14d). Our flow cytometric
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finding of increased GITR expression was supported by these Treg proteomes (Fig.
3.14d). Surprisingly, proteins associated with increased mTORC1 activity were
increased in Ndfip1-deficient eTreg cells. This included Lamtor1 (Fig. 3.14d), as
well as the V-ATPase subunit d1 and Lamtor3, which are components of the vATPase-ragulator complex that drives mTORC1 activation in cells219–221. We then
performed network visualization of gene-ontology-enrichment analysis for
differentially regulated proteins in Ndfip1 sufficient and deficient eTreg cells and
identified clusters of nodes relating to metabolic processes that were significantly
enriched (Fig. 3.14e). Thus, loss of Ndfip1 led to an altered proteomic profile
indicative of altered metabolic activity.
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FIGURE 3.14 A comparison of proteomes from WT and Ndfip1fl/fl Foxp3-Cre eTreg cells suggest
altered metabolic activity.
(a) Representative flow cytometry dot plots and gel pixelation to illustrate procedure used to analyze
cTreg and eTreg cell proteomes using mass spectrometry. (b) Area-proportional Venn diagrams
illustrating the reproducibility of proteins identified in cTreg (left) or eTreg (right) cells from 3
independent experiments. WT cells were compared for this analysis and data was compiled using the
intensity based absolute quantification (iBAQ) method. (c) A volcano plot illustrating differentially
expressed proteins between eTreg versus cTreg cells in WT mice. (d) A volcano plot representing
differentially expressed proteins between eTreg cells from Ndfip1fl/fl Foxp3-Cre or WT animals. (e)
Network diagram of enriched GO terms with nodes representing GO annotations and edges
connecting similar terms based on the GO hierarchy. The size of the nodes corresponds to the
number of genes associated with the respective GO term and the color of the nodes corresponds to
the level of significance of the enrichment of the respective term in the dataset (darker color
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annotated to identify broad functional similarity. Data is shown for YFP+ eTreg cells were sorted
from 9-12 week old WT or Ndfip1fl/fl Foxp3-Cre male mice.
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Ndfip1-deficient Treg cells have increased glycolysis
Based on this proteomics profiling, we sought to analyze the metabolic
capacity of Ndfip1-deficient Treg cells. To obtain sufficient cell numbers for
metabolic testing, we used in vitro IL-2 expanded Treg cells. We evaluated the
bioenergetics of these expanded WT and Ndfip1fl/flFoxp3-Cre Treg cells at “rest” and
also upon re-stimulation. We measured the extracellular acidification rate (ECAR)
under glycolytic stress conditions (Fig. 3.15a-d) and oxygen consumption rate
(OCR) under mitochondrial stress conditions (Fig. 3.15e-h). Prior to stimulation,
WT Treg cells had low basal rates of glycolysis, but rates increased when cells were
stimulated (Fig. 3.15a,b). In Ndfip1-deficient Treg cells, the “resting” glycolytic rate
was only modestly increased over WT cells (Fig. 3.15a,c). However, re-stimulated
Ndfip1-deficient Treg cells had a considerably increased glycolytic rate and
glycolytic capacity compared to restimulated WT Treg cells (Fig. 3.15b-d). To
assess mitochondrial function, we measured cell respiratory control, which is a
general test of mitochondrial function in cells. Loss of Ndfip1 did not change the
maximum respiratory capacity of Treg cells and caused a slight decrease in the
spare respiratory capacity of Treg cells (Fig. 3.15e-h). Taken together, these data
indicate that the loss of Ndfip1 drives a metabolic switch in activated regulatory T
cells, promoting a more effector cell-like reliance on glycolysis to supply cellular
energetic demands.
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FIGURE 3.15 Ndfip1-deficient Treg cells have a significantly increased rate of glycolysis.
(a-h) YFP+ Treg cells were sorted from Ndfip1+/+ Foxp3-Cre WT or Ndfip1fl/fl Foxp3-Cre mice,
expanded in culture, and then were left unstimulated or were re-stimulated before metabolic
function was assessed. (a-b) Extracellular acidification rate (ECAR) was measured during a glycolysis
stress test in (a) unstimulated or (b) stimulated Treg cells treated with drugs as indicated. (c) Rate of
glycolysis is the difference in ECAR between post-glucose addition and baseline. (d) Glycolytic
capacity is the difference between post-Oligomycin ECAR and baseline ECAR. (e-f) Oxygen
consumption rate (OCR) changes during a mitochondrial function assessmenT test in (e)
unstimulated or (f) stimulated WT or Ndfip1fl/fl Foxp3-Cre Treg cells treated with drugs as indicated.
(g) Maximum respiratory capacity is the difference in OCR after addition of rotenone/Antimycin A,
versus after addition of FCCP. (h) Spare respiratory capacity is the difference in increased OCR
following addition of FCCP (fluoro-carbonyl cyanide phenylhydrazone) compared to baseline. Graphs
show mean ± SEM. (a-d) represents n=4 mice (male or female, 7-12 week old) per genotype in two
independent experiments. Final Foxp3% after in vitro expansion was 74.45% ± 8.03 for Ndfip1 fl/fl
Foxp3-Cre+ versus 74.8 ± 9.80 for Ndfip1+/+ Foxp3-Cre +. e-h represents n=6-8 mice (male or female,
7-12 week old) in three experiments. Final Foxp3% was 88.1 ± 2.08 for Ndfip1 fl/fl Foxp3-Cre+
versus 86.43 ± 1.94 for Ndfip1+/+ Foxp3-Cre +. P values were calculated by one-way ANOVA. * p<0.05
** p<0.01 *** p<0.001 ****p<0.0001.
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Ndfip1-deficient Treg cells have elevated mTORC1 activity
Effector T cells utilize glycolysis while regulatory T cells are more dependent
on oxidative phosphorylation as their main source of energy222–226. High glycolytic
activity in Treg cells, as can occur when mTORC1 activity is increased, has been
associated Treg cell dysfunction204,205,227. To investigate whether mTORC1 activity
was increased in Ndfip1-deficient Treg cells, we cultured WT and Ndfip1fl/fl Foxp3Cre Treg cells in vitro. We found that Ndfip1fl/flFoxp3-Cre Treg cells quickly
outnumbered their WT counterparts (Fig. 3.16a), were increased in cell size (Fig.
3.16b), and proliferated more (Fig. 3.16c). This, together with observed increases
in ICOS and GITR expression (Fig. 3.16d-e), suggested that this in vitro culture
system recapitulates the phenotype of Ndfip1-deficient Treg cells in vivo. Given that
ICOS can be driven by mTORC1227 activity, we examined other proteins in the
mTORC1 pathway, including the amino acid transporter, CD98 and phosphorylated
S6 (pS6). CD98 and pS6 (Fig. 3.16f-g) were both increased in Ndfip1fl/flFoxp3-Cre
Treg cells. Co-culture confirmed that these changes are not directly linked to IL-4
signaling (Fig. 3.16h).
Increased responsiveness to IL-2 could explain the fitness of Ndfip1-deficient
Treg cells in this IL-2 expansion system. To test this, we sorted Ndfip1-sufficient and
deficient Treg cells and rested them overnight without cytokine or TCR stimulation.
Upon brief IL-2 stimulation, we detected STAT5 phosphorylation by flow cytometry.
pSTAT5 levels (MFI) were similar between WT and Ndfip1-deficient Treg cells
before and after IL-2 stimulation (Fig. 3.17a,b). This is consistent with our recent
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report showing that both Ndfip1 and its homologue, Ndfip2, are required in Tconv
cells to drive the degradation of Jak1, and decrease STAT5 phosphorylation in
response to cytokine such as IL-2177. Therefore, the increased metabolic activity of
Ndfip1fl/flFoxp3-Cre+ Treg cells is cell-intrinsic but not just because of enhanced
responsiveness to IL-2.
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FIGURE 3.16 Loss of Ndfip1 in Treg cells leads to elevated mTORC1 signaling and this
correlates with their increased metabolic fitness and proliferative capacity.
(a-h) Treg cells were sorted from congenically distinct CD45.1 WT or CD45.2 Ndfip1fl/fl Foxp3-Cre
mice. Treg cells were expanded in vitro (a-g) individually or (h) in mixed co-cultures. (a) Cell
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mTORC1 signaling drives increased GITR levels on Ndfip1-deficient Treg cells
Finally, we investigated the effect of blocking mTORC1 on some of the
observed phenotypes in the Ndfip1-deficient Treg cells. We found that treatment
with the mTORC1 inhibitor, rapamycin, did not change the percentage of Foxp3+
cells in culture (Fig. 3.18a), However, in preliminary results, inhibition of mTORC1
reduced Ndfip1-deficient Treg cell proliferation to the levels seen in a treated WT
Treg cell (Fig. 3.18b). Furthermore, inhibition of mTORC1 decreased GITR levels on
Ndfip1-deficient Treg cells to levels found in untreated WT Treg cells (Fig. 3.18c)
indicating that the increased GITR expression is mTORC1-driven and is unique to
Treg cells that lack Ndfip1. Over the 4-day in vitro culture, ICOS levels on the Ndfip1deficient Treg cells were not significantly higher than the WT Treg levels (Fig.
3.18d). This may be due to differences in level of ICOS induction in response to
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plate-bound antibody stimulation (4day culture) versus the anti-CD3/CD28 bead
stimulation (used in the 7day in vitro expansion) or in response to different amount
of IL-2: 200U/ml (4day culture) versus 2000U/ml (used in the 7day in vitro
expansion). However, treatment with rapamycin decreased the ICOS levels on the
Ndfip1-deficient Treg cells similar to the reduction seen in WT Treg cells (Fig.
3.18d). Furthermore, when glycolysis was inhibited via treatment with
dichloroacetate, both GITR and ICOS levels in Ndfip1-deficient Treg cells dropped
below the levels found in treated WT Treg cells (Fig. 3.18e,f). These preliminary
data suggest that GITR levels (unlike ICOS levels) on Ndfip1-deficient Treg cells are
mTORC1-dependent.
In additional preliminary data, we also found that IL-4 secretion in this
culture system over the four-day period is minimal (preliminary data not shown).
We detected low levels of IL-4 in the supernatant from Ndfip1-deficient Treg cells
treated with DMSO. Addition of rapamycin did not decrease IL-4 secretion from
these cells. Furthermore, WT Treg cells did not produce IL-4 whether DMSO or
rapamycin was added (preliminary data not shown). Taken together, our data
suggests that increased GITR expression on the Ndfip1-deficient Treg cells is
downstream of the increased mTORC1 signaling and thus can be decreased by
mTORC1 inhibition. Furthermore, mTORC1 signaling may be dissociated from the
IL-4 production in Ndfip1-deficient Treg cells.
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FIGURE 3.18 mTORC1 drives increased levels of GITR on Ndfip1-deficient Treg cells.
Treg cells were sorted from WT or Ndfip1fl/fl Foxp3-Cre mice. Treg cells were plated with plate-bound
TCR stimulation in the presence or absence of 50nM rapamycin (mTORC1 inhibitor) or 10mM
Sodium dicholoracetate, DCA, (glycolysis inhibitor) in complete RPMI media. After 4 days, cells were
analyzed by flow cytometry for (a) Foxp3 expression (b) Ki67 expression, or surface levels of (c,e)
GITR or (d,f) ICOS in response to rapamycin treatment (c-d) pr dichloroacetate treatment (e-f). Each
dot represents an individual mouse. All experiments were performed on at least two independent
occasions using age-matched male or female, 9-16 week old mice of each genotype. P values were
calculated by one-way ANOVA. * p<0.05 ** p<0.01 *** p<0.001 ****p<0.0001. Error bars indicate
mean ± SEM

Discussion
Therapies using adoptively transferred Treg cells or that target Treg cell
function are now being developed, making it essential to understand mechanisms
that maintain Treg cell identity and how these pathways integrate with TCR
activation and cellular metabolic processes. Our data identify Ndfip1, an activator of
E3 ubiquitin ligases, as a new molecular target impacting Treg stability and function.
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We demonstrated that Ndfip1-deficient Treg cells are highly proliferative, and
concomitantly gain the capacity to produce the proinflammatory cytokine IL-4.
Importantly, Ndfip1 deficiency can lead to the expansion of Treg cells and loss of
Foxp3 in vivo.
Both mTORC1 and mTORC2 play important roles in preventing Treg cells
from adopting a glycolytic metabolic profile. mTORC1-mediated glycolytic activity in
Treg cells is modulated by the serine threonine phosphatase PP2A and by the
autophagy proteins, Atg5 and Atg7205,206. The lipid phosphatase, PTEN, inhibits
mTORC2-mediated metabolic pathways in Treg cells to prevent Treg cell instability
and maintain suppression of Th1 and Tfh effector T cell functions228,229. Ndfip1deficient Treg cells have increased protein levels of ICOS, CD98 and pS6, all
indicators of high mTORC1 signaling. mTORC1 deletion in Treg cells leads to defects
in efficiently synthesizing lipids from glucose, and to defects in homeostatic
proliferation in vivo227. Therefore it is not surprising that Ndfip1-deficient Treg cells,
with high mTORC1 signature, show greater homeostatic expansion in vivo, show
greater metabolic fitness in vitro and in vivo, and are more efficient at glycolysis.
This altered glycolytic metabolism fuels dysfunction in vivo by driving the expansion
of e Treg cells that are prone to produce IL-4 and lose Foxp3.
We propose that Treg cells lacking Ndfip1 progress through a series of
changes that is precipitated by increased proliferation of activated (CD44+) Treg
cells and accompanied by the acquisition of IL-4 production. These changes are
likely initiated in eTreg cells since Ndfip1 is inducibly expressed upon T cell
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activation. The elevated glycolytic metabolism in these cells drives further
expansion of IL-4-producing current and former Treg cells. Autocrine IL-4 signaling
can then lead to loss of Foxp3. Supporting this, CD44+ Ndfip1-deficient Treg cells
have increased methylation at the CNS2 region of the Foxp3 locus, indicating
susceptibility towards instability. Ndfip1-deficient Th2 cells are capable of driving
tissue damage and inflammation as already described by our lab and
others25,117,153,177.
Loss of IL-4 did not affect the activation, proliferation and in vivo expansion
of Ndfip1-deficient Treg cells leading us to conclude that the metabolic fitness in
Ndfip1-deficient Treg cells precedes or is independent of the gain in Treg cellintrinsic IL-4 production. Furthermore, IL-4-overexpressing transgenic mice have
been described and have increased recruitment of different immune cell subsets
into the skin but do not develop spontaneous dermatitis230 as observed in
Ndfip1fl/flFoxp3-Cre mice. Lastly, loss of the mTORC1 subunit, raptor, in Treg cells
does not lead to a cell-intrinsic increase in Treg cell IL-4 or other effector
cytokines227 suggesting that cytokine regulation and metabolic regulation by raptor
in Treg cells may be two independent events227. An attractive hypothesis that
warrants further future investigation is whether two parallel (but perhaps crosstalking) cellular pathways are regulated by Ndfip1: one which dampens mTORC1
activity and glycolysis in order to limit Treg cell activation and proliferation, and a
second that limits Treg cell IL-4 production. These pathways, though independent,
may cooperate to account for the severity of the inflammation observed in
Ndfip1fl/flFoxp3-Cre mice. Thus, by promoting stable Foxp3 expression and limiting
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cytokine production in Treg cells, Ndfip1 ensures two important aspects of Treg
stability.
Ndfip1 is a known activator of Itch49,50,177. Mice bearing a Treg-specific
deletion of Itch show some overlapping features with the Ndfip1fl/flFoxp3-Cre mice
described here104: Itch-deficient Treg cells have an effector Treg cell phenotype, an
increase in proliferation, and intact suppression in traditional in vivo and in vitro
suppression assays. Itch-deficient Treg cells are unstable as defined by their
increased production of IL-4 but these Treg cells do not have defects in their ability
to maintain Foxp3 expression in a lymphoreplete animal104. Future work will be
needed to determine whether mTORC1 signaling is elevated in Itch-deficient Treg
cells and whether this contributes to their dysfunction. Future studies on Itch and
Ndfip1 will be of particular interest as therapies that activate or inhibit these
pathways are being developed. If such therapeutic strategies can be used to regulate
Treg cell functions, their use in the clinic could have broad potential.
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CHAPTER 4: Discussion and future directions
Discussion:
At first glance, the observation that both Th17 cells and Treg cells are
increased in Ndfip1 global knockout animals is confusing, given the well described
antagonicity between Th17 cells and Treg cells. That is, if Th17 cells are
proinflammatory drivers of disease and Treg cells are anti-inflammatory cells, then
why isn’t an increase in Th17 cells accompanied by a decrease in Treg cells? Or why
doesn’t the increase in Treg cell number lead to a decrease in the Th17 cell
population? Our investigations have revealed cell-autonomous roles for Ndfip1 in
Th17 and Treg cell abundance and function. Our data indicate that Ndfip1 limits the
numbers and functions of Th17 cells but also limits the numbers of Treg cells while
promoting Treg lineage stability. The net effect of Ndfip1 is thus to balance the
abundance of proinflammatory Th17 cells with the numbers of anti-inflammatory
Treg cells and maintain normal immune homeostasis.
Ndfip1 limits the abundance of RORγT protein, which is essential for the
identity of Th17 cells. By so doing, Ndfip1 also limits the pathogenicity of Th17 cells
since RORγT also drives the production of proinflammatory Th17 cytokines such as
IL-17A and GM-CSF. In Treg cells, Ndfip1 promotes lineage stability by preventing
excessive expansion while limiting the production of the destabilizing cytokine, IL-4.
In spite of Ndfip1’s reciprocal effects on the identity of Th17 and Treg cells, loss of
Ndfip1 has similarly negative consequences in both cells with regards to immune
homeostasis; both Th17 and Treg cells that lack Ndfip1 are more pathogenic in vivo.
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For Th17 cells, we showed this by transferring Ndfip1-deficient Th17 cells into RAG/-

hosts with resulting evidence of severe colitis. For Treg cells, we showed that the

loss of Ndfip1 specifically only in Treg cells was sufficient to cause spontaneous
auto-inflammatory disease. Therefore, by repressing Th17 identity, Ndfip1 limits
the pathogenicity that Th17 cells could drive if they were increased in number and
function. Simultaneously, by promoting lineage stability of the anti-inflammatory
Treg cells, Ndfip1 prevents the spontaneous autoinflammatory disease that would
result from having very metabolically active, IL-4 producing current and former
Treg cells. This highlights the long-proclaimed paradigm of Th17 cells and Treg cells
as antagonistic and suggests that, by repressing proinflammatory Th17 identity and
by promoting Treg stability and anti-inflammatory function, Ndfip1 promotes a
general state of anti-inflammation.

FIGURE 4.1 Model for how Ndfip1 regulates Th17 cells and Treg cells
Ndfip1 drives the degradation of RORγT and limits cytokine production from Th17 cells. This
prevents Th17-mediated inflammation. Ndfip1 also promotes lineage stability by preventing the loss
of Foxp3, and also prevents destabilizing IL-4 production, from Treg cells. Together, these actions by
Ndfip1 result in protection from spontaneous auto-inflammatory disease.
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The role of Ndfip1 in Th17 cells: Unresolved questions and future
directions
The work presented here supports a model in which Th17 differentiation
does not require Ndfip1. However, once differentiated, Th17 cells require Ndfip1 to
limit RORγT protein levels in response to TCR stimulation, to limit their
proliferation, and to dampen proinflammatory cytokine secretion (Fig 4.2). This
work and model however raise a few unresolved questions.

RORγT

IFNγ

RORγT
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Naive CD4
T cell

IL-17A

RORγT

RORγT
RORγT
Th17 cell
Ndfip1
(+ Itch E3 ubiquitin ligase)
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Neutrophils
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FIGURE 4.2 Model for how Ndfip1 functions in Th17 cells.
Activation of a naïve CD4 T cell during Th17 differentiation results in a production of Ndfip1 and Itch.
Ndfip1 activates Itch in order to degrade RORγT protein and to prevent Th17 cell proliferation,
decrease protein levels of RORγT and to prevent production and secretion of cytokines such as IL17A, IFNγ and GM-CSF. This results in decreased recruitment of neutrophils and also prevents direct
damage from these proinflammatory cytokines at the mucosal site and prevents auto-inflammatory
disease.
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Why do Ndfip1-deficient CD4 T cells not have increased Th17 differentiation
in vitro?
It is striking that under different conditions of Th17 differentiation, including
low TGFβ (Fig 2.10), high TGFβ (Fig 2.5), minimal Th17-polarizing cytokines (Fig
2.5), excessive Th17-polarizing cytokines (Fig 2.10), and even in a TCR-transgenic
model with altered peptide ligands (Fig 2.6), we see no role for Ndfip1 in influencing
the differentiation of Th17 cells from naïve CD4 T cells. This is unusual as many
other factors that influence Th17 abundance in vivo do so by affecting the
differentiation of these cells from naïve CD4 cells. RORγT-/-, IRF4-/-, Batf-/- and IL23R-/- mice have very little to no Th17 cell differentiation in vivo66,77,231,232 and
overexpression of these factors drives increased Th17 cell differentiation.
Furthermore, BATF (basic leucine zipper transcription factor ATF-like) can form
dimers with JunB (an Ndfip1-Itch substrate) to drive transcription of IL-17A, IL-21
and IL-22 and Th17 differentiation. Therefore given that loss of Ndfip1 would be
expected to increase both the levels of JunB protein and RORγT protein, it is
surprising net effect is not aberrantly increased Th17 cell differentiation. This may
be due to several reasons, I will discuss three here.
First, the timing of Ndfip1 and RORγT protein production in naïve CD4 T cells
undergoing Th17 differentiation is not addressed by my work. Ndfip1 is expressed
in very low levels in resting, naive CD4 T cells and its expression increases upon TCR
stimulation. Therefore at the start of Th17 differentiation, Ndfip1 protein levels may
be very low. If the timing of Ndfip1 protein and RORγT protein levels do not
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coincide, Ndfip1 may be too late to regulate the levels of RORγT needed for Th17
differentiation. Rorc, the gene that drives RORγT protein levels, has been shown to
increase at 4hrs after the start of Th17 differentiation233.. However, RORγT protein
levels do not increase until 20hrs after the start of differentiation233. The time
course of Ndfip1 protein during Th17 differentiation is unknown. The hypothesis
that non-overlapping timing of protein expression of Ndfip1 and RORγT may make
Th17 differentiation independent of Ndfip1 may be tested in vitro. First, protein
levels of RORγT and Ndfip1 may be determined during a time course of naïve CD4 T
cell stimulation and differentiation in Th17 cells. Additionally, by forced overexpression of Ndfip1 at different time points during Th17 differentiation, it may be
possible to determine whether Ndfip1 can regulate Th17 differentiation when
protein abundance is timed appropriately. Furthermore, a system using tamoxifeninduced knockdown of Ndfip1 may be able to establish whether the timing of
expression of Ndfip1 and RORγT protein explains the lack of Ndfip1 regulation of
Th17 cells differentiation.
Alternatively, it is possible that there is an intrinsic differentiation threshold
for RORγT protein levels required to drive Th17 cell differentiation. This would
represent a digital differentiation or on-off system. It has been shown that RORγT
has a strong impact on a very small number of Th17 loci during Th17
differentiation234 i.e. RORγT takes advantage of a chromatin landscape already
established by key transcription factors such as IRF4, BATF4 and STAT3 in order to
activate and repress its target genes. Therefore it is possible that Th17
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differentiation depends on a minimal amount of RORγT protein. Thus, in Ndfip1deficient T cells, the loss of the ability to degrade RORγT may mean there are excess
levels of RORγT protein beyond the minimum amount needed to pass the threshold
and to support Th17 differentiation. Therefore, this would result in no additional
increase in Th17 differentiation in Ndfip1-deficient CD4 T cells. This could be tested
in vitro by the over expression of graded amounts of RORγT protein to determine
effect on Th17 differentiation.
Lastly, it is possible that Ndfip1 does directly affect differentiation of Th17
cells and that the in vitro assays used in our study were not adequate to answer the
question of Th17 differentiation. In support of this, when we injected Ndfip1deficient and sufficient naïve CD4 T cells into RAG-/- mice for seven weeks, we were
able to recover greater numbers of Th17 cells from the mice that received Ndfip1deficient naïve CD4 cells (Fig. 2.7 and 2.9). While this increase may be explained by
increased proliferation by these cells, it does not rule out a role for increased in vivo
Th17 differentiation in driving the Th17 abundance. The use of T cell transgenic
mice on a RAG-/- background may help address the contribution of both in vivo
differentiation and proliferation to the abundance of Th17 cells seen in Ndfip1deficient animals. This may be done by injecting antigen into the mice in the context
of in vivo labeling such as BrdU, and measuring Th17 generation before the onset of
extensive proliferation in vivo (for example, within the first 48 hours).
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How does Ndfip1 influence the RORγT transcriptional co-factor landscape?
The pathogenicity of Th17 cells lacking Ndfip1 suggests that failure to
degrade RORγT may result in a modified co-factor landscape for Th17 cells, in favor
of new protein-protein or protein-DNA interactions that favor the production of
proinflammatory cytokines such as IL-17A, IFNγ, GM-CSF and others. In spite of
recent advances, the normal transcription factor landscape required for Th17
differentiation and for RORγT-mediated thymopoiesis is currently not well
understood235. It is thought that in order to drive Th17 cell differentiation, pioneer
factors such as IRF4 and BATF need to complex with lineage-specifying factors such
as STAT3, as well as other factors such as p-300 and HIF1α169. Furthermore, in
pathogenic Th17 cells, exposure to IL-23 is thought to drive increased Blimp1
protein levels and to allow such cells to express genes such as Csf2, Il23r and
Il17a169.
However, it has never been addressed whether there are IL-23Rindependent pathways that can drive Th17 pathogenicity. In Ndfip1-deficient Th17
cells, we did not detect increased levels of IL-23R gene expression in spite of
exposure to IL-23. Therefore Ndfip1 may regulate Th17 pathogenicity independent
of IL-23R levels. If this is true, this represents a departure from the way the field has
traditionally thought of Th17 pathogenicity and requires further study. Regulation
of RORγT protein may involve modulating amount of RORγT available to bind DNA
directly as well as the amount available to bind coactivators. Perhaps Ndfip1 and
Itch work to limit RORγT levels so that there is enough RORγT to drive Th17
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differentiation but not excessive amounts of RORγT that may drive binding of RORγT
to additional sites or coactivators associated with Th17 cell pathogenicity. If this is
true, CHIP-seq (Chromatin Immunoprecipitation sequencing) and ATAC-seq (Assay
for Transposase-Accessible Chromatin with high throughput sequencing) analysis
of RORγT-binding sites in Ndfip1-deficient versus sufficient Th17 cells would be
expected to show that there is a core set of binding sites that would be preserved in
Ndfip1-deficient Th17 cells. However, we would also expect to find enhanced RORγT
binding to additional sites in Ndfip1-deficient Th17 cells, particularly sites that are
associated with Th17 pathogenicity such as Ccl5 and Csf2. Furthermore, one would
predict that in Ndfip1-deficient Th17 cells, there might be enhanced binding of
RORγT to coactivators associated with pathogenicity, such as Blimp-1 and others.
This is an exciting area for future work that will provide much-needed
insight into our understanding of how ubiquitylation affects the generation of
pathogenic Th17 cells. Furthermore, understanding how Ndfip1 contributes to these
processes is sure to provide opportunities for therapeutics that can target specific
aspects of Th17 cell function in a more precise manner.
Does Ndfip1 influence other functions of RORγT?
RORγT is initially expressed in the thymus where T cell factor (TCF)-1 drives
its expression in CD4+ CD8+ double positive (DP) cells. The expression of RORγT
enhances survival of these DP cells, giving them more time to undergo positive or
negative selection236. Yet the gene expression directed by RORγT in the thymus is
very different from the periphery237 suggesting that the effects of Ndfip1 on Th17
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cells in the periphery do not predict an effect of Ndfip1 on RORγT+ DP cells in the
thymus. In our studies of Ndfip1-deficient animals, we have not observed evidence
of a cell-intrinsic defect in the thymus that would indicate alterations in positive or
negative selection. Therefore, if Ndfip1 affects RORγT expression in the thymus, this
is a very subtle defect. However, it would be worth examining in finer detail
whether Ndfip1-deficient thymocytes show any evidence of greater survival at the
DP thymocyte stage.
RORγT is also important for the development of Lymphoid Tissue Inducer
cells (LTis). LTis are critical early colonizers of developing lymph nodes and secrete
lymphotoxin-α1β2 which binds to receptors on stromal cells found in the lymph
node. This results in the upregulation of factors that attract and retain other
hematopoietic cells in the lymph node and help it gain structure and form238.
Without RORγT, LTis do not develop and consequently peyer’s patches, cryopatches
and peripheral lymph nodes do not form, even though a spleen forms. Given that
Itch E3 ligase has been shown to regulate RORγT in type 3 innate lymphoid (ILC3)
cells173, it is possible that Ndfip1 and Itch regulation of RORγT is not limited to just
Th17 cells and ILC3s. It is possible that Ndfip1 and Itch may regulate RORγT protein
levels in LTi cells as well. It remains to be explored whether LTi cells express Ndfip1
and whether in the absence of Ndfip1, an increase in RORγT and unchecked LTi
development can explain the increased recruitment of lymphocytes into the
peripheral lymph nodes and the resulting lymphadenopathy in Ndfip1-deficient
animals.
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RORγT-expressing regulatory T cells have also been described239. These are
mostly peripherally generated Treg cells that are found in the colon and in the small
intestine and are important enforcers of colonic integrity. These cells suppress
spontaneous Th2 responses and regulate commensal immune responses240,241. Since
Ndfip1 is expressed in RORγT+ Th17 cells and in Foxp3+ Treg cells, it will be
important to determine the role of Ndfip1 in RORγT+ Foxp3+, so-called “biTreg”
cells. These cells are known to express IRF4 and STAT3 and to show high IL-10
production239. It is possible that the surprising lack of spontaneous colon pathology
in Ndfip1fl/fl Foxp3-Cre animals is due to an increase in the number or function of
these RORγT+ Foxp3+ Treg cells leading to a tissue-specific protection of the colon
from the pathology seen in other sites such as the lungs, skin and spleens, where
these cells are lacking. Whether this hypothesis is supported remains to be
investigated.
How does a trans-membrane protein like Ndfip1 regulate the protein levels of
a nuclear protein like RORγT?
This is an interesting question not addressed by my current work. Ndfip1
interacts with several different Nedd4 E3 ligases to ubiquitinylate a variety of
protein substrates. In the case of PTEN, Ndfip1 activates Nedd4 and Nedd4-2 E3
ligases in order to ubiquitinylate cytosolic PTEN and drive its nuclear
translocation242. Of particular interest, Ndfip1 also activates the Nedd4 family E3
ligase, Itch, in order to drive the ubiquitylation of the transcription factor, JunB, in
CD4 T cells (as previously discussed)25,50. Intriguingly, using a technique called
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ubiquitin-mediated fluorescence complementation, it has been shown that nonubiquitylated JunB, is predominantly nuclear but ubiquitylated JunB is found
localized in lysosomes243. This sets a precedent for how Ndfip1 and Itch may
regulate a nuclear receptor such as RORγT. Interestingly, the HECT E3 ligase, UBR5,
which has also been reported to degrade RORγT, is found both in the cytoplasm and
in the nucleus and so may have access to RORγT in both locations. Further work is
needed to establish whether RORγT is shuttled between cytoplasm and nucleus in
order to gain access to Ndfip1 and Itch. It is alternatively possible that there is an
initial modification of nuclear RORγT that may allow it to exit the nucleus and be
recognized and ubiquitylated by Ndfip1 and Itch in the cytoplasmic space. It remains
to be explored whether this latter alternative occurs and whether UBR5 could be
involved in such a mechanism.
These are interesting areas for further work as any information that
contributes to our understanding of possible off-target effects of an Ndfip1
therapeutic intervention will be crucial in tailoring therapeutics for maximal ontarget benefits.

The role of Ndfip1 in Treg cells: unresolved questions and future
directions
Our work in Treg cells has revealed Ndfip1 is indispensable for normal
immune homeostasis. We show that Ndfip1 is important in Treg cells to prevent
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proliferation and excessive activation in Treg cells following TCR stimulation.
Ndfip1 limits the cell-autonomous expression of GITR and ICOS proteins on the
surface of Treg cells, although the consequence of this regulation is not yet
understood. Furthermore, Ndfip1 prevents IL-4 production from activated WT Treg
cells, helping to prevent methylation of CNS2 and protecting Treg cells from loss of
Foxp3 during periods of extensive proliferation. Finally, Ndfip1 reins in mTORC1
signaling in order to prevent glycolysis and proliferation that would fuel
unregulated growth of the Treg cells (Fig 4.3). Several questions that remain about
this current work and the future implications for other work are discussed next.
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FIGURE 4.3 Model for how Ndfip1 functions in Treg cells.

Ndfip1 is induced upon T cell stimulation and carries out two important functions: dampens
signaling via mTORC1 to limit Treg cell proliferation and growth, and inhibits IL-4
production from Treg cells.

Can dysregulated mTORC1 signaling in Treg cells be beneficial if the resulting
Treg cells do not make IL-4?
We propose at the end of our Treg study that Ndfip1 regulates IL-4
production and mTORC1 signaling via two distinct pathways. However, to further
extend this hypothesis, I propose that the excessive proliferation fueled by the
mTORC1 signaling may be sufficient to drive loss of Foxp3 independent of IL-4
signaling (Fig 4.3). It has been shown by others that Treg proliferation, even in WT
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Treg cells, leads to detectable loss of Foxp3 after several progressive rounds of cell
division213. The CNS2 region in the Foxp3 gene exists to slow down this loss of Foxp3
by recruiting STAT5 and preventing methyltransferases from binding and
methylating the Foxp3 locus. However, with Ndfip1-deficiency, we see a significant
increase in the ability of Treg cells to proliferate and this may set up the Treg cells to
lose Foxp3 in vivo in spite of intact CNS2 function. Future work will need to explore
whether in vivo mTORC1 inhibition -for example, during the adoptive transfer
experiment- will prevent loss of Foxp3 in the Ndfip1-deficient Treg cells. This will
need to be done in the context of IL-4 sufficient and IL-4-deficient Treg cells.
Furthermore, the generation of Ndfip1fl/fl Foxp3-Cre IL-4KO animals will provide
sufficient evidence of the extent to which mTORC1 and IL-4 pathways in Ndfip1deficient Treg cells may be dissociated from each other.
Of note, mice bearing a conditional knockout of a negative regulator of
mTORC1 signaling called TSC1 have been generated. As expected, these TSC1-/- Treg
animals have increased mTORC1 signaling (pS6K and pS6). Additionally, however,
they have increased IL-17A cytokine production. This is particularly interesting
because TSC1-/- T conventional or effector cells are more likely to make IL-17A and
to differentiate into Th17 cells. The production of IL-17A by these Tregs is a
consequence of increased mTORC1 signaling, specifically, increased S6K1. Thus
inhibition of this mTORC1 substrate led to abrogation of IL-17A production.
Juxtaposing this data with that gathered from our Ndfip1fl/fl Foxp3-Cre mice, it is
surprising that increased mTORC1 signaling in our mice also drives increased pS6
and yet it is IL-4 that is intrinsically produced by these Treg cells, and not IL-17A. It
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is not understand why an alteration in mTORC1 signaling leads to dysregulated
production of different cytokines – IL-17A versus IL-4 versus other cytokines. This
might suggest that downstream of mTORC1 signaling, there may be differential
regulation of substrates of mTORC1 according to other effects mediated by the
protein that has been knocked down. In Ndfip1fl/fl Foxp3-Cre, it is possible that
downstream of mTORC1 there is a general increase in protein translation and cell
proliferation and that in the context of a cell that also has dysregulated IL-4
production, possibly due to un-degraded JunB or an unknown substrate, this may
lead to the expansion of IL-4 producing Treg cells. This hypothesis argues (as others
have done244) for more research into understanding how coordination of the actions
of mTORC1/mTORC2 complexes directs Treg metabolism, cytokine production,
function and lineage stability.
Therefore, in short, I predict that dysregulated mTORC1 signaling in Treg
cells even in the context of IL-4 deficient mice will still lead to autoinflammatory
disease, albeit with a delayed timeline of onset and progression, and perhaps with a
different cytokine that is dysregulated, compared to what is observed in Ndfip1fl/fl
Foxp3-Cre mice.
What is the significance of increased ICOS protein levels on the Ndfip1deficient Treg cells?
ICOS, a co-stimulatory receptor and a CD28 family member, is induced on
Tconventional and Treg cells alike in response to T cell activation245–247. ICOS binds
the ligand called B7H2 (also called CD275, B7RP1 or ICOSL), which is expressed on
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B cells, dendritic cells, monocytes/macrophages, and on T cells. It is found in
extremely low levels on naïve CD4 T cells and therefore its abundance on Ndfip1deficient Treg cells is not likely to be the cause of their activation. Instead, ICOS
induction on these Treg cells very likely occurs after the cells are already activated.
ICOS signaling drives proliferation, as well as cytokine production, from activated
effector T cells245. ICOS expression on Treg cells has been correlated with increased
suppressive function and protection against lung pathology and autoimmune
disease248,249. IL-4 production is particularly tied to ICOS expression. ICOS-/- CD4 T
cells are impaired in their ability to differentiate into Th2 cells and consequently in
their ability to fight Th2-biased lung pathology. It is thought that ICOS-/- CD4 T cells
are unable to phosphorylate STAT6 and increase IL-4R levels in response to IL-4.
Thus ICOS-/- CD4 T cells are unable to respond to IL-4 in order to secrete more IL4250. Furthermore, ICOS signaling increases c-MAF expression to drive IL-4
transcription251. C-Maf has also been shown to cooperate with JunB protein (the
Ndfip1 and Itch substrate) to drive IL-4 transcription51,251. Therefore ICOS has been
tied to Treg suppressive function as well as IL-4 production by CD4+ T cells.
Treg cells isolated from Ndfip1fl/fl Foxp3-Cre male and female animals show
increased expression of ICOS. After a 7 day in vitro expansion using high dose IL-2
(2000U/ml) and αCD3/αCD28 activator beads, Ndfip1-deficient Treg cells have
higher expression of ICOS and this is true even in co-culture settings (Fig 3.16).
Interestingly, in a 4day culture using a 10fold lower dose of IL-2 (200U/ml) and
plate-bound TCR stimulation, Ndfip1-deficient Treg cells do not have the same high
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levels of ICOS (Fig 3.18). This may be consistent with knowledge that ICOS
expression on Treg cells is critically sensitive to IL-2 exposure248. We show that in
spite of high ICOS expression on Ndfip1-deficient Treg cells in vivo, the mice get sick.
Furthermore, when tested in an in vitro suppression assay, these ICOShi Ndfip1deficient Tregs cells were not better suppressors of Tconventional cells. Therefore
the high ICOS expression on these Treg cells is unlikely to be affecting their
suppressive function. However, it is possible that the high ICOS levels on these Tregs
may signal through c-Maf to contribute to IL-4 production by these Treg cells.
Testing of this hypothesis could be done by treating mixed chimeras WT/Ndfip1fl/fl
Foxp3-Cre chimera animals with ICOS blocking antibodies in order to determine the
effect on IL-4 production by Ndfip1-deficient Treg cells. An extension of the work
presented in Figure 3.16 would also be useful here. Specifically, Ndfip1-deficient
versus WT Treg cells could be treated in vitro with ICOS blocking antibodies, with or
without rapamycin, in order to detect effect on IL-4 production. This would help
determine whether the IL-4 production is regulated via ICOS-c-Maf signaling or via
mTORC1-dependent pathways in Ndfip1-deficient Treg cells.
What is the significance of increased GITR protein levels on the Ndfip1deficient Treg cells?
GITR, also known as Tumor necrosis factor receptor superfamily member 18
(TNFRSF18), is expressed on activated T effector cells and on Treg cells. GITR is
expressed at low levels on naïve CD4 T cells but is upregulated in response to
activation. GITR binds to GITR Ligand, which is constitutively expressed by B cells,
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macrophages, and dendritic cells (particularly plasmacytoid dendritic cells). Effector
CD4 (activated CD4+ CD25-) T cells respond to GITR stimulation by increasing the
threshold for Treg suppression and thus becoming resistant to Treg suppression252.
However, in response to stimulation via GITR, both T effector cells and Foxp3+ Treg
cells have increased proliferation and expansion in vivo253. The effect of GITRstimulation on Treg cell suppressive function is still contested. Some studies show
loss of suppressive function of GITR-stimulated Treg cells while others show no
effect on Treg suppression. GITR stimulation of Treg cells (defined as CD4+ CD25+
cells) may lead to increased JNK2 signaling and loss of suppression254. In the tumor
environment, agonistic GITR signaling does not alter frequencies of Treg cells or
their suppressive function, instead GITR stimulation may promote loss of Foxp3
expression in vivo, leading to the generation of Foxp3- ex-Treg cells255. However,
agonistic GITR signaling may also lead to death of Treg cells transferred into a
lymphopenic mouse256. In short, the effect of GITR stimulation on Treg cells, as these
and other studies have shown, is contextual. To avoid the use of agonistic GITR
antibodies in studying the effects of GITR stimulation on Treg cells as all of the
existing studies have done, there is the need for the generation of GITRfl/fl Foxp3-Cre
mice. The current studies, however, support that increased GITR expression on
Ndfip1-deficient Treg cells may contribute to their expansion the lymphoreplete
Ndfip1fl/fl Foxp3-Cre mice, and possibly to the loss of Foxp3 expression after
transfer into the lymphopenic RAG1-/- mice. However, if GITR stimulation does lead
to the suppression of Treg cell activity, high GITR levels on the Ndfip1-deficient Treg
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cells cannot explain their normal suppression of WT cells in the in vitro suppression
assay and in the adoptive T cell transfer colitis models (Figure 3.3).
Increased levels of GITR on Ndfip1-deficient Treg cells could indicate a
failure to degrade GITR in the absence of Ndfip1. While the protein sequence of
GITR does not reveal a P-P-X-Y or L-P-X-Y or P-P-L-P motif that would suggest that it
can bind directly to the WW domains of an E3 ubiquitin ligase, it would be
interesting to explore whether GITR is a direct substrate downstream of Ndfip1
activity since Ndfip1 and its homolog Ndfip2 are known to promote the
ubiquitylation of proteins that do not have PY motifs (e.g. endophilin)49. Future
experiments could determine GITR protein levels in response to TCR stimulation; in
response to inhibition of protein translation with cycloheximide; or in response to
inhibition of proteasomal/lysosomal degradation by Mg132 and chloroquine in
Ndfip1-deficient versus WT Treg cells. This would provide clarity on whether GITR
levels are upregulated because of a direct failure of degradation or because of
alterations in pathways that drives up transcription and/or translation of GITR.
These experiments would be beneficial for ICOS as well.
Does Ndfip1 promote autophagy in Treg cells?
mTORC1 signaling is an important coordinator of different metabolic and
cellular processes in a cell. During nutrient-rich periods in the cell, sensing of amino
acids, glucose and oxygen can all drive increased mTORC1 signaling. Increased
mTORC1 signaling drives increased lipid synthesis (mediated by mTORC1
substrates SREBP1 and PPARγ); increased mRNA translation to support protein
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translation (mediated by substrates S6K and eIF4E); and inhibition of
macroautophagy (also called autophagy, mediated by substrate ULK1). Autophagy is
a process that is initiated in a nutrient starved cell and involves the degradation of
cytoplasmic organelles in the lysosome in order to generate nutrients and energy
that can be recycled to support cell function. When mTORC1 is activated during a
time of nutrient abundance, it carries out the inhibitory phosphorylation of ULK1257,
preventing ULK from undergoing activating phosphorylation at a nearby site. ULK1
(also called Autophagy-related gene 1, Atg1) forms part of the Atg1 kinase complex,
which is the earliest complex to assemble in the pre-autophagosomal structure, and
is required for autophagy to occur258. Therefore mTORC1 inhibition of ULK1/Atg1
activation prevents autophagy from occurring during a time of nutrient abundance.
The increased mTORC1 signaling in Ndfip1-deficient Treg cells would be expected to
signal to the cells that there is nutrient abundance and therefore no need to carry
out autophagy. Therefore an important question that we do not address in our
current work is what is the consequence of the elevated mTORC1 signaling on
autophagy. It was recently shown that autophagy is essential for the functions of
Treg cells. Atg5 and Atg7 are two components of the autophagosome that when
deleted specifically in Foxp3+ cells leads to abrogation of autophagy206.
Interestingly, deletion of autophagy in Treg cells led to a spontaneous autoinflammatory disease in mice, marked by lymphadenopathy, increased activation of
T cells and increased Th1 and Th17 effector subsets but a decrease in Treg total
numbers. Further work revealed that while mTORC1 can inhibit autophagy,
autophagy is also important for restraining mTORC1 activation as a way of
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maintaining Treg cell stability206. The results of that study indicate that the defects
observed in our Ndfip1-deficient Treg cells are unlikely to be wholly due to
inhibition of autophagy in the Treg cells since primary defects in autophagy would
not explain why Ndfip1-deficient Treg cells are more likely to proliferate and
expand in vivo or why it is IL-4 cytokine production (and not IFNγ or IL-17A) that is
dysregulated in Ndfip1-deficient Treg cells. It is possible that the elevated mTORC1
signaling in Ndfip1-deficient Treg cells inhibits autophagy in those cells, further
contributing to elevated mTORC1 signaling. Future studies in Ndfip1fl/fl Foxp3-Cre
mice looking at protein levels of autophagy related proteins, as well as microscopy
work to determine whether autophagy is active or inhibited in these Ndfip1deficient Treg cells will be a good place to start to understand a role for Ndfip1 in
promoting autophagy in Treg cells.
How does Ndfip1 control of Treg cell proliferation influence an immune
response?
The initial phases of an immune response are characterized by increased
production of IL-2 resulting in extensive proliferation of proximal Treg cells and
leading to enhancement in Treg cell suppressive function259,260. This is
counterintuitive since one expects that during an immune response Treg cells would
be quiescent and allow effector T cells to eliminate the pathogen. It has been
proposed that this initial expansion of suppressive Treg cells is to control the
initiated response and to prevent immunopathology as the effector T cells respond
to antigen259. Based on the data from the adoptive transfer of Tconv and Treg cells
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into RAG1-/- animals (Figure 3.11), I predict that, physiologically, it is at this early
stage of an immune response where there is a simultaneous increase in IL-2 from
Tconv cells and increased demand for extensive proliferation that Ndfip1-deficient
Treg cells would increase in number, increase production of IL-4, and be especially
susceptible to loss of Foxp3 protein. Therefore in response to a live bacterial or viral
infection, I would predict that Ndfip1-deficient Treg cells would initially very
heavily expand and make IL-4. Then I would expect a loss of Foxp3 expression in
these cells, and the corresponding in vivo generation of IL-4-producing ex-Treg cells.
I would predict that the resolution stages of the immune response would be delayed
due to the presence of these ex-Tregs instead of Treg cells. Whether these ex-Treg
cells contribute to pathology due to resistance to Treg cell suppression or in some
other manner has not been fully explored. Therefore, future studies might uncover
an additional role for Ndfip1 in Treg cells at the initiation phases of an immune
response and explore how this might affect the generation of immune memory.
Concluding thoughts
Ndfip1-deficient Th17 and Treg cells both have an intrinsic tendency to
proliferate and to expand in vivo. In Treg cells, this in vivo advantage is due to
increased mTORC1 signaling. We have not explored whether Ndfip1-deficient Th17
cells also have increased mTORC1 signaling. T effector subsets generally do have
heavy dependence on mTORC1 signaling and on the use of glycolysis to fuel
metabolic demands. It would be intriguing to discover whether Ndfip1 suppresses
these pathways in both T effector and Treg cells in order to prevent excessive
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proliferation in vivo. Since T effector cells need to rely on glycolysis, one would
expect that if Ndfip1 dampens glycolysis in both T effector and in Treg cells, it might
require different additional regulation of the degree to which this process is
inhibited in T effector cells so these cells can still predominantly perform glycolysis.
In both Ndfp1-deficient Th17 cells and Treg cells there is an increase in
secretion of proinflammatory cytokines. In Th17 cells, secretion of IL-17A, IFNγ and
GM-CSF is due to a failure to degrade the Ndfip1-Itch substrate, RORγT. In Treg cells,
the substrate responsible for the IL-4 production remains unclear. Failure to
degrade JunB in Ndfip1-deficient CD4+ T cells drives IL-4 production but we have
not explored whether it is this same substrate in Treg cells, which explains the IL-4
production. A study in Itch-deficient Treg cells, which largely phenocopy the Ndfip1deficient Treg cells, failed to find evidence to support JunB as the IL-4 driving
substrate104. Therefore, it warrants investigation in future studies to determine
whether Ndfip1-deicient Treg cells secrete excess IL-4 because of GITR-c-Maf-IL-4
pathways or because of JunB-IL-4 pathways. Elucidating the substrate underpinning
this phenomenon will also help clarify whether the IL-4 production and the
metabolic fitness are two independent but converging pathways that are both
downstream on Ndfip1 activity.
The holy grail of studies involving Ndfip1 may be to fully understand the
molecular mechanisms through which Ndfip1 dampens T cell activation. Our work
with Th17 cells revealed that while activation alone does not explain Ndfip1
regulation of Th17 cells, at least part of the difference in Th17 abundance between
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Ndfip1-deficient and sufficient mice is explained by Ndfip1 regulation of activation.
Specifically, when we examined IL-17A+ cells gated through CD4+ versus CD44+
cells, we found that after accounting for CD44+ cells (activation), there was a
smaller but still significant difference between Ndfip1-sufficient and –deficient T
cells. This extra difference beyond activation is explained by the ability of the
Ndfip1-deficient Th17 cells to proliferate and expand in vivo. Similarly, in Treg cells,
Ndfip1-deficient eTreg cells or activated Treg cells, but not the quiescent cTregs, had
the most dramatic differences in surface marker expression and in proliferation.
This reinforces the concept that since Ndfip1 is expressed after activation, it is in
previously activated T cells that we see the biggest effects when Ndfip1 is absent.
Why? We know that Ndfip1 is not just induced upon T cell activation, but also works
to dampen T cell activation in a negative regulatory loop. Ndfip1-deficient T cells fail
to exit the cell cycle, preferring to stay in cycle and to undergo many extra rounds of
activation and division153. Given that Ndfip1’s only known function is as an activator
of Nedd4 family HECT E3 ligases, the role(s) of Ndfip1 in T cell activation would be
predicted to somehow involve ubiquitylation of specific substrates. Yet the
biochemical pathways used by Ndfip1 to dampen T cell activation and proliferation
remain elusive. Our lab is turning to large-scale mass spectrometry proteomic work
using several emerging ubiquitylation tools with subsequent in vitro validation
studies in order to determine exactly how Ndfip1 drives the ubiquitylation of T cell
proteins to limit excessive activation. Work of this nature is crucial since Ndfip1
regulation of T cell activation is unlikely to be dependent on a single substrate alone.
It is more likely that there are several proteins whose degradation depends on
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Ndfip1 in order to limit different pathways downstream of T cell activation as well
as influence other aspects of T cell differentiation and function, such as proliferation
and cytokine production. Furthermore, rather than limiting our investigations of the
ubiquitin E3 ligases involved to the relatively well-studied ones such as Itch, mass
spectrometry data will have the added advantage of revealing little-known E3
ligases as well as little-studied ubiquitin linkages that are dependent on Ndfip1.
These studies may prove central to a greater and more holistic understanding of
how these CD4 T cell subsets are regulated.
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CHAPTER 5: Materials and Methods
Mice.
Th17 work: Ndfip1-/-, Ndfip1fl/fl CD4-Cre+, IL-4-/- and Ndfip1-/- IL-4-/- (DKO) mice

have been generated previously25,68,154,155. IL-17A GFP mice were purchased from
Jackson laboratory (C57BL/6-Il17atm1Bcgen/J, stock# 018472), were crossed to inhouse IL-4-/- (Jackson laboratory, B6.129P2-Il4tm1Cgn/J, stock #002253) or Ndfip1-/IL-4-/- (DKO) mice, and bred for one copy of the IL-17A GFP gene. Itch IL-4 DKO mice
were generated by crossing previously described Itch-/- animals26 to in-house IL-4-/animals. CD45.1 IL-4-/- mice were obtained by crossing in-house CD45.1
(C57BL6.SJL-Ptprca Pepcb/BoyJ) mice to in-house IL-4-/- animals for more than 10
generations. The T cell transgenic B3K506 mice have been described
previously179,261, were obtained from the laboratory of Eric Huseby, and crossed to
Ndfip1-/- RAG1-/- animals. In all experiments described, male and female mice were
appropriately age and sex-matched in experiments and data was pooled. Primers for
Ndfip1-/- , CD4-Cre+, IL-4-/- , IL-17A GFP, RAG1-/- mice are available on the Jackson
Laboratories website (https://www.jax.org/). CD45.1 mice were genotyped by
staining peripheral blood lymphocytes for CD45.1 versus CD45.2, while B3K mice
were genotyped by staining peripheral blood lymphocytes for B220-, CD4+ Vb8.1+ T
cells.
Treg work: Ndfip1fl/fl mice (previously described155) were crossed to Foxp3-YFP-Cre

reporter mice (Jackson laboratory, B6.129(Cg)-Foxp3tm4(YFP/icre)Ayr/J, stock #016959),
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also referred to as Foxp3-Cre, and bred for only one copy of the Cre gene to generate
Ndfip1fl/fl Foxp3-Cre male mice and Ndfip1fl/fl Foxp3-Cre+/- female mice. Control
mice were: Ndfip1+/+ Foxp3-Cre+ male and Ndfip1+/+ Foxp3-Cre+/- female mice. We
generated congenic CD45.1/CD45.2 control mice by crossing Ndfip1+/+ Foxp3-Cre+
mice to CD45.1+ mice (Jackson laboratory). CD45.1 and RAG1-/- are maintained in
house. Animals were used ages indicated in each figure legend. Genotyping primer
sequences for Ndfip1 flox alleles and Foxp3-YFP-Cre have been described
previously155,207 and sequences for Il-4 and Foxp3 are available from the Jackson
laboratory website.
Mice were maintained in a barrier facility at the Children’s Hospital of Philadelphia.
The Institutional Care and Use Committee of the Children’s Hospital of Philadelphia
approved all procedures.
Mixed chimeras.
Fetal liver was harvested from embryos between days E13-E17 old. Fetal livers
were crushed through a 35um FACS tube with strainer cap and washed with plain
DMEM media. After centrifugation, pellets were resuspended in 90% FCS 10%
DMSO freezing media and stored at -80°C until needed. Bone marrow was harvested
from donor mice by flushing the femurs and tibias with a 22G needle and 10ml
syringe containing DMEM. The flushed cells were strained though a 70um strainer
cap and 5ul of purified anti CD4 (clone GK1.5) and anti CD8 (clone 53-6.7)
antibodies were added to 5ml of bone marrow cells and rotated at 4 degrees for
30mins-1hr. Cells were washed with extra DMEM and resuspended in 1ml of
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suspension. 1.5ml of goat anti rat IgG magnetic beads were washed in a dynamagnet
and the 1ml of bone marrow suspension was added to the washed beads and placed
on a dynamagnet. Supernatant containing untouched, T cell depleted bone marrow
was collected, washed, resuspended in freezing media and frozen at -80°C until
needed. RAG1-/- recipient animals were sublethally irradiated with 400cGy 18-24
hours before injection. Frozen fetal liver or T cell-depleted bone marrow was
thawed and resuspended in sterile PBS. The irradiated mice were reconstituted with
a total of 0.5- 1.0x10^6 total cells per 100ul via the intravenous route (tail vein or
retroorbitally). Mice were allowed 7-10 weeks for reconstitution. No difference was
observed between fetal liver- versus bone marrow-reconstituted animals.
Histology.
Stool was removed from colons by lightly pressing out using curved forceps. 1-2mm
sections of the most distal colon were taken and fixed in 10% neutral buffered
formalin for at least 24h. Skin (ear) and esophagus were dissected and fixed in 10%
neutral buffered formalin for at least 24 h. Lung were obtained after manual
transcardial perfusion with 10ml syringes containing 10% neutral buffered
formalin. All organs were then embedded in paraffin, sectioned to 5µm thickness
and stained with Hematoxylin and Eosin (H&E). Images were obtained using a Leica
DM4000B upright scope paired with a Spot RT/SE Slider camera (Children’s
Hospital of Philadelphia Pathology Core).
Tissue processing for flow cytometry.
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After transcardial perfusion of lungs and flushing colons with cold HBSS buffer, they
were minced with DMEM (Dulbecco’s minimal essential medium) containing 0.9
mg/ml of collagenase A, 0.8 mg/ml of collagenase 1A, and 20 µg/ml of DNase I and
rotated end-over-end for 1h at room temperature. FCS was added at 15% v/v and
the mixture was filtered sequentially through a 100um and 40um filter before
centrifugation. Lung pellets were RBC-lysed using in-house ammonium-chloridepotassium (ACK) lysis buffer, washed, resuspended in complete DMEM media and
refiltered. Spleens and thymi were crushed with the back end of a 1ml syringe
through a 70um filter and into a petri dish containing complete DMEM media. Thymi
were directly resuspended in complete media for staining while spleens were RBClysed before being resuspended and filtered in complete T cell media for flow
cytometry.

Complete

T

cell

media

contained

DMEM,

10%

FCS,

1%

Penicillin/Streptomycin, 1% glutamax and 0.12mM beta-mercaptoethanol. Tissue
homogenates were stimulated with PMA (30ng/ml), Ionomycin (1uM) and Golgi
plug inhibitor (1:1000, BD Biosciences) for 4hrs at 37 degrees in a 5% CO2
incubator. Surface and intracellular staining were performed for surface antigens
and cytokines, respectively, before flow cytometric analysis. For flow cytometry
panels where only surface proteins were required, no PMA/Ionomycin stimulation
was performed. In expanded Treg cell cultures, cells from the 7-day expansion were
restimulated with mouse T cell activator beads (Gibco, 11456D) at a 1:1 cell:bead
ratio for 4 hours. Samples were immediately fixed at a final concentration of 2%
PFA, permeabilized in 90% methanol, and then stained for pS6 and surface markers
together in Fc block.
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Flow cytometry.
Freshly prepared or PMA/Ionomycin-stimulated tissue homogenates in FACs tubes
were washed once with PBS and stained at 1:60 with 10ul live dead blue viability
stain for 5mins on ice, stained for an additional 5mins with 50ul Fc block at 1:25
(anti-CD16/32, clone 2.4G2) and then for 20mins on ice with 50ul of cell surface
stains. Cells were then fixed overnight (~16 hours) with the foxp3 ebioscience
fix/perm kit and stained for intracellular proteins for 45mins on ice. Flow cytometry
data were acquired on an LSR Fortessa and analyzed using Flowjo software (Tree
Star). Events analyzed were viability dye-negative cells; FSC-A by FSC-H singlet
cells; SSC-H by SSC-W singlet cells; and FSC A by SSC A lymphocytes.
Antibodies for Th17 work: αCD4 (ebioscience, GK1.5); αIL-17A (ebioscience,

eBio17B7,), αCD3 (Biolegend, 17A2); αCD44 (Biolegend, IM7); αTNFα (BD, MP6XT22), αCD25 (ebioscience, PC61.5); αCD45.2 (Biolegend, 104); αCD45.1
(Biolegend, A20), αLy6G (BD, 1A8), αLy6C (Biolegend, HK1.4); αKi67 (Biolegend,
16A8); αGM-CSF (Biolegend, MP1-22E9); αRORγT (ebioscience, B2D); αSiglec F (BD,
E502440); αCD11b (Biolegend, M1/70) and αIL-10 (ebioscience, JES5-16E3).
Additional antibodies for Treg work: αGITR (YGITR765), αICOS (C398.4A), αPD-1

(RMP1-30), αYFP/GFP (Life technologies,A-21311), αIFNγ (BD biosciences, XMG1.2)
and αKi67 (BD biosciences, B56), Biotinylated αphospho-S6 (Cell Signaling
Technologies, D57.2.2E), αCD25 (eBioscience PC61.5), αCD62L (eBioscience,MEL14), αIL-4 (ebioscience, 11B11), αIL-10 (ebioscience, JES5-16E3), αFoxp3-biotin
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(ebioscience, FJK-16s). Biotinylated αFoxp3 and αpS6 were detected with
fluorophore-conjugated streptavidin (S32354 Invitrogen).
ELISA.
Th17 work: 5 days after differentiation, Th1 or Th17 cells were harvested, re-plated

at 1x10^6/ml in 50U/ml IL-2 and expanded for 72h, splitting cells daily. After 3
days, cells were resuspended at 1x10^6 cells/ml and 0.5x10^6 of these Th1 or Th17
cells were restimulated via plate-bound 5ug/ml anti-CD3/CD28 for 0.5, 2, 4, 6, 11 or
24hrs in 48 well plates. Supernatants were collected and kept frozen at -80°C until
needed. ELISAs were carried in out triplicate and according to the manufacturer’s
protocols for IL-17A (ebioscience, 88-7371), IFNγ (ebioscience, 88-7314) and GMCSF (ebioscience, 88-7334).
Treg work: Serum was isolated from 8-16 week old male Ndfip1 sufficient and

deficient Foxp3-Cre+ mice. The concentrations of Ig subclasses in mouse sera were
determined using isotype-specific antibodies with a sandwich ELISA protocol.
Monoclonal anti-mouse IgA-HRP, IgM-HRP, IgG1-HRP, IgG2C-HRP and IgE-HRP were
purchased from South Biotech. Flat-bottom, 96-well plate (Nunc) was coated with
capture antibody overnight. Plates were blocked with 10% FCS in PBS buffer for 2
hours and incubated with sample serum for 2 hours at room temperature, and
detected with HRP-conjugated Ig subclass antibody for 1 hour at room temperature.
Plates were developed with TMB substrate solution (eBioscience).
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Absorbance (450nm) for the ELISA samples was read using a Synergy HT Microplate
Reader.
qPCR.
Th17 work: Cultured cells were harvested with sterile PBS, resuspended in trizol

reagent and frozen at -80 C until needed. RNA was extracted using the RNeasy Mini
Kit (Qiagen). Isolated RNA was converted to cDNA using the High Capacity RNA-tocDNA kit (Applied Biosystems, #4387406). qPCR plates were set up using the
Taqman Gene expression master mix (Applied Biosystems, #4369514) and primers
for Ndfip1117, Actin (4352933E), Ccl5 (Mm01302427_m1), Csf2 (Mm01290062_m1),
Rorc (Mm01261022_m1), Tbx21 (Mm00450960_m1), Tnf (Mm00443258_m1), Ifng
(Mm01168134_m1),

Blimp1/Prdm1(Mm00476128_m1),

all

from

Applied

Biosystems. Each qPCR sample was run in triplicate on a 7500 Real-Time PCR
system (Applied Biosytems) using 8-10ng/ul of cDNA.
Treg work: 10ng of cDNA was added to TaqMan Gene Expression Master Mix and

TaqMan Gene Expression primer/probe mix specific for Ndfip1 (Applied
Biosystems) for a final reaction volume of 20µl. qPCR was performed using an
Applied Biosystems 7500 Real-Time PCR system. Each sample was assayed in
triplicate along with the endogenous control (actin). ACTB primer/probe
(4352933E) was obtained from Applied Biosystems.
Relative mRNA expression was calculated as 2^dCt, where dCt represents threshold
cycle (Ct) of actin beta minus Ct of gene of interest.
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Statistical Analysis.
All statistical analyses were performed using Graphpad prism software with p
values less than or equal to 0.05 considered statistically significant. In mixed
chimera experiments and in co-transfer experiments, p values were calculated via a
paired t test. In ex vivo flow cytometric analysis, p values were calculated by
unpaired ttest or ANOVA, as appropriate. In time course ELISA experiments, p
values were calculated by 2-way ANOVA. The heatmap was generated in prism 7. All
data are shown as average +/- SEM, with a cutoff of p<0.05 for statistical
significance: * p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001.
Th17-specific protocols:
In vitro Th17 cell differentiation protocols.
Single cell suspensions of spleen and lymph nodes were sorted on a Moflo Astrios
for naïve CD4+ cells (CD8- CD44- CD62L+ CD25-). 0.5x10^6 naïve cells were
cultured for 5 days in Th17 polarizing media containing TGF-β (PeproTech),
20ng/ml IL-6 (R&D Systems), 20ng/ml IL-1β (PeproTech) and 50ng/ml IL-23 (R&D
Systems). In the experiments shown in Figure 2.5a and b, 5ng/ml of TGFβ was used;
all other experiments used 0.5ng/ml. For Th1 polarizing conditions, 50U/ml
(~10ng/ml) rhIL-2 and 20ng/ml IL-12 was added to the media. In both cases, cells
were cultured on plates coated with 500ul of 5ug/ml anti-CD3 (clone 145-2C11)
and 5ug/ml anti-CD28 (clone 37.51) antibodies. After harvest, cells were
restimulated with PMA (30ng/ml), Ionomycin (1uM) and Golgi plug inhibitor
(1:1000) for 4h before intracellular cytokine staining.
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Th17 differentiation of B3k Trangenic (Tg) T cells.
CD4+ T cells were isolated from 7-12 week old RAG1-/- B3K Tg or Ndfip1-/- RAG1-/B3K Tg animals and incubated for 5 days in Th17-polarizing media: and in the
presence of 20ug/ml anti-IL-4. Each well also contained 10x10^5 congenically
marked (CD45.1) APCs pulsed for 2 hours with 10ug/ml of peptide (p3K, p-1K or p1A). On day 5, cells were harvested and restimulated with PMA (30ng/ml),
Ionomycin (1uM) and Golgi plug inhibitor (1:1000) for 4hrs before intracellular
cytokine staining.
Western blotting.
Naïve CD4+ T cells were differentiated into Th17 cells for 5 days using 0.5ng/ml
TGFβ, 20ng/ml IL-6, 20ng/ml IL-1β, 50ng/ml IL-23 and plate bound 5ug/ml
αCD3/CD28. On day 5, Th17 cells were harvested and resuspended at 1-2x10^6
cells/ml and restimulated with plate bound 5ug/ml αCD3/CD28 for 0.5hrs or 4hrs
+/- 10ug/ml final concentration of cycloheximide. Harvested cells were washed
with PBS and lysed by incubating pellets with 1% Nonidet P-40 lysis buffer on ice
for 20mins, followed by spinning at 4degrees at 15 000 rpm for 10mins and saving
the lysate. The lysis buffer contained 1% Nonidet P-40, 50 mM Tris-HCl (pH 8), 150
mM NaCl, 5mM NaF, 1mM Na Orthovanadate and complete protease inhibitors
(Roche). 4x SDS sample buffer was added to lysate to a 1x dilution and this lysate
was boiled for 10mins at 95 degrees prior to loading on an SDS PAGE gel (Criterion
pre-cast gels, Biorad). After transfer to a PVDF membrane, membranes were
blocked for 1hour with odyssey blocking buffer and probed with anti-RORγT and
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anti-GAPDH antibodies. RORγ (H-190) rabbit polyclonal from Santa Cruz was used
at 1:1000 and GAPDH (mab374) mouse monoclonal from Millipore was used at
1:5000. Membranes were probed using anti-rabbit or anti-mouse IR800 and A680
secondary antibodies and imaged on an odyssey imager. Data was quantified using
the Image Studio Lite software.
Adoptive Th17 transfer experiments.
WT or Ndfip1-deficient naïve CD4+ T cells were sorted from IL-17A GFP reporter
mice (Ndfip1-/- IL-4-/- IL-17A-GFP versus IL-4-/- IL-17A GFP) and differentiated into
Th17 cells using 0.5ng/ml TGFβ, 20ng/ml IL-6, 20ng/ml IL-1β, 50ng/ml IL-23,
20ug/ml anti-IL-2, and plate bound 5ug/ml antiCD3/antiCD28 for 4-5 days. Pure
Th17 cells were sorted as CD4+ (IL-17A)-GFP+ cells and 2x10^5 of these cells were
introduced via intraperitoneal injection (IP) into each recipient RAG-/- host. After 57 weeks, animals were analyzed in experiments.
Treg specific protocols:
T cell isolation.
YFP+ CD4+ Treg cells were isolated by cell sorting from spleen and lymph node
enriched for CD4+ T cells by negative selection using rat αmouse CD8α (2.43;
Biolegend) and rat αmouse I-A/I-E (M5/114.15.2; Biolegend). Cell suspensions were
incubated with antibodies in complete DMEM for 30 minutes with end-over-end
rotation at 4C, washed and incubated with Biomag goat αrat IgG magnetic beads
(Qiagen) for 10 minutes with end-over-end rotation at room temperature; unbound
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cells were collected using a Dynal magnet (Invitrogen). Enriched CD4+ T cells were
then stained with antibodies against CD4, CD44, and CD62L. Naïve CD4+ T cells
were isolated from single cell suspensions of spleen and lymph nodes stained with
antibodies against CD4, CD44, CD8α, CD25 and CD62L. Cells were filtered through
35uM filter cap polystyrene FACS tube (BD Biosciences), and sorted under high
speed on a MoFlow Astrios (Beckman Coulter) or a FACs Aria (BD Biosciences).
Total Treg cells were sorted as CD4+YFP+, cTreg cells as CD4+YFP+CD62LhighCD44-,
eTreg cells as CD4+YFP+CD62LlowCD44+. Naïve cells were identified as
CD4+CD62LhighCD44-CD25-.
Bisulfite sequencing.
Sodium bisulfite conversion followed by PCR amplification and sequencing of
individual clones was used to determine the extent of CpG DNA methylation at the
CNS2 and promoter regions of the Foxp3 gene. CD4+YFP+CD62LlowCD44+eTreg cells
were sorted from YFP+ WT and Ndfip1fl/fl Foxp3-Cre+ mice. Naïve CD4+ T cells were
sorted from WT mice. DNA was extracted using the Quiagen DNeasy blood and
tissue kit. Approximately 1 µg of DNA purified from CD4+ Treg cells was bisulfite
converted as previously described262. The DNA was desalted using the Wizard DNA
clean-up system (Promega), desulfonated with 0.3 M NaOH, neutralized with 3 M
ammonium acetate, and precipitated with 100% ethanol. The CNS2 region of the
Foxp3 gene was PCR amplified using the following primers: Foxp3 Intron Forward1
5’-GGGTTTTGGGATATTAATATATATAGTAAG-3’,
CCACTATATTAACTTAACCCATATAACTAA-3’,
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Foxp3
Foxp3

Intron
Intron

Reverse1

5’-

Forward2

5’-

TTGAGTTTTTGTTATTATAGTATTTGAAGAT-3’,

Foxp3

Intron

Reverse2

5’-

ACTAAAAACCTAAAAAACTAAACTAACCAA-3’. The promoter region was amplified
with

the

following

primers:

Foxp3

Promoter

Forward1

5’-

GTTTGGAGTAGAAGGAAGTTTTTGGAGAT-3’,

Foxp3

Promoter

Reverse1

5’-

TATCTAAAAACCAACTACTCCACCTATCTA-3’,

Foxp3

Promoter

Forward2

5’-

GGTTGTTTTTTATTTATATGGTAGGT-3’,

Foxp3

Promoter

Reverse2

5’-

CCAAAATCCTTACCTAAAATAACTA-3’. Following nested PCR, bands of appropriate
sizes were gel purified and cloned into pGEM-T Easy vector (Promega). Single
colonies were miniprepped with the QIAprep spin miniprep DNA purification kit
(Qiagen) and sequenced with SP6 primer. Only sequences derived from fully
converted alleles were used for methylation analysis.
In vitro cell culture.
For

the

in

vitro

Treg

cell

suppression

assay,

sorted

naïve

CD45.1+

CD4+CD62LhighCD44-CD25- T cells were stained with 2.5uM CFSE, mixed with
sorted YFP+CD4+CD45.2+ Treg cells with at varying Treg to Tconv ratios, and
cultured with irradiated CD45.2+ splenocytes (1X105), 1ug/mL soluble αCD3 (1452C11; Biolegend), and 50U/ml IL-2 for 4 days. For expanded Treg cultures, sorted
YFP+CD4+ total Treg cells or CD4+YFP+CD62LhighCD44- cTreg cells, were
resuspended at 1x10^6 cells/mL in media containing 2000U/ml IL-2 and stimulated
at a 1:3 (cell:bead) ratio with mouse αCD3/αCD28 T cell activator Dynabeads
(Gibco, 11456D). After 48 hours, cultures were counted and split daily with IL-2
media. Cells were assayed by flow cytometry after 6 or 7 days in cultures. For
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analysis of RNA, expanded Treg cells were restimulated on day seven of culture at a
1:1 ratio with αCD3/CD28 beads for the indicated periods. Supernatant was saved
for ELISA and cells were harvested for qPCR. For co-cultures, sorted WT and Ndfip-1
deficient Treg cells were mixed in a 1:1 ratio before being plated. All cultured cells,
unless otherwise noted, were cultured at 10% CO2 in DMEM (Mediatech)
supplemented with 10% fetal calf serum (Atlanta Biologicals), 1% pen/strep
(Invitrogen), 1% Glutamax (Invitrogen), 1% MEM-NEAA (Invitrogen), 20mM HEPES
(Invitrogen), 1mM Sodium Pyruvate, and 0.12mM betamercaptoethanol (Sigma)
supplemented with recombinant human IL-2 (obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS, National Institute of Allergy and
Infectious Diseases, National Institutes of Health).
Metabolic function assays.
YFP+CD44-CD62L+ Treg cells (cTreg cells) or YFP+CD4+ Treg cells (total Treg cells)
were sorted from 7-12 week old, age-matched male and female, congenically
marked CD45.1 WT or CD45.2 Ndfip1fl/fl Foxp3-Cre+ (cKO) mice. After sorting, the
WT or cKO Treg cells were expanded with a 1:3 (cell:bead) ratio with mouse
αCD3/α CD28 beads for 7 days. On day 7, cells were harvested and resuspended at
5x10^6 cells/ml in appropriate Seahorse media. 40ul of cells were added to 140ul of
appropriate seahorse media or 140ul of Seahorse media containing fresh mouse
αCD3/α CD28 beads at a 1:1 (cell: bead) ratio. Cells were plated in XF96 cell culture
microplates that were precoated with 25ul of Cell tak reagent overnight according
to manufacturer’s instructions (Corning, 354240). For examining glycolysis, the
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glyo-stress test kit (Seahorse bioscience) was used with additions of the following
reagents to cells in glucose-free Seahorse media: 10mM glucose, 2uM oligomycin
and 50mM 2-DG. To determine the rate of glycolysis, Treg cells were incubated in
glucose-free medium and the increased ECAR response upon stimulation of
glycolysis by glucose and oligomycin was determined. Oligomycin inhibits
mitochondrial ATP synthase (complex V) forcing glycolysis to compensate for the
lack of ATP production in oxidative phosphorylation. Finally, 2-Dexoglucose (2DG)
was added to inhibit glycolysis. Glycolysis was calculated as the difference between
the ECAR after addition of glucose and the baseline ECAR. Glycolytic capacity was
calculated as the difference between the ECAR after addition of oligomycin and the
baseline ECAR. For examining mitochondrial function, a mito-stress kit was used
with additions of the following reagents to cells in appropriate Seahorse media: 2uM
Oligomycin, 1.5uM fluoro-carbonyl cyanide phenylhydrazone (FCCP, an uncoupler
of respiration and oxidative ATP synthesis), and pre-mixed 100nM rotenone + 1uM
antimycin A solution (Electron Transport Chain complex I and III inhibitors).
Maximum respiratory capacity was calculated as the difference between the Oxygen
Consumption Rate (OCR) after addition of FCCP and the OCR after addition of
rotenone/Antimycin A. Spare respiratory capacity was calculated as the difference
between maximal (post FCCP) and basal respiration. Plates were run on an XF96
Seahorse assay instrument, using settings that have previously been described263.
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Treg cell transfer colitis.
Naïve CD4+ T cells from CD45.1+ WT mice and CD4+YFP+ Treg cells from CD45.2+
Ndfip1fl/fl Foxp3-Cre+ and Ndfip1+/+ Foxp3-Cre+ mice were isolated from spleens
and lymph nodes. Cells were resuspended in sterile PBS and congenic naïve T cells
were mixed at a 5:1 ratio with YFP+ Treg cells. A total of 0.36x10^6 cells were
injected intraperitoneally into 6-8 week old RAG1-/- mice. In the transfer experiment
involving Treg cells without T conventional cells, a total of 0.06x10^6 YFP+ Treg
cells from CD45.2+ Ndfip1fl/fl Foxp3-Cre+ and CD45.2+ Ndfip1+/+ Foxp3-Cre+ mice
were used. Mice were weighed weekly. Recipients of both genotypes were cohoused. At sacrifice, mice were weighed, spleens were weighed, and spleens and
lung were processed for flow cytometry as described above. A fraction of the total
lung/spleen single cell suspensions were stained with antibodies against CD4,
CD45.1 and CD45.2, and sorted using a Moflow Astrios as described above for
analysis of Ndfip1 mRNA in cells from Ndfip1fl/fl Foxp3-Cre+ and Ndfip1+/+ Foxp3Cre+ donor Treg cells. Sorted cells were CD4+CD45.2+CD45.1-YFP+ (current Treg
cells)

or

CD4+CD45.2+CD45.1-YFP-

(former

Treg

cells)

or

CD4+CD45.2-

CD45.1+YFP- (T conventional cells). Cells were stimulated for 5hrs with plate-bound
5ug/ml αCD3/CD28 at 3x10^5 cells/mL and harvested in trizol for qPCR. The
remaining fractions of total lung/spleen single cell suspensions were either stained
directly for flow cytometry or stimulated for 4 hrs with PMA/ionomycin in the
presence of Brefeldin A to analyzed cytokine production by flow cytometry.
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Preparation of lysates for whole cell proteome analysis. [CHOP protein core,
Claire O’Leary, Guoping Deng]
Ndfip1 sufficient and deficient cTreg cells and eTreg cells were isolated and lysed
using a lysis buffer containing 100mM Tris-HCl, pH 8.0, 0.15M NaCl, 5mM EDTA, 1%
NP-40, 0.5% Triton-X 100, protease inhibitor cocktail (Roche, 11697498001), 5mM
of 1,10-phenyanthroline (o-PA), 5mM N-Ethymaleimide (NEM) and 0.1mM PR-619.
10ul of lysis buffer was used for every 10x10^6 cells. Protein was quantified by BCA
(Pierce, 23227). ~15ug of lysate was mixed 1:1 with 4x Laemmli sample buffer for
whole proteome analysis. Samples were boiled and run ~2cm past the stacking gel
in 10% Criterion pre-cast Tris-HCL gels (Biorad). Gels were fixed overnight and
stained briefly with Coomassie blue. Each lane of the Coomassie-stained gel was
divided into 8-10 2mm x 9mm ‘pixels,’ each cut into 1 mm3 cubes264. They were
destained with 50% Methanol/1.25% Acetic Acid, reduced with 5mM dithiothreitol
(Thermo), and alkylated with 40mM iodoacetamide (Sigma). Gel pieces were then
washed with 20mM ammonium bicarbonate (Sigma) and dehydrated with
acetonitrile (Fisher). Trypsin (5ng/uL in 20mM ammonium bicarbonate, Promega)
was added to the gel pieces and proteolysis was allowed to proceed overnight at 37
ºC. Peptides were extracted with 0.3% triflouroacetic acid (J.T.Baker), followed by
50% acetonitrile. Extracts were combined and the volume was reduced by vacuum
centrifugation.
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Mass Spectrometry. [CHOP protein core]
Tryptic digests were analyzed by LC-MS/MS on a hybrid LTQ Orbitrap Elite mass
spectrometer coupled with a Dionex Ultimate 3000 (Thermofisher Scientific San
Jose, CA). Peptides were separated by reverse phase (RP)-HPLC on a nanocapillary
column, 75μm id × 30 cm Reprosil-pur 1.9uM (Dr. Maisch, Germany). Mobile phase
A consisted of 0.1% formic acid (Thermo) and mobile phase B of 0.1% formic in
acetonitrile. Peptides were eluted into the mass spectrometer at 300nL/min with
each RP-LC run comprising a 90 minute gradient from 3 to 45 % B in 90 minutes.
The mass spectrometer was set to repetitively scan m/z from 300 to 1800 (R =
240,000 for LTQ-Orbitrap Elite) followed by data-dependent MS/MS scans on the
twenty most abundant ions, with a minimum signal of 1500, dynamic exclusion with
a repeat count of 1, repeat duration of 30s, exclusion size of 5000 and duration of
60s, isolation width of 2.0, normalized collision energy of 33, and waveform
injection and dynamic exclusion enabled. FTMS full scan AGC target value was 1e6,
while MSn AGC was 1e4, respectively. FTMS full scan maximum fill time was 10ms,
while ion trap MSn fill time was 100ms; microscans were set at one. FT preview
mode; charge state screening, and monoisotopic precursor selection were all
enabled with rejection of unassigned and 1+ charge states.
Proteomic data analysis. [Claire O’Leary, Joe Dybas]
Proteomic data were analyzed using Maxquant version 1.5.0.30 searching against
the Uniprot complete mouse reference proteome, including isoforms, (updated Sept
19, 2013) and common laboratory contaminants. A minimum peptide length of 6
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amino acids and a peptide and protein false discovery of 1% was required. The 3
biologic replicates for Ndfip1 sufficient and deficient eTreg cells and cTreg cells
were analyzed together, with match between runs and requantify turned on. Label
free quantification via intensity based absolute quantification (iBAQ) was calculated
in MaxQuant. Quantification data was normalized by the mean quantification value
of identified proteins in each replicate and log2 transformed. Comparisons of
protein hits from WT or Ndfip1-deficient eTreg or cTreg cells were calculated by
log2 fold changes and evaluated for significance using a one-sample t-test. Area
proportional Venn diagrams were generated with eulerAPE version 3.0
(http://www.eulerdiagrams.org/eulerAPE/)265. The gene-ontology analysis and
corresponding network diagram was generated with the BiNGO application266 in
Cytoscape267 The differentially regulated proteins identified in WT vs cKO eTreg
comparisons were compared against the Mus Musculus GO Biological Process
annotation using a hypergeometric significance test with Benjamini-Hochberg FDR
correction. A threshold of adjusted p-value of <0.01 was required for enrichment.
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